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There continues to be a need for more effective analgesics. The α2-adrenoceptor
(AR) agonist clonidine is an analgesic whose use is severely limited by undesirable side
effects. meta-Chlorophenylguanidine (MD-354), an agent developed in our laboratory,
selectively potentiates the antinociceptive effects of clonidine in a biphasic manner.
Mechanistic studies suggest that both 5-HT3 receptor and α2-AR mechanisms are
involved.
To further evaluate mechanisms underlying the analgesia-potentiating effect of
clonidine by MD-354, pharmacological studies using more established 5-HT3 receptor
agonists: meta-chlorophenylbiguanide (mCPBG) and centrally-acting SR57227A, and
non-selective α2-adrenoceptor ligand TDIQ, administered alone and in combination with
xxvii

xxix

clonidine, were conducted in mouse antinociceptive assays. None of the examined
analogs produced an antinociceptive effect when administered alone. Nevertheless,
mCPBG potentiated the antinociceptive actions of clonidine in a monophasic manner
and the effect was antagonized by the 5-HT3 receptor antagonist tropisetron but not by
tropisetron methiodide, suggesting that potentiation is, at least in part, due to a central
5-HT3 receptor mechanism. SR57227A did not alter the antinociceptive actions of
clonidine. TDIQ was found to potentiate the analgesic actions of clonidine in a
synergistic manner (as determined by an isobolographic analysis) and the effect was
blocked by α2-AR antagonists (BRL-44408, imiloxan, ARC-239; α2A-, α2B-, and α2C-AR
antagonists, respectively). This supports the hypothesis that MD-354 could be
potentiating the analgesic actions of clonidine via an α2-AR agonist mechanism.
In order to explore the role of the ring nitrogen atoms and the chloro substituent
of conformationally-constrained rotamers of MD-354, analogs of 2-amino-7-chloro-3,4dihydroquinazoline, with a varying number of nitrogen atoms in the ring were
synthesized. Preliminary binding affinity results indicated that the ring nitrogen atoms
are essential for 5-HT3 receptor binding.
In attempt to explain the varied binding and functional activity of MD-354 at α2ARs, 3D homology models of α2A-, α2B- and α2C-AR were generated and docking studies
of the low-energy rotamers of MD-354 were conducted.
The present studies support a role for the involvement of 5-HT3 receptors and α2ARs in antinociception. Analgesic adjuvants with a dual mechanism of action such as
MD-354 might represent a promising avenue to pain treatment.
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I. Introduction

Cancer, which is one of the most deadly diseases among Americans, is
commonly associated with various types of pain with various degrees of intensity and
duration due to multiple sources.1,2 In general, cancer pain is due to (a) direct invasion
of tumor into bones, soft tissue, nerves, tendons, or connective tissue, (b) metastases,
and/or (c) cancer-related treatments such as surgery, radiation and chemotherapy. 2
The World Health Organization (WHO) developed a three-step analgesic ladder
that communicated guidelines for cancer pain management. 3 The first line of therapy
for cancer pain therapy is administration of nonopioids such as nonsteroidal antiinflammatory

drugs

(NSAIDs)

or

acetaminophen.2-4

However,

NSAIDs

that

nonspecifically inhibit cyclooxygenases type 1 and 2 can cause undesirable effects such
as renal and gastrointestinal effects (e.g., ulceration and bleeding).5,6 Although NSAIDs
that are selective for cyclooxygenase type 2 are devoid of these side effects, recent
studies indicate that these agents increase the risk of stroke and heart attack.5,6 In the
second line of therapy, WHO recommends adding opioids to the treatment.2-4 Although
opioids have been found to be very effective analgesics, physicians and patients have
concerns that physical dependence and tolerance will result from opioid treatments and,
furthermore, adverse effects of such agents include respiratory depression, nausea and
sedation.7,8
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Adjuvant analgesics might be a solution for individual patients due to their
particular symptoms of cancer-related pain and/or their sensitivity to certain adverse
effects.7 For example, the α2-adrenoceptor (AR) agonist clonidine is used to relieve
severe cancer pain.9
Behavioral,

neurochemical,

and

electrophysiological

studies

indicate

an

adrenoceptor role in antinociception via spinal administration of norepinephrine (NE; 1)
or electrical stimulation of cerebral AR cell nuclei.10-15

The descending pathway is

influenced by NE (1), which is receptor-dependent and affects the nociceptive
threshold.16 Regarding the receptor subtypes of α2-ARs (α2A-, α2B- and α2C-ARs), there
are knockout mouse studies as well as pharmacological studies such as systemic/spinal
administration of selective α2A-AR agonists and antagonists that indicate an α 2A-AR role
in analgesia, but an antinociceptive role for α2B- and α2C-ARs is unclear.16-18
Additionally, serotonin receptors seem to modulate mechanisms of descending
inhibition and decending facilitation in the dorsal horn. 16 Leading to both pronociceptive
and antinociceptive actions, various studies such as electrical brain stimulation,
morphine-induced antinociception, and direct administration of serotonin (5-HT) into the
spinal cord suggest that descending serotonergic pathways exert opposing nociceptive
effects (modulation of descending and facilitating inhibitory pathways).19,20

These

varying effects produced by the endogenous ligand 5-HT could be due to the multiple
subtypes of 5-HT receptors (i.e., it is the receptor, rather than the neurotransmitter, that
is responsible for the excitatory or inhibitory action) and/or the localization of specific 5HT receptors.

2

With regard to the 5-HT3 receptor subtype, most of the current studies indicate an
excitatory role in neuronal activity; specifically, phospholipase C activity is enhanced by
activation of 5-HT3 receptors, which, in turn, influences neuronal activity.21-24 However,
to date, the mechanism of pronociception is unclear, possibly due to incomplete
characterization of 5-HT3 receptors (e.g., 5-HT3A vs. 5-HT3AB receptors), and more
research is necessary to fully understand 5-HT3 receptors’ role in the descending
control of pain,.
In vivo pharmacological results are also, ambiguous; for example, the analgesic
action of phenylbiguanide seems to be dependent on the nociceptive animal model, as
it produces an antinociceptive effect in the rat hot-plate assay, whereas it shows salinelike effects in the rat tail-flick assay.25 Furthermore, different analgesic effects observed
in the tail-flick assay are seemingly due to species; 5-HT3 receptor agonists (e.g.,
phenylbiguanide and meta-chlorophenylbiguanide) produce saline-like effects in the rat
tail-flick assay, but show antinociceptive effects in the mouse model.25-28 Although there
are a few exceptions, in general, 5-HT3 receptor antagonists (e.g., tropisetron and
zacopride) produce saline-like effects in antinociceptive animal models.29
In view of the roles of α2-ARs and 5-HT3 receptors in pain, metachlorophenylguanidine (MD-354), which was identified in our laboratory, was found to
possess a rather selective binding profile. MD-354 was shown to display high affinity to
the ligand-gated ion channel 5-HT3 receptors (Ki = 35 nM), and to the low- and highaffinity states of the G protein-coupled α2-adrenoceptors (Ki: α2A-AR, 110 and 825 nM;
α2B-AR, 220 and 25 nM; α2C-AR, 4,700 and 140 nM, respectively).30-33 In vitro functional
assays ([35S]GTPγS assay) indicated that MD-354 behaves as a weak partial agonist at
3

α2A-ARs, but at high concentrations MD-354 nonselectively antagonizes the agonist
effect of NE at all three receptor subtypes.31
As MD-354 has an interesting binding profile with regards to antinociception, its
functional activity in the mouse tail-flick and hot-plate assays have been investigated.
However, in both assays, MD-354 failed to produce a statistically significant
antinociceptive effect.33 Although MD-354 produced saline-like effects in the mouse tailflick and hot-plate assays, it was found to potentiate the antinociceptive effect of an
“inactive” dose of clonidine (an α2-AR agonist) in the mouse tail-flick assay in a biphasic
manner.33

That is, as MD-354 doses increased, the antinociceptive properties of

clonidine were potentiated by MD-354 in a biphasic manner (dose-response curve
displays two peaks at 1.0 and 10.0 mg/kg doses of MD-354). Clonidine, one of the few
non-opioid FDA-approved treatments for cancer pain, is a potent analgesic agent, but
also produces undesirable side effects including sedation. However, MD-354 displayed
selective potentiation of clonidine; specifically, MD-354 potentiated the analgesic
properties of clonidine in the mouse tail-flick assay, but did not potentiate the adverse
sedative effect of clonidine in the mouse locomotor activity assay, which could have
substantial clinical ramifications for the treatment of cancer-related pain.29,33
The potentiating effect could be due to different mechanisms; for example, the
low-dose potentiating effect might be caused by activation of 5-HT3 receptors, whereas
the high-dose potentiating effect might be due to action at one or more of the α2-ARs. In
fact, mechanistic studies suggest that the low-dose potentiation of clonidine by MD-354
may be due, at least in part, to a 5-HT3 receptor agonist mechanism.34 However, when
5-HT3 receptor antagonists (e.g., zacopride and tropisetron) were co-admininstered with
4

the clonidine/MD-354 (high dose) combination, neither potentiation nor attenuation of
the antinociceptive effect occurred, which indicates that the high-dose potentaion is
unlikely due to the 5-HT3 receptor character of MD-354.29 Due to MD-354’s binding
affinity at α2-ARs, various α2-ARs antagonists with different binding selectivity were
examined for their antinociceptive properties both alone and in combination with lowand high doses of MD-354 and clonidine. However, difficulty arises in such mechanistic
studies because of a lack of highly selective ligands at the three subtypes of α 2-ARs.
The mouse tail-flick assay results incorporating various α2-AR antagonists such as the
non-selective α2-AR antagonist yohimbine, the moderately selective α2B- and α2A-AR
antagonists imiloxan and BRL44408, respectively, in combination with clonidine suggest
that α2B-AR antagonists can potentiate the action of clonidine.31,33 In other words, if
MD-354 behaves as an α2B-AR antagonist, then it might be potentiating the
antinociceptive effect of clonidine (either the low-dose or high-dose peak) via an α2B-AR
antagonist mechanism of action.

Nevertheless, a possible α 2A- and/or α2C-AR

mechanism cannot be ruled out. When the abovementioned α 2-AR antagonists were
co-administered with the clonidine/MD-354 combination (low dose), attenuation of the
antinociceptive effect occurred.31 Because, by definition, antagonists block the effect of
agonists, these observations suggest an α2-AR agonist mechanism in the actions
associated with the potentiation of clonidine by a low dose of MD-354. Therefore, from
the

abovementioned

mechanistic

studies,

MD-354

seems

to

potentiate

the

antinociceptive actions of an inactive dose of clonidine, at least in part, via a 5-HT3
receptor and an α2-AR mechanism.
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Such results lead to the current project objectives.

The first main goal is to

determine the mechanism of action of the analgesia-potentiating effect of clonidine by
MD-354. In the present investigation, this mechanism of action will be evaluated by
studying the more established 5-HT3 receptor agonist meta-chlorophenylbiguanide, the
known centrally-acting 5-HT3 recpeptor agonist SR57227A, and the non-selective α2-AR
ligand TDIQ. Second, an objective of this study is to explore the conformationallyconstrained rotamers of MD-354 as such conformational constraint might enlighten the
manner in which MD-354 binds to 5-HT3 receptors. Furthermore, the role of the ring
nitrogen atoms and the chloro substituent in 5-HT3 receptor binding will be evaluated by
synthesizing conformationally-constrained analogs of MD-354 (analogs which lack one
or more nitrogen atoms or chloro substituents as compared to MD-354). Also, as MD354 has high binding affinity at all three subtypes of α2-ARs, docking studies of MD-354
at the low- and high-affinity states of α2A-, α2B- and α2C-AR homology models will be
performed in order to better explain the binding affinity and functional activity of MD354.
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II. Background

A. Current therapy for cancer pain

After heart disease, cancer is the most deadly disease among Americans. 1 In
2010, approximately 1.5 million new cancer cases were expected to be diagnosed in the
United States alone and 0.5 million Americans were expected to die from cancer. 1
Many cancer patients deal with various types of pain throughout their treatment
program. Statistical data suggest a high incidence of cancer-related pain in patients
specifically affecting 9 million people each year.35
Cancer-related pain is multifaceted; there are multiple types of pain with various
degrees of intensity and duration due to multiple sources. 2 Cancer pain is a result of:
(a) direct invasion of tumor into bones, soft tissue, nerves, tendons, or connective
tissue, (b) metastases, and/or (c) cancer-related treatments including surgery, radiation
and chemotherapy.2
The three main physiological types of pain associated with cancer are
nociceptive/somatic, visceral, and neuropathic pain, which are caused by the disease,
itself and by side effects of various cancer treatments.2 Nociceptive pain (similar to
somatic pain) is due to nociceptor activation, which results from tissue injury from
surgery or from the tumor, itself.2 Cancer patients may also develop pain that originates
from the organs within the abdomen, pelvis or thorax, which is comprehensively called
7

visceral pain.2

And, finally, neuropathic pain results from injury to the central or

peripheral nervous system and, specifically in cancer patients, it arises due to cancer
treatments such as surgery, radiation, and chemotherapy.2
In 1986, the WHO developed a three-step analgesic ladder that described
guidelines for the management of cancer pain. 3 The general guidelines describe steps
that progressively increase the strength of required analgesic agents.2-4 It suggests that
cancer patients dealing with pain start with nonopioid therapies such as NSAIDs or
acetaminophen (with or without adjuvant agents).2-4 If the pain persists or the intensity
increases, physicians are recommended to administer combination products, which
include weak opioid and nonopioid analgesics (e.g., acetaminophen or acetylsalicylic
acid plus codeine, hydrocodone, or oxycodone).2-4 And, finally, if pain continues to
persist, step 3 of the WHO cancer pain ladder proposes the use of stronger opioids
such as morphine.2-4

1. Nonopioid therapies

As suggested by the WHO guidelines for cancer pain therapy, the first line of
therapy

is

administration

of

nonopioids.2-4

Traditional

NSAIDs,

selective

cyclooxygenase type 2 (COX-2) inhibitors, and acetylsalicylic acid reduce inflammatory
pain by blocking prostanoid production.36 NSAIDs that nonspecifically inhibit both types
of cyclooxygenases (type 1 and 2) can cause renal and gastrointestinal side effects
including ulceration and bleeding.5,6 Even though selective COX-2 inhibitors are devoid
of this gastric side effect while maintaining analgesic properties, these agents have
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been recently shown to increase the risk of stroke and heart attack when administered
in high doses.5,6 Although NSAIDs have been found to effectively control cancer pain, 7
these side-effect concerns have resulted in product discontinuation or black box
warnings.5,6 Acetaminophen, which displays analgesic and antipyretic properties, is
also used for mild to moderate pain in cancer patients.2 The main concern with the
administration of high doses of acetaminophen is an increased risk of hepatotoxicity. 2

2. Opioid therapies

Based on the cancer pain step ladder developed by the WHO, various opioids
are added to the treatment starting in the second step. 2-4 Whether the agent is a full
agonist, partial agonist, or mixed agonist-antagonist, most opioid drugs act at mu opioid
receptors, but some are non-selective and, therefore, also bind to kappa and delta
opioid receptors.2 In addition to continued use of acetaminophen or acetylsalicylic acid,
mild opioids such as codeine, hydrocodone, or oxycodone are used in the second step
of cancer pain treatment.2 If pain persists after step 2, stronger opioids (e.g., morphine,
hydromorphone, fentanyl) replace the milder agents.2 Although these stronger opioid
agents are typically very effective as analgesics, physicians and patients have concerns
that opioids will result in physical dependence and tolerance. 7,8 Additional adverse
effects of opioids include respiratory depression, nausea, constipation, and sedation. 7
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3. Adjuvant therapies

Cancer pain is multifaceted; thus, it is difficult to control. Adjuvant analgesics are
drugs that were originally developed for a different indication; many of these agents
have no effect when administered alone, but enhance the antinociceptive properties of a
known analgesic.37 Adjuvant analgesics are a promising solution for individual patients
due to their particular symptoms of cancer-related pain and/or their sensitivity to certain
adverse effects.7

The main groups of adjuvant therapies for cancer pain are

corticosteroids (e.g., dexamethasone), antidepressants (e.g., tricyclic antidepressants),
and anticonvulsants (e.g., gabapentin).5-8 An additional adjuvant analgesic, clonidine,
which is an α2-AR agonist, is used to relieve severe cancer pain especially in
neuropathic pain.9

4. Pain pathways and pain control theories

In the mid-17th century, the reflex theory was developed by René Descartes in
an attempt to describe pain.38 The reflex theory stated that pain messages were sent
from pain receptors in the skin to pain centers in the brain through a specific pain
pathway.39 The reflex theory was used both for the pain pathway and the treatment of
pain for more than 300 years. It was thought that if the reflex theory was correct, then
alleviation of pain could result from disconnection of the pain pathway. 39 This theory
was not refuted until 1965 with Melzack and Wall’s gate theory.40 The gate theory
suggested that the dorsal horn of the spinal cord acts as a gate, which can open (or
10

close) to allow (or block) pain messages to travel to the brain and back to the site of
pain.40
Two pain pathways describe the chain of nerve fibers along which impulses can
travel: (a) afferent or ascending pathways transmit impulses from the periphery to the
brain and (b) efferent or descending pathways transmit impulses from the brain to the
spinal cord.16 In general, serotonergic and adrenergic neurons have been found to play
a role in the descending pathway of pain perception in the raphe nuclei and locus
coeruleus, respectively.41,42 These descending neurons transmit pain signals from the
brain into the dorsal horn where they display inhibitory actions that can hinder the
perception of pain stimuli.16

B. Adrenoceptors

1. Classification

Norepinephrine (1; NE; noradrenaline) and epinephrine (2; EPI; adrenaline)
(Figure 1) are endogenous neurotransmitters that produce various functional effects
such as hypotension, sedation, and analgesia via ARs.43 In 1948, Alquist proposed two
classes of ARs; α-ARs, which produce excitatory effects and β-ARs, which produce
inhibitory effects.44

About 25 years later, α-ARs were divided into α1- and α2-AR

subpopulations based on in vitro experiments that suggested α1-ARs were located postsynaptically, whereas α2-ARs were presynaptic receptors.45 Although this theory was
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later negated, the same nomenclature of α-ARs (α1- and α2-ARs) was subsequently
proposed due to the relative affinities of various agonists and antagonists. 46

HO

OH


NH2

HO

HO

OH


H
N

CH3

HO
Epinephrine (2)

Norepinephrine (1)

Figure 1.
Structures of adrenergic neurotransmitters: norepinephrine (1) and
epinephrine (2).

The α1- and α2-ARs were later differentiated into six subpopulations (α1A-, α1B-,
α1D-, α2A-, α2B-, and α2C-ARs) based on radioligand binding studies47,48 and molecular
cloning studies.48-51

Similar studies discovered subpopulations of the β-ARs and

eventually Bylund and co-workers54 identified a total of nine types of adrenoceptors by
molecular cloning and proposed the following nomenclature: α 1-, α2-, and β-ARs, that
were subdivided into α1A-, α1B-, α1D-, α2A-, α2B-, α2C-, β1-, β2-, and β3-AR subclasses
(Figure 2).

Figure 2. Classification of adrenoceptors.54
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There is a hole in the current adrenoceptor nomenclature because there is not an
α1C-AR subtype. This subtype was initially proposed but was later determined to be
incorrectly identified.53

2. α2-Adrenoceptors

a) Structure and distribution

All three subtypes of α2-ARs are members of the G protein-coupled receptor
(GPCR) family, which are integral membrane proteins structurally characterized by 7 αhelical transmembrane-spanning domains (TM1-TM7) connected by three intracellular
loops (IL1-IL3), three extracellular loops (EL1-EL3), an extracellular amino-terminal
domain, and an intracellular carboxyl-terminal domain (Figures 3 and 4)53 Interaction of
the receptor with an agonist supposedly induces a conformational change in the
receptor which allows it to associate with a G protein and this, in turn, initiates a
signaling cascade that produces an effect.43,53
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Figure 3. A generalized representation of the structure of a GPCR.

Figure 4. Extracellular view of the structure of GPCRs.

In the past decade, the structure and function of GPCRs have been studied
progressively due to an increase in the availability of crystal structure data of various
receptors such as bovine rhodopsin, human β2-AR, turkey β1-AR, and human A2A
adenosine receptors.55-59

There are two main mechanisms of GPCR activation, that

incorporate highly conserved residues amongst most GPCRs.
14

The ionic lock is

represented by an interaction between an arginine (R) residue in the conserved TM3
DRY motif and a negatively-charged residue (either D or E) in TM6 of bovine rhodopsin,
that seems to hold the intracellular ends of TM3 and TM6 together to, thereby, restrain
the receptor in an inactive state.55
constitutive activity of the receptor.60

The ionic lock has been associated with the
Although this locking mechanism has been

postulated for many GPCRs, there is evidence that it does not exist in all receptors
including turkey β1-ARs, human β2-ARs, human A2A adenosine receptors, and human
histamine H4 receptors.60
The rotameric switch, which is thought to be associated with the global toggle
switch, involves the highly conserved CWxP motif in TM6. 61 Although current crystal
structures do not show torsion angle changes of tryptophan (W), spectroscopic studies
suggest that the conserved W of the CWxP motif exchanges between rotameric states
(g+ and trans). This change in W’s rotameric state appears to be associated with a TM6
conformational change during activation.62,63 The active conformation of W can interact
with the aromatic ring of a highly conserved phenylalanine (F) moiety in TM5.

In

addition, it has been recently found that site-directed mutations at the conserved W
eliminates constitutive activity.64 Although there is no crystal structure of inactive or
active conformations of the α2-ARs, there is a relatively high homology between the
sequence of α2A/2B/2C-ARs and β2-ARs, as well as with other GPCRs, especially within
conserved residues and/or motifs.
Although the receptor densities of the three subtypes of α 2-ARs are dissimilar in
humans, all three α2-adrenoceptors are generally found throughout peripheral tissues
and in many neuronal populations within the central nervous system (CNS).65 Gene
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expression studies in rat brain show a high density of mRNA encoding α 2A-ARs in the
locus coeruleus,66 as well as in the brain stem, cerebral cortex, dorsal horn, and
hypothalamus.67 In addition to wide distribution throughout the CNS, α2A-AR mRNA has
been found both pre- and post-synaptically in rat brain.68

Though the other two

subtypes were found in lower expression levels compared to α2A-ARs throughout the
brain, mRNA encoding α2C-ARs was found mainly in the rat hippocampus, olfactory
system, dorsal horn, striatum, and cerebral cortex, while that for the α2B-ARs was mainly
expressed in the thalamus.66

b) Adrenoceptor agonists

1) Pharmacology and clinical relevance

NE (1) and EPI (2), both of which are endogenous adrenoceptor agonists, bind to
ARs and are believed to induce a conformational change in the receptor that leads to
activation of heterotrimeric GTP-binding proteins (G proteins). The specific intracellular
signal is dependent on the type of G protein associated with the receptor.69 Three of
the known signal transduction pathways of α2-AR agonists are: (a) activation of Gi
proteins, which leads to the inhibition of adenylyl cyclase, thereby inhibiting the
production of cyclic adenosine monophosphate, (b) suppression of voltage-activated
calcium channels, which decreases extracellular Ca2+ flow into target cells, via Go
proteins, and (c) stimulation of K+ channels via Gi proteins. 69
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Studies with genetically modified α2-AR knockout mice have provided insight on
subtype specific functions.17 For example, knockout mouse studies indicate that α2AARs are mainly implicated in adrenoceptor functions such as hypotension, sedation,
and analgesia, whereas α2B-ARs seem to play a role in NO-induced analgesia and saltinduced hypertension.18,70 Studies from knockout mice suggest that CNS effects, such
as locomotion and stress response, are due to the α2C-AR subtype.70,71

2) Structure-affinity relationships (SAFIRs)

The two main classes of α2-AR agonists are phenylethylamines and
imidazolines.70 The phenylethylamines, such as the endogenous agonists NE (1) and
EPI (2; Figure 1), in general, contain an aromatic ring and a two-carbon chain with a βhydroxy group and a terminal amine. R-Enantiomers are the eutomers and, therefore,
have greater affinity at α2-ARs than agents with the S-configuration of the β-OH group.53
Affinity at α2-ARs is maximal when the amine is N-methyl-substituted, but dramatically
decreases as the size of the N-substituent increases.53

For example, EPI (2) has

greater affinity than NE (1), but less than the β-AR-selective ligand isoproterenol (3;
Figure 1), where the N-substituent is an isopropyl group (Table 1).53

A methyl

substituent at the α-position (e.g., α-methylnorepinephrine, 4) is tolerated but not the
ethyl homolog (e.g., ethylnorepinephrine), which has diminished α-AR binding, thereby
producing a β-AR-selective ligand.53 The dihydroxy groups found in the endogenous
agonists (or other catechol-containing compounds) provide binding activity at all α- and
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β-AR subtypes, but if the p-OH group is removed β-AR affinity is abolished while α-AR
affinity is only reduced (e.g., phenylephrine; 5; Figure 5).53

HO
HO

OH
 H
N

CH3
CH3

Isoproterenol (3)

HO m

OH
 NH
2

β

α

CH3
HO p
Methylnorepinephrine (4)

HO

OH
 H
N

CH3

O
NH

O
Phenylephrine (5)

TDIQ (6)

Figure 5. Structures of representative adrenoceptor ligands from the phenylethylamine
class: the β-AR-selective ligand isoproterenol (3), the α-AR-selective ligand
methylnorepinephrine (4), the α-AR-selective ligand phenylephrine (5), and the α2-ARselective ligand TDIQ (6; Ki: α2A = 75, α2B = 97, α2C = 65 nM, which is nonselective
amongst the three α2A-adrenoceptors).53

Described structurally as a conformationally-restricted phenylalkylamine, TDIQ
(6; 5,6,7,8-tetrahydro-1,3-dioxolo[4,5-g]isoquinoline; Figure 5), synthesized in our
laboratory, is an agent that binds rather non-selectively at all three α2-AR subtypes (Ki:
α2A = 75, α2B = 97, and α2C = 65 nM), but possesses little affinity for other
neurotransmitter receptors.72 In fact, amongst 31 receptors and transporters examined,
TDIQ (6) only had modest affinity at two receptors (Ki: dopamine D3 = 1,440 nM and
serotonin 5-HT7 = 1,750 nM).72
The second class of α2-AR agonists is the imidazolines, that includes the FDAapproved antihypertensive and analgesic agent clonidine (7).73,74

Clonidine (7)

behaves as a partial agonist at all three α2-AR subtypes, but also shows some activity at
α1-ARs and imidazoline receptors.53,75 Extensive SAFIR studies indicate the following:
(a) binding affinity at α2-ARs decreases when the o-position is modified: Cl > Br > CF3
>> F, but is unaffected when modified to a methyl group, (b) clonidine-constrained
18

analogs indicate that the anti-periplanar orientation of the imidazoline/aromatic ring is
the preferred conformation of these ligands, (c) the aniline NH is not required for binding
affinity (e.g., oxymetazoline; 8), and (d) the guanidine moiety could be changed by
opening the imidazoline ring [e.g., guanabenz (9) and guanfacine (10)] without reducing
activity, but changing the binding affinities (Table 2).53,70,76

Table 1. Affinity of norepinephrine (1) at α2A-, α2B-, and α2C-ARs; radioligand binding
data ([3H]RX821002) are reported as Ki values (nM) at human cloned α2-ARs expressed
in Chinese hamster ovary (CHO) cells.76
Ki (nM)
Compound

α2A-AR

α2B-AR

α2C-AR

195

182

98

OH
HO



NH2

HO
(R)-Norepinephrine (1)
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Table 2. Binding profile of the imidazoline class of α2-AR agonists at α2A-, α2B-, and α2CARs; radioligand binding ([3H]RX821002) are reported as Ki values (nM) at human
cloned α2-ARs expressed in Chinese hamster ovary (CHO) cells.76
Ki (nM)
Compound

α2A-AR

α2B-AR

α2C-AR

16

36

59

3

>1,000

107

5

112

200

25

309

>1,000

HN
N
Cl

HN
Cl

Clonidine (7)
HN
N
CH3

H3C

H3C

CH
CH3 3

Oxymetazoline (8)

NH
NH2

HN
N
Cl

Cl
Guanabenz (9)
NH
NH2

HN
Cl

O
Cl
Guanfacine (10)
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Guanabenz (9) and guanfacine (10) are FDA-approved agents for the treatment
of hypertension and attention deficit hyperactivity disorder, respectively. 77,78 Both of
these agents display increased selectivity for α2-ARs over α1-ARs in comparison with
clonidine (7), but they still cause adverse effects such as hypotension, bradycardia, and
sedation.70

c) Adrenoceptor antagonists

1) Pharmacology and clinical relevance

By definition, α2-AR antagonists block the actions produced by α2-AR agonists,
which, in general, include activation of Gi/o proteins. Therefore, pharmacologically, α2AR antagonists have affinity but no efficacy at α2-ARs. Antagonists can either bind at
the orthosteric site (i.e., the binding site for the endogenous agonist – norepinephrine)
or an allosteric site; these agents will directly or indirectly inhibit agonist binding,
respectively.

2) Structure-affinity relationships (SAFIRs)

There is a wide variety of structural diversity amongst α2-AR antagonists, but
these agents display little selectivity amongst the three α2-AR subtypes. On one hand,
these antagonists can be, structurally, much larger than the typical agonist, while, on
the other hand, they can be analogous to the structure of an agonist with only a minor
21

chemical modification.70

Their lack of selectivity limits their ability to function as

pharmacological tools, which is one of the reasons that the biological function of each
subtype is unclear.
The most common non-selective α2-AR antagonist is yohimbine (11; Figure 6),
an alkaloid derived from Pausinystlia yohimbe bark and Rauwolfia root.53 Yohimbine
(11) was historically used as an aphrodisiac in Africa. 79 It is now used for the treatment
of erectile dysfunction, but its efficacy has not been adequately confirmed and,
therefore, it is not commonly used.79 The main therapeutic uses of α2-AR antagonists
revolve around the treatment of depression and diabetes.70,80 Yohimbine (11) has a
high affinity for α2-ARs (Figure 6), but also has moderate affinity and antagonistic
behavior at α1-ARs (Ki: α1A = 200, α1B = 158, and α1D = 158 nM), 5-HT1A (Ki = 50 nM), 5HT1D (Ki = 25 nM), and dopamine D2 (Ki = 398 nM) receptors.53,81
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1,336 nM
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005.68 nM
651 nM
150 nM

Figure 6. Structures of α2-AR antagonists; α2A/2B/2C-AR binding affinity reported as Ki
values (nM).31,53,70,81,82
Due to yohimbine’s (11) non-selective binding profile, other α2-AR antagonists
have been developed as pharmacological tools such as imiloxan (12) and phentolamine
(13; Figure 6).31,70,81 Recently, there have been some small improvements on receptor
subtype selectivity. For example, ARC-239 (14) displays 50-fold selectivity for α2B/2Cover α2A-AR, while BRL44408 (15) has selectivity for α2A-ARs amongst the three α2-AR
subtypes (Figure 6).82
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d) Binding mode of α2-adrenoceptor agonists

The Easson-Stedman hypothesis83,84 suggests a three-point interaction between
adrenoceptors and catecholamines [e.g., NE (1) and EPI (2)]:

(a)

the protonated

aliphatic amine, (b) the catecholic hydroxyl groups, and (c) the β-hydroxyl group. The
introduction of a chiral center at the β-position of these ligands extended the hypothesis
to suggest the following relative potencies: R(-) > S(+) = desoxy, which was later
verified by their binding affinities at all α-ARs.83,84
Molecular modeling studies, in some cases combined with site-directed
mutagenesis data, support the Easson-Stedman hypothesis. These studies predicted
the following interactions between α2-ARs and catecholamines: (a) an ionic interaction
between the highly conserved D3.32 aspartate moiety and the charged nitrogen atom of
the catecholamine, (b) a hydrogen bond interaction between two serines (S5.42 and
S5.46) and the meta- and para-hydroxyl groups of the catecholamine, respectively, and
(c) a possible hydrogen bond interaction between either S2.61 or Y6.55 and the βhydroxyl group.70,85,86 These amino acid residues are common in all three subtypes of
α2-ARs.
The numbering of the amino acid residues is based on Ballesteros-Weinstein
nomenclature.87 Each transmembrane amino acid is assigned two numbers separated
by a period: the first number corresponds to the transmembrane number (TM1-7) and
the second number corresponds to the distance from the most highly conserved residue
in each transmembrane amongst all GPCRs.87 This highly conserved amino acid is
arbitrarily given a value of 50 and any amino acid in the same transmembrane segment
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that is closer to the carboxy-terminus is given a value >50, while those amino acids that
are closer to the amino-terminus are given a value of <50.87 For example, the amino
acid D3.32 is an aspartate residue located in TM3 and is 17 amino acids closer to the
amino-terminus in comparison to the most highly conserved amino acid of all GPCRs in
TM3 (3.50).

e) Descending control of pain

Behavioral,

neurochemical,

and

electrophysiological

studies

indicate

an

adrenoceptor role in antinociception via spinal administration of NE (1) or electrical
stimulation of cerebral AR cell nuclei.10-15 There is overwhelming evidence of postsynaptic mechanisms involved in the analgesic properties of NE (1) and only preliminary
and less-compelling data to suggest a pre-synaptic mechanism.12,88 In addition, NE (1)
affects the descending pathway associated with the serotonergic pathway from the
nucleus raphae magnus to the dorsal horn.16 The nucleus raphae magnus contains a
high concentration of pre- and post-synaptic, inhibitory α2-ARs.16
The descending pathway is influenced by NE (1), which is receptor-dependent
and affects the nociceptive threshold.16 As for the α2A-AR subtype, density and
distribution in the dorsal horn seem to correlate with its role in antinociception.67 An α2AAR role in analgesia is supported by systemic and spinal administration of selective α 2AAR agonists and antagonists as well as by studies using α2A-AR knockout mice.16-18
There are some data that suggest an antinociceptive role for α 2B- and α2C-ARs in
the descending pathway, but these are unclear; lack of α 2-AR subtype-selective agents
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magnifies this ambiguous hypothesis. For example, α 2B-AR knockout mice failed to
exhibit antinociceptive effects to nitrous oxide (N2O), a known anesthetic and analgesic
agent.89 Unfortunately, this is difficult to explain neurochemically because of the density
and distribution of α2B-ARs (e.g., low concentration of α2B-ARs in the spinal cord).66 On
the other hand, α2C-ARs seem to play a pro-nociceptive role in the dorsal horn via
excitatory effects of the descending noradrenergic pathway, but just like the α 2B-ARs,
the α2C-AR subtype is poorly expressed in the human dorsal horn.12

C. Serotonin receptors

1. Classification

Serotonin (5-hydroxytryptamine or 5-HT; 16, Figure 7) is a monoamine
neurotransmitter that has been implicated in various disease states such as depression,
anxiety, migraine, pain, and schizophrenia.90 Serotonin (16) binds to 5-HT receptors,
which are all GPCRs except for the ligand-gated ion channel (LGIC) 5-HT3 receptors.90
Theories have been proposed and modified throughout the long history since the
discovery of serotonin receptors, which have, in turn, often enhanced 5-HT receptor
nomenclature.91
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NH2
HO
N
H
Serotonin (16)

Figure 7. Structure of the neurotransmitter serotonin (16).

The criteria for the classification of 5-HT receptors began with functional data
only, but over time it became more robust with additional experimental evidence
including operational, structural, and transductional verification.92 For example, 5-HT1C
receptors were later renamed 5-HT2C receptors due to their high sequence homology
with other 5-HT2 receptors and their common phosphoinositol second messenger
system as opposed to the adenylate cyclase second messenger system associated with
5-HT1 receptors.90,93

The second messenger systems of the serotonin receptors

include coupling to adenylate cylcase (AC) or phospholipase C (PLC); this is
summarized in Table 3.
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Table 3. Summary of the second messenger systems involved in 5-HT receptor
transduction.94,95
Receptor subpopulation
5-HT1A
5-HT1B
5-HT1D
5-ht1e
5-HT1F
5-HT2A
5-HT2B
5-HT2C
5-HT3A
5-HT3AB
5-HT4
5-ht5a
5-HT6
5-HT7

Transducer
Gi/Go
Gi/Go
Gi/Go
Gi/Go
Gi/Go
Gi/Go, Gq/G11
Gq/G11
Gi/Go, Gq/G11
N/A
N/A
Gs
Gi/Go, Gq/G11
Gs, Gq/G11
Gs

Effector
AC inhibition
AC inhibition
AC inhibition
AC inhibition
AC inhibition
AC inhibition, PLC stimulation
PLC stimulation
AC inhibition, PLC stimulation
Cation channel
Cation channel
AC stimulation
AC inhibition, PLC stimulation
AC stimulation, PLC stimulation
AC stimulation

The Nomenclature Committee of the International Union of Pharmacology
currently classifies 5-HT receptors as: 5-HT1A, 5-HT1B, 5-HT1D, 5-ht1e, 5-HT1F, 5-HT2A, 5HT2B, 5-HT2C, 5-HT3A, 5-HT3AB, 5-HT4, 5-ht5a, 5-HT6, and 5-HT7.94,95 This receptor
classification was based on the following criteria: operational or drug-binding
characteristics, transductional or receptor-effector coupling, and structural or nucleotide/
amino acid sequence of the gene/receptor.90,93

Lower case receptor nomenclature

(e.g., 5-ht1e and 5-ht5a) is used until all the receptor population criteria have been met. 93
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2. 5-HT3 receptors

a) Structure and distribution

In contrast to the other G protein-coupled serotonin receptors, 5-HT3 receptors
are LGIC receptors. These receptors are cation-selective and part of the Cys-loop
superfamily of LGICs, which include similar proteins such as nicotinic acetylcholine and
gamma-aminobutyric acid (GABAA/C) receptors.96 5-HT3 receptors are composed of 5
subunits (pentamers) that surround a central core that forms an ion channel (Figure
8).97 Each subunit is composed of a large extracellular amine terminus, four
transmembrane-spanning domains (M1-M4) connected by intracellular and extracellular
loops, and an extracellular carboxyl terminus (Figure 8a).97 The M2 transmembrane
domain lines the ion channel (Figure 8b).97
Five human 5-HT3 receptor subunits have been cloned and termed 5-HT3A, 5HT3B, 5-HT3C, 5-HT3D, and 5-HT3E subunits, but current data suggest that a 5-HT3A
subunit is required for receptor function.96 5-HT3A, but not 5-HT3B, subunits have been
shown to assemble into functional homopentamers via expression in Xenopus laevis
oocytes.21,97-99 Co-expression of 5-HT3A and 5-HT3B subunits provides evidence for a
functional heteromeric receptor97-100 and atomic-force microscopy studies indicate that
the 5-HT3AB receptor has two 5-HT3A and three 5-HT3B subunits in the following
subunit arrangement: B-B-A-B-A.101 To date, the role of the 5-HT3C, 5-HT3D, and 5HT3E subunits in receptor function is unclear.
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Although the two known functional 5-HT3 receptors (5-HT3A and 5-HT3AB) seem
to be very similar; there is a slight difference in ion selectivity. Both receptors have
monovalent cation permeability (e.g., Na+ and K+) and negligible anion permeability,
whereas the homomeric 5-HT3A receptors are also permeable to divalent cations such
as Ca2+.97,102-104 This difference in cation selectivity seems to be due to differences in
transmembrane M2 residues that line the channel.103
(a)

(b)

Figure 8. Representation of the structure of ligand-gated ion channels: (a) receptor
subunit containing four transmembrane spanning helices and (b) a pentameric structure
of the receptor with M2 (shaded) lining the ion channel.97
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Although 5-HT3 receptors (originally referred to as 5-HT-M receptors due to their
sensitivity to morphine) were first found in the peripheral nervous system, their highest
densities are in the CNS.105,106 Within the CNS, autoradiographical studies indicate
highest levels in the brainstem including the area postrema, the dorsal motor nucleus of
the vagus nerve, and the nucleus tractus solitarius and lower levels in the forebrain. 107109

and

In addition to their various CNS distribution, 5-HT3 receptors can be found both prepost-synaptically.105

Presynaptic

5-HT3

receptors

seem

to

modulate

neurotransmitter (e.g., dopamine, GABA, and acetylcholine) release following Ca2+
influx.105

b) 5-HT3 receptor agonists

There are various types of chemical structures that bind to 5-HT3 receptors and
that behave as partial or full agonists. The endogenous neurotransmitter, 5-HT (16),
binds in a non-selective manner to human 5-HT3 receptors with modest affinity (Ki =
1,000 nM) and, although its 2-methyl analog (i.e., 17, 2-methyl-5-HT) has slightly lower
affinity (Ki = 1,300 nM) and reduced agonistic activity, it has increased selectivity for 5HT3 receptors (Figure 9).110,111 Due to its greater selectivity, 2-methyl-5-HT (17) was
used in early 5-HT3 receptor research, but, unfortunately, more recently it has been
found to also bind to 5-HT6 receptors.112 Another analog of 5-HT (16), N,N,N-trimethyl5-HT (18; 5-HTQ), was found to have greater selectivity and affinity at 5-HT3 receptors
in comparison to 5-HT (16), but systemic administration of the quaternary amine 18
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might not readily penetrate the blood-brain barrier (BBB) minimizing its central effect
(Figure 9).111
(a)
NH2
HO

Ki: 5-HT3

HO
N
H
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H3C CH3
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35 nM

Figure 9. Structures of 5-HT3 receptor agonists: (a) serotonin (16) and analogs (17, 18)
and (b) arylbiguanides (19, 20) and an arylguanidine (21); 5-HT3 receptor binding
affinity is reported as Ki values (nM).110,111,113

Structurally different than 5-HT (16), phenylbiguanide (19, PBG) has modest 5HT3 receptor affinity (Ki = 1,000 nM) and behaves as an agonist (Figure 9).111 Structural
modifications of 19 have led to many agonists with greater affinity. For example, the
meta-chloro analog (20, mCPBG) has 60-fold increased affinity at human 5-HT3
receptors (Ki = 17 nM; Figure 9).111 Aryl substitution of 19 with chloro group(s) at
various positions (e.g., 2-chloro-PBG and 3,4,5-trichloro-PBG) showed decreased Ki
values to the low nanomolar range in comparison to PBG (19).32,114
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Affinity was

retained when the biguanide moiety of mCPBG (20) was deconstructed to a guanidine
as in meta-chlorophenylguanidine (21, mCPG, MD-354; Ki = 35 nM; Figure 9).111,113
Just like the arylbiguanides, the arylguanidines have improved affinity with the addition
of chloro groups to the phenyl ring.111,113
SR57227A (22; 1-(6-chloropyrid-2-yl)-4-piperidinylamine; Figure 10) is a selective
5-HT3 receptor agonist (Ki = 103 nM), which can penetrate the BBB.115 This agent (i.e.,
22) has been found to behave as an agonist both at central and peripheral 5-HT3
receptors, which makes it a powerful pharmacological tool for detection of CNS effects
mediated by 5-HT3 receptors.115

NH2
Cl

Ki: 5-HT3

N

N

SR57227A (22)
103 nM

Figure 10. Structure of the 5-HT3 receptor agonist SR57227A (22); 5-HT3 receptor
binding affinity reported as a Ki value (nM).115

Although there are no current high-resolution structural data for the 5-HT3
receptor, homology models have been generated based on the similar acetylcholine
binding protein crystal structure.116-118 In addition to these 5-HT3 receptor homology
models, site-directed mutagenesis studies indicate an agonist and, therefore, a
competitive antagonist, extracellular binding site at the interface of two subunits of the
5-HT3 receptor.119,120
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c) 5-HT3 receptor antagonists

Various 5-HT3 receptor antagonists such as ondansetron (23; trade name:
Zofran; Figure 11) and granisetron (trade name: Kytril) are used clinically to treat
chemotherapy-induced nausea and vomiting.121 Also, zacopride (24; Figure 11), a 5HT3 receptor antagonist and 5-HT4 receptor agonist, has been shown to be a useful
antiemetic agent for cancer patients.121 In addition, preliminary results suggest that 5HT3 receptor antagonists influence the reward pathway (e.g., they reduce drug-induced
self-administration of drugs such as ethanol or amphetamine), regulate food intake,
produce anxiolytic effects, and attenuate chronic neuropathic pain.91,121
Antagonists at 5-HT3 receptors were first discovered by modifying the chemical
structure of cocaine, which was found to be a weak antagonist at 5-HT-M
receptors.90,122

Modifications led to the first selective 5-HT3 receptor antagonists,

bemesetron (MDL 72222) and tropisetron (25; Figure 11).90,123,124 In fact, the centrally
acting 5-HT3 receptor antagonist, tropisetron (25; Figure 11), has become a valuable
pharmacological tool because its quaternary amine analog, tropisetron methiodide,
retains 5-HT3 receptor antagonist activity but only at peripheral receptors due to its
inability to cross the BBB.113 Numerous similar compounds, which were classified as
keto compounds, were synthesized. This class typically contains a carbonyl-containing
linker between an aromatic/heteroaromatic ring and a basic amine. 91,124 Most of these
ligands are selective for 5-HT3 receptors, but some have affinity at 5-HT1P and/or 5-HT4
receptors.91
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Figure 11. Structures of some representative 5-HT3 receptor antagonists (23-25); 5HT3 receptor binding affinity reported as Ki values (nM).125,126

In general, the basic aliphatic amine can tolerate small substituents; specifically,
a methyl substituent is optimal as in tropisetron (25).91,124 Binding affinity at 5-HT3
receptors seems to be favorable when the aromatic/heteroaromatic ring is a fused 6,5ring system (e.g., an indole in 23 and 25).91,124 Also, the carbonyl group is typically
coplanar with the aromatic system.91,124 Extensive structure-affinity relationships of 5HT3 receptor antagonists have provided selective and high-affinity ligands.90,91

d) Descending control of pain

Serotonin receptors seem to modulate mechanisms of descending inhibition and
descending facilitation in the dorsal horn.16 Serotonergic input is involved with primary
afferent fibers, projection neurons, and inhibitory interneurons and, therefore, 5-HT (16)
is associated with conveying information from tissues and organs into the CNS and
transmitting signals from the CNS to the effector cells.16
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It was first thought that 5-HT (16) reduced nociceptive transmission in the dorsal
horn, but there is a plethora of contradicting studies.19

Various studies such as

electrical brain stimulation, morphine-induced antinociception, and direct administration
of 5-HT (16) into the spinal cord suggest that descending serotonergic pathways exert
opposing nociceptive processing effects in the dorsal horn: modulation of descending
and facilitating inhibitory pathways.19,20

This leads to both pronociceptive and

antinociceptive actions; there are two possible reasons for these contradictory actions
from one neurotransmitter. Varying effects could be due to: (a) the multiple subtypes of
5-HT receptors (i.e., it is the receptor, rather than the neurotransmitter, that is
responsible for the excitatory or inhibitory action) and/or (b) the localization of specific 5HT receptors.
Focusing on the 5-HT3 receptor subtype, most of the current data indicate an
excitatory role in neuronal activity. Upon activation of 5-HT3 receptors, phospholipase C
activity is enhanced which, in turn, causes a cytosolic calcium influx leading to a
cascade of intracellular changes and activity.21-24 In conjunction with behavioral studies
suggesting a pronociceptive role of 5-HT3 receptors, it has been reported that they
potentiate the release of the pronociceptive transmitter substance P in the dorsal
horn.20,24

In addition to an unclear mechanism, there are some contradictory data

suggesting a suppression in substance P release.16 Although, to date, it is clear that
more research is necessary to fully understand 5-HT3 receptors’ role in the descending
control of pain, it is possible that the ambiguous data are due to incomplete
characterization of 5-HT3 receptors (e.g., 5-HT3A vs. 5-HT3AB receptors).
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Previously reported in vivo studies present contradictory analgesic effects of 5HT3 receptor agents in nociceptive animal studies (summarized in Table 4). Similar to
the pharmacological profile of various 5-HT3 receptor antagonists, 5-HT3 receptor
agonists can display anti- or pronociceptive effects. This might be due to the species,
the animal model, or the route of drug administration. For example, the analgesic action
of PBG (19) seems to be dependent on the nociceptive animal model; PBG (19, i.t.)
produces an antinociceptive effect in the rat hot-plate assay, whereas it shows salinelike effects in the rat tail-flick assay.25 Likewise, the more potent 5-HT3 receptor agonist
mCPBG (20; i.t.) displayed analgesic effects in the rat formalin and paw pressure assay,
but no effect was observed in the rat tail-flick assay.26,127,128 Different analgesic effects
observed in the tail-flick assay are seemingly due to species; 5-HT3 receptor agonists
produce saline-like effects in the rat tail-flick assay, but show antinociceptive effects in
the mouse model.25-28
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Table 4. Summary of the analgesic activity of 5-HT3 receptor ligands in nociceptive
animal models (routes of administrations: i.t., intrathecal; i.p., intraperitoneal; s.c.,
subcutaneous; i.c.v, intracerebroventricular).
Animal
Model

Agonist or
antagonist

Species

Admin
route

mCPBG
PBG
2-Me-5-HT

agonist
agonist
agonist

rat
rat
mouse

i.t.
i.t.
i.t.

SR57227A

agonist

mouse

i.p.

tropisetron

antagonist

rat
rat
mouse

zacopride

antagonist

ondansetron

Hot-plate

Paw
pressure

Tail-flick

Agent

Ref
26
25
28

i.t.
s.c.
s.c.

no
no
yes, blocked by
tropisetron &
zacopride
yes, blocked by
bemesetron &
zacopride
no
no
no

rat
mouse
mouse

i.t.
i.p.
s.c.

no
no
no

30
29
29

antagonist

mouse
mouse

s.c.
s.c.

no

29

PBG
2-Me-5-HT
tropisetron
ondansetron

agonist
agonist
antagonist
antagonist

rat
rat
rat
rat

i.t.
i.t.
s.c.
i.t.

yes
yes
no
no

25
130
129
129

5-HT

agonist

rat

i.t.

yes, blocked by
granisetron &
tropisetron

127,
128

2-Me-5-HT
mCPBG

agonist
agonist

rat
rat

i.t.
i.c.v.
i.t.

no
no blocked by
yes,
tropisetron &
granisetron

128
128
127,
128,
131

i.p.
i.t.
i.p.
i.t.
i.t.

yes
no
yes
no
no

132
127,128,
131
132

i.t.
s.c.
i.t.

yes
yes
no

133
129
129,133

granisetron

antagonist

rat
rat
rat
rat
rat

mCPBG
tropisetron
ondansetron

agonist
antagonist
antagonist

rat
rat
rat

tropisetron
ondansetron

Formalin

Analgesic
activity

antagonist
antagonist
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27

26
129
29

131
128,131

In general, administration of 5-HT3 receptor antagonists produces saline-like
effects in antinociceptive animal models, but there are some exceptions. For example,
s.c. administration of tropisetron (25) showed analgesic actions in the rat formalin
test.129 Also, ondansetron (23) showed antinociceptive effects upon i.p. administration
in a mechanical nociceptive animal model (rat paw pressure assay). 132 Thus far, these
contradictory observations are inadequately understood.

D. MD-354 (21)

1. Binding affinity

The 5-HT3 receptor ligand MD-354 (21) was identified in our laboratory in 1996. 32
Radioligand binding assays at 30 different aminergic receptors indicated that MD-354
(21) possesses a rather selective binding profile. The receptors for which MD-354 (21)
displays high affinity include the ligand-gated ion channel serotonin 5-HT3 receptors
(Table 5).32 Subsequently, MD-354 (21) was found to bind to the low- and high-affinity
states of the G protein-coupled α2-adrenoceptors as determined using the antagonist
radioligand ([ethyl-3H]RS-79948-197) and the agonist radioligand ([125I]clonidine),
respectively (Table 5).31,33 It is thought that radiolabeled agonists label the high-affinity
state of the receptor, whereas radiolabeled antagonists label both high- and low-affinity
states of the receptor.134
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Table 5. MD-354 (21) binding profile.31-33
Receptor population

Ki (nM)

5-HT3

35a

α2A-ARs

110b, 825c

α2B-ARs

220b, 25c

α2C-ARs

4,700b, 140c

Radioligands used in binding assays: a[3H]GR65630 (a 5-HT3 receptor antagonist),
b
[ethyl-3H]RS-79948-197 (an adrenoceptor antagonist) and c[125I]clonidine (an
adrenoceptor agonist).

Additionally, MD-354 (21) has very modest affinity for 5-HT1A (Ki = 4,100 nM), 5HT5A (Ki = 4,160 nM), and 5-HT7 (Ki = 680 nM) receptors as well as α1A- (Ki = 300 nM)
and α1B- (Ki = 1,900 nM) ARs, but no affinity (i.e., Ki > 10,000 nM) at the remaining
serotonin receptor and adrenoceptor subtypes, dopamine D1-D5 receptors, mu and
kappa opioid receptors, m1-m5 muscarinic receptors, rat H1 histamine receptors,
phencyclidine receptors, NMDA receptors, benzodiazepine receptors, and the aminergic
transporters (serotonin, dopamine, and norepinephrine).33

2. In vitro functional activity

Functional [35S]GTPγS assays were performed with two types of buffer
conditions: low and high concentrations of NaCl. Experimental conditions with low salt
concentrations have been found optimal for the detection of partial agonist activity. 134
As concluded by these assays, MD-354 (21) behaves as a weak partial agonist at α2A40

ARs in low and high salt conditions (EC50 = 0.83 and 1.4 μM, respectively).31 At high
concentrations (>100 μM), MD-354 (21) nonselectively antagonized the agonist effect of
norepinephrine (1; NE) at all three receptor subtypes.31

3. In vivo functional activity

a) MD-354 (21) administered alone

Numerous in vivo pharmacological studies involving 5-HT3 receptor agents, such
as MD-354 (21), have been reported. Initial MD-354 (21) functional studies included the
rat von Bezold-Jarisch assay, which examined reflex bradycardia, and the rabbit
bladder assay.32 Although MD-354 (21) behaved as an agonist in both of these assays,
it showed reduced potency in comparison to the biguanide analog mCPBG (20).32 Low
doses (e.g., 10 mg/kg, i.p.) of MD-354 (21) also were shown to reduce cisplatin-induced
emesis, whereas higher doses (40 mg/kg, i.p.) elicited an emetic effect in the shrew. 113
MD-354 (21) has been used as a training drug in drug discrimination studies. The
discriminative stimulus effects of MD-354 (21) in rats (training dose = 2.0 mg/kg) seems
to be a central 5-HT3 receptor-mediated effect because it is usually only centrally-acting
agents that serve as discriminative stimuli, and because the stimulus effects of MD-354
(21) were antagonized by the 5-HT3 receptor antagonists zacopride (24) and tropisetron
(25), but not by tropisetron methiodide.113,135 This quaternary analog (tropisetron
methiodide) retains the antagonist properties of tropisetron (25) but is not able to readily
cross the BBB.113,135
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Since 5-HT3 receptors and α2-ARs both have been implicated in pain, MD-354
(21) was examined in mouse tail-flick and hot-plate assays. In the mouse tail-flick
assay, MD-354 (21; doses: 1.0-30 mg/kg, s.c.) showed saline-like effects using various
pretreatment times.33 Similarly, MD-354 (21) failed to produce a statistically significant
antinociceptive effect (in comparison to saline control) at various doses (3.0-30 mg/kg,
s.c.) and pretreatment times in the mouse hot-plate assay.33

And, finally, the

spontaneous activity of MD-354 (21) was examined and MD-354 (21) was found to
produce saline-like effects in mice indicating it is neither a CNS stimulant nor a CNS
depressant.31,33,135

Another possible conclusion is that MD-354 (21) is unable to

penetrate the BBB to produce its effect(s).

b) MD-354 (21) administered in combination with clonidine (7)

Although MD-354 (21; 1.0-30 mg/kg) produced no analgesic effects when
administered alone, it potentiated the antinociceptive effect of an “inactive” dose of
clonidine (7) in the mouse tail-flick assay [MD-354 (21) doses 1.0-30 mg/kg], but didn’t
significantly potentiate or attenuate the effect of clonidine (7) in the mouse hot-plate
assay [MD-354 (21) doses 10-30 mg/kg].33 Moreover, in the mouse tail-flick assay the
analgesic effect of the MD-354/clonidine (21/7) combination appeared to be biphasic
(Figure 12).34 The antinociceptive properties of clonidine (7) were potentiated by MD354 (21) as depicted by both peaks [Peaks A and B at 1.0 and 10 mg/kg doses of MD354 (21), respectively] of the biphasic dose-response curve (Figure 12). The
potentiating effect of MD-354 (21) in combination with clonidine (7) illustrated by Peaks
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A and B could be due to different mechanisms such as: (a) 5-HT3 receptor agonism or
antagonism, (b) action at one or more α2-ARs (α2A-, α2B-, and/or α2C-ARs), or (c) action
at neither 5-HT3 receptors nor α2-ARs.34

Alternatively, the biphasic actions of the

combination might be due to a combination of these mechanisms. For example, the lowdose potentiating effect (i.e., effect illustrated by Peak A) might be caused by activation
of 5-HT3 receptors, whereas the potentiating effect produced by a higher dose of MD354 (21; 10 mg/kg; Peak B) might be due to action at one or more of the α 2-ARs (α2A-,
α2B-, and/or α2C-ARs).34
Peak B
100
Peak A

*

80

% MPE

**

60

40

20

0
0.3

1.0

10.0

30.0

MD-354 Dose (mg/kg)
MD-354 doses + Clonidine 0.25 mg/kg
Clonidine 0.25 mg/kg

Figure 12. Potentiation of the antinociceptive effect (± S.E.M.) of an “inactive”
antinocicpetive dose of clonidine (7; 0.25 mg/kg) by MD-354 (21; 0.3-30 mg/kg) in the
mouse tail-flick assay. Asterisks denote a significant difference compared to the control
group [clonidine (7) 0.25 mg/kg]; *P < 0.05, **P < 0.01, one-way ANOVA followed by
Dunnett’s post hoc test. 34
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The role of 5-HT3 receptors in the potentiation of clonidine (7)-induced
antinociception by MD-354 (21) depicted by Peaks A and B (Figure 12). Since MD-354
(21) is a 5-HT3 receptor partial agonist, it is possible that its potentiating effect on
clonidine (7) antinociception is due to either 5-HT3 receptor agonism or antagonism.
The role of 5-HT3 receptors in the potentiation of clonidine (7) antinociception by a lowand high dose of MD-354 (21) illustrated by Peaks A and B (Figure 12), respectively,
was examined by co-administration of 5-HT3 receptor antagonists with: (a) clonidine (7)
alone and (b) the combination of MD-354 (21; 1.0 or 6.0 mg/kg) and clonidine (7; 0.25
mg/kg).
When administered alone via the s.c. route, three 5-HT3 receptor antagonists
[ondansetron (23; 0.02-2.0 mg/kg), zacopride (24; 0.0001-2.0 mg/kg), and tropisetron
(25; 0.0001-1.0 mg/kg)] showed saline-like effects in the mouse tail-flick assay, but
significantly potentiated the antinociceptive effect of an “inactive” dose of clonidine (7;
0.25 mg/kg).29 This potentiating effect suggests that blockade of 5-HT3 receptors can
augment the analgesic properties of clonidine (7). Therefore, it is possible that 5-HT3
receptor antagonism could be implicated in the mechanism underlying Peak A and/or B.
Tropisetron (25) attenuated the antinociceptive effect observed in Peak A [i.e.,
the effect produced by the co-administration of MD-354 (21; 1.0 mg/kg) and clonidine
(7; 0.25 mg/kg].34 This observation supports a 5-HT3 receptor agonist mechanism for
MD-354 (21) in Peak A.
The role of 5-HT3 receptors in Peak B was examined by mechanistic studies
involving 5-HT3 receptor antagonists.

For example, the 5-HT3 receptor antagonist

zacopride (24) failed to potentiate the antinociceptive effect of MD-354 (21) in the
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mouse tail-flick assay; that is, co-administration of zacopride (24) and MD-354 (21)
produced saline-like effects.29 Also, the potentiation of clonidine (7; 0.25 mg/kg) by a
high dose of MD-354 (21; 6.0 mg/kg) was neither potentiated nor attenuated by
zacopride (24). 29,33 This suggests that the effect represented by Peak B is not due to 5HT3 receptor agonist action.
Additional mechanistic studies were conducted. In the mouse tail-flick assay, the
more selective 5-HT3 receptor antagonist tropisetron (25; 0.0001-1.0 mg/kg) in
comparison to zacopride (24; acts at both 5-HT3 and 5-HT4 receptors) was also found to
neither potentiate nor attenuate the antinociceptive effect of the MD-354/clonidine (21/7)
combination when a high dose of MD-354 (21; 6 mg/kg) was administered.29 These
combined results indicated a 5-HT3 receptor agonist mechanism associated with Peak
A only.
It seems rather unlikely that the potentiating effect associated with Peak B is due
to the 5-HT3 receptor agonist character of MD-354 (21) because two structurally diverse
5-HT3 receptor antagonists [zacopride (24) and tropisetron (25)] failed to block the
antinociceptive effect of the MD-354/clonidine (21/7) combination (Peak B).29
Alternatively, it is possible that the potentiation of the antinociceptive effect of clonidine
(7) by a high dose (6.0 mg/kg) of MD-354 (21) might be due to 5-HT3 receptor
antagonism.

This hypothesis was supported by the potentiating action of 5-HT3

receptor antagonists [e.g., zacopride (24), tropisetron (25), and ondansetron (23)] coadministered with clonidine (7) in the mouse tail-flick assay.29
The role of α2-ARs in the potentiation of clonidine (7)-induced antinociception by
MD-354 (21) depicted by Peaks A and B (Figure 12). Various α2-AR antagonists with
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different binding selectivity were examined for their antinociceptive properties both
alone and in combination with low and high doses (1.0 or 6.0 mg/kg, respectively) of
MD-354 (21) and 0.25 mg/kg of clonidine (7). One difficulty in mechanistic studies
involving the three subtypes of α2-ARs is the lack of highly selective ligands. Only
preferentially adrenoceptor-selective antagonists are known; for example, imiloxan (12)
and BRL44408 (15) have modest selectivity at α2B- and α2A-ARs, respectively (see
Figure 6 for α2-AR binding affinities). 82,136,137
The non-selective α2-AR antagonist yohimbine (11; 0.1-1.0 mg/kg) and the
moderately selective α2B- and α2A-AR antagonists imiloxan (12; 0.1-1.0 mg/kg) and
BRL44408 (15; 0.3-10 mg/kg), respectively, showed no antinociceptive effects when
administered alone.31,33

Yohimbine (11) and BRL44408 (15) failed to affect the

analgesic properties of an “inactive” dose of clonidine (7; 0.25 mg/kg); that is, the coadministration of yohimbine (11) and clonidine (7), as well as BRL44408 (15) and
clonidine (7), produced saline-like effects in the tail-flick assay.31 Conversely, imiloxan
(12; 0.1-3.0 mg/kg) significantly potentiated the antinociceptive effect of a saline-like
dose of clonidine (7; 0.25 mg/kg).31 Although this does not rule out a possible α 2A- or
α2C-AR mechanism, the results obtained with imiloxan (12) suggest that α2B-AR
antagonists can potentiate the action of clonidine (7). In other words, if MD-354 (21)
behaves as an α2B-AR antagonist, then it might be potentiating the antinociceptive effect
of clonidine (7; Peak A and/or B) via an α2B-AR antagonist mechanism of action.
In the mouse tail-flick assay, the non-selective α2-AR antagonist yohimbine (11)
blocked the analgesic effect of Peak A [1.0 mg/kg dose of MD-354 (21) + 0.25 mg/kg
dose of clonidine (7)] in a dose-dependent manner (AD50 = 0.33 mg/kg), which suggests
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that at least one of the α2-AR subtypes is involved in the action.31 Next, preferentially
selective agents were studied; imiloxan (12) and BRL44408 (15) both attenuated the
antinociceptive effect of the co-administration of MD-354 (21; 1.0 mg/kg) and clonidine
(7; 0.25 mg/kg) in a dose-dependent fashion (AD50 = 0.17 and 2.1 mg/kg,
respectively).31 Because, by definition, antagonists block the effect of agonists, these
observations suggest an α2-AR agonist mechanism in the actions associated with Peak
A.
Thus far, imiloxan (12) is the only α2-AR agent that has been examined in
mechanistic studies of Peak B. And, although imiloxan (12) was found to attenuate the
effect of a lower dose of MD-354 (21; 1 mg/kg) in combination with clonidine (7; 0.25
mg/kg) illustrated by Peak A, it failed to alter the enhanced antinociception produced by
administration of a 6 mg/kg dose of MD-354 (21) in combination with clonidine (7; 0.25
mg/kg) depicted by Peak B.31,33 These results suggest that the antinociceptive effect
produced by co-administration of a lower dose (1.0 mg/kg) of MD-354 (21) and 0.25
mg/kg dose of clonidine (7) is mediated by an α2B-AR agonist mechanism (i.e., an α2BAR agonist mechanism seems to play a role in the effect associated with Peak A, but
not Peak B; Figure 12).
Initial binding data for imiloxan (12) at cloned human α2-ARs (Ki: α2A = 1584, α2B
= 126, α2C = 1000 nM)136 suggested α2B-AR preferential selectivity, but later studies
showed reduced binding selectivity (Ki: α2A = 3,109, α2B = 562, and α2C = 1,025 nM), as
well as functional activity ([35S] GTPγS assay; Ki: α2A = 316, α2B = 68, α2C = 151
nM).31,137 The latter studies showed very modest selectivity with an α2B-AR activity of
only five- and two-times greater than that for α2A-AR and α2C-AR activity, respectively.
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Due to possible low α2-AR subtype selectivity, it is difficult to rule out an α 2B-AR
involvement in the action for Peak B.
To date, MD-354 (21) seems to potentiate the antinociceptive effect of clonidine
(7), at least in part, via a 5-HT3 receptor and an α2-AR mechanism.31,29 It is unclear
which AR subtypes are specifically involved; α2A- and α2B-ARs seem to play a role due
to attenuation of the effect of the MD-354/clonidine (21/7) combination by the
reasonably selective antagonists BRL44408 (15) and imiloxan (12), respectively, but an
α2C-AR mechanism cannot be ruled out because imiloxan (12) has moderate affinity and
activity at α2C-ARS.31
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III. Specific aims and rationale

A. To further investigate the mechanism of action of the analgesia-potentiating
effect of clonidine (7) by MD-354 (21)

Epidural administration of clonidine (7), an α2-AR agonist, is one of the few nonopioid FDA-approved treatments of cancer pain. Although clonidine (7) is a potent
analgesic agent, it produces undesirable side effects, including sedation and
hypotension, limiting its use to clinical settings.70,73,74 One of the main goals of our
laboratory is to develop adjuvant agents to minimize the side effects of clonidine (7)
while retaining its analgesic action. It has been previously shown by our laboratory that
MD-354 (21) is a 5-HT3 receptor/α2-AR ligand. Although MD-354 (21) is inactive when
administered alone, it selectively potentiates the antinociceptive actions of an “inactive”
analgesic dose of clonidine (7).29,33 This seems to be a selective effect because MD354 (21) did not potentiate the sedative effect of clonidine (7).29,33 In other words, MD354 (21) potentiates the desired analgesic, but not the adverse sedative effects of
clonidine (7).

This could have substantial clinical ramifications for the treatment of

cancer-related pain.
More specifically, when MD-354 (21; 0.3-30 mg/kg) and a sub-threshold (i.e., an
“inactive”) analgesic dose of clonidine (7; 0.25 mg/kg) were co-administered, a biphasic
analgesic effect was observed (Figure 12).34 Analgesic potentiation of clonidine (7)49

induced antinociception produced by MD-354 (21), illustrated by Peaks A and B (Figure
12), might be due to different mechanisms (e.g., 5-HT3 receptor agonism/antagonism,
α2A-, α2B-, or α2C-AR action, or a combination of these mechanisms).

Mechanistic

studies have determined that this analgesic potentiation is due, at least in part, to a 5HT3 receptor and an α2-adrenoceptor mechanism. 29,33
Since mechanistic studies of Peak A indicate potentiation by 5-HT3 receptor
agonism,

then

the

more

established

5-HT3

receptor

agonist

meta-

chlorophenylbiguanide (20; mCPBG) should produce a similar effect in combination with
clonidine (7). In previous in vivo studies, i.t. administration of mCPBG (20) produced
antinociceptive effects in some animal models (e.g., rat paw pressure and formalin test;
Table 4).127-133 However, in the rat tail-flick assay, mCPBG (20; i.t.) failed to produce a
significant effect.26 But, mCPBG (20) has not been examined in this assay via s.c.
administration.

Similarly, i.t. administered PBG [19; a much lower-affinity 5-HT3

receptor agonist, the des-chloro analog of mCPBG (20)], produced saline-like effects in
the tail-flick assay but, in contrast, showed antinociceptive effects in the hot-plate assay
when administered by an i.t. route.25 To the best of our knowledge, examination of the
antinociceptive effect of mCPBG (20) in the hot-plate assay has not been reported.
In this study, we will determine the antinociceptive actions of mCPBG (20) when
administered alone in mice via s.c. administration. Since, mCPBG (20) has not been
previously examined in the mouse tail-flick assay via a s.c. route of administration, a
time-course study will be undertaken to determine optimal pre-injection times. Then,
combination studies [co-administration of mCPBG (20) and clonidine (7)] will be
evaluated to determine if mCPBG (20) behaves in a manner similar to MD-354 (21) in
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the tail-flick assay [i.e., to determine if it potentiates the antinociceptive actions of
clonidine (7)].

If an ED50 dose (a dose that produces 50% MPE or 50% maximal

possible effect) of clonidine (7) is administered in combination with mCPBG (20), it will
be possible to detect either attenuation or potentiation of the effect. If potentiation by
mCPBG (20) is observed, 5-HT3 antagonists [e.g., ondansetron (23) and tropisetron
(25)] will be examined to assess mCPBG’s (20) mechanism of action.

If a 5-HT3

receptor antagonist blocks the antinociceptive effect of the mCPBG/clonidine (20/7)
combination, this will provide evidence for a 5-HT3 receptor agonist-mediated
mechanism of action.
Literature data concerning mCPBG (20) and related compounds acting as central
agents is unclear and limited. Contradictory data describing the ability of mCPBG (20) to
cross the BBB is presented in Table 6. There seems to be a species-related difference;
mCPBG (20) appears to cross the BBB in rat but, perhaps, not in mice. 115,138,139 Also,
there is a discrepancy in the log P value depending on the experimental method
employed. A log P value for mCPBG of -0.38 has been reported using the shake-flask
method, whereas our laboratory has shown mCPBG (20) to be more lipophilic (log P =
1.70) using an HPLC (high performance liquid chromatography) technique.

118,140

In

general, drugs with log P values ranging from 1.5 to 2.5 can penetrate the BBB.141
Therefore, the log P value obtained from the shake-flask method indicates negligible
BBB penetration, whereas data from the HPLC method suggests that mCPBG (20)
should cross the BBB. However, it should be noted that the study with mCPBG (20)
and MD-354 (21) in the shake-flask method employed their water soluble salts
(hydrochloride and nitrate salts, respectively).
51

Table 6. Literature summary of the ability of mCPBG (20) to cross the BBB.
mCPBG (20) does cross the BBB

mCPBG (20) does not cross the BBB

 mCPBG (20) displaced [3H]GR67330 in
rat entorhinal cortex.139

 mCPBG (20) did not displace [3H]
granisetron
in
mouse
cortical
115
membranes.

 [3H]mCPBG labeled 5-HT3 receptor
recognition sites in rat brain.138
 Relative retention times using HPLC:
mCPBG (20) log P = 1.70118

 Shake-flask method: mCPBG (20) log
P = -0.38140
 mCPBG (20) showed hypothermic
effects [blocked by ondansetron (23)]
by i.c.v., but not i.p., routes in mice.142

There is evidence that mCPBG (20) does not penetrate the BBB (Table 6). This
might also be a species related effect. Therefore, in addition to receptor mechanism
studies, central versus peripheral activity will be evaluated. If mCPBG (20) is acting via
a centrally-mediated 5-HT3 receptor agonist mechanism, it should be possible to
antagonize the effect with the centrally-acting 5-HT3 receptor antagonist tropisetron
(25). The quaternary amine analog of tropisetron (25), tropisetron methiodide, behaves
as a 5-HT3 receptor antagonist that does not readily penetrate the BBB. Therefore,
tropisetron methiodide can be utilized as a control because it should only produce a
peripheral antagonist effect.
If a 5-HT3 receptor mechanism is supported in the above studies, the role of this
mechanism in clonidine’s (7) potentiation by MD-354 (21) will be further evaluated by
examining a centrally-acting 5-HT3 receptor agonist.

Unlike mCPBG (20), there is

compelling evidence that SR57227A (22; 1-(6-chloropyrid-2-yl)-4-piperidinylamine;
Figure 10) behaves as an agonist at central 5-HT3 receptors.115
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SR57227A (22)

displays affinity at 5-HT3 receptors (Ki = 103 nM) but lacks an α2-AR component.115 In
fact, i.p. administration of SR57227A (22; 1.0-20 mg/kg) has been previously shown to
produce antinociceptive effects in the mouse tail-flick assay.27 Due to these functional
properties, the effect of SR57227A (22; s.c.) will be studied when administered alone
and in combination with clonidine (7) in mouse thermal antinociceptive assays. A s.c.
route of administration will be used because our previous studies employed s.c.
injections and SR57227A (22) can penetrate the BBB and, therefore, should produce
peripheral and/or central effects via the s.c. route. Just as in the case of mCPBG (20),
a time course study is critical in determining optimal pre-injection times. If MD-354 (21)
potentiates the antinociceptive effect of clonidine (7) via a central 5-HT3 receptor
agonist mechanism, the centrally-acting 5-HT3 receptor agonist SR57227A (22) should
also potentiate the effect of an “inactive” dose of clonidine (7). In fact, it is expected that
an additive antinociceptive effect will be displayed due to the analgesic actions of
SR57227A (22) and clonidine (7) when administered alone. 27,33 Analgesic potentiation
of clonidine (7) by SR57227A (22) will give additional support for a central 5-HT3
receptor agonist mechanism for Peak A ( Figure 12).
Since mechanistic studies of the analgesia-potentiating effect of clonidine (7) by
MD-354 (21) have also suggested a role for α2-ARs (e.g., an α2-AR agonist mechanism
in Peak A), TDIQ (6; 5,6,7,8-tetrahydro-1,3-dioxolo[4,5-g]isoquinoline; Figure 5) will be
examined in mouse antinociceptive assays.

TDIQ (6), an agent developed in our

laboratory, binds to all three α2-AR subtypes (Ki: α2A = 75, α2B = 97, and α2C = 65 nM)
but possesses no affinity for 5-HT3 receptors.72 Since TDIQ (6) and clonidine (7) have
similar binding profiles (i.e., they bind nonselectively to α 2-ARs), it is expected that TDIQ
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(6) will display antinociceptive effects in the tail-flick assay. The goal of this study
includes the examination of the analgesic effect of TDIQ (6) alone and in combination
with clonidine (7), as well as mechanistic studies involving selected α2-AR antagonists.
That is, if TDIQ (6) augments the antinociceptive effect of clonidine (7), then selective
α2-AR antagonists [e.g., imiloxan (12), ARC-239 (14), and BRL44408 (15)] will be coadministered with the TDIQ/clonidine (6/7) combination to help explain the mechanism
of action. In addition to mechanistic studies, if TDIQ (6) is found to potentiate the
antinociceptive actions of clonidine (7), an isobolographic analysis will be conducted to
determine the nature of the potentiation because, due to its similar binding profile, TDIQ
(6) might simply be another clonidine (7)-like agent. In this case, the effect should be
additive. More specifically, an isobolographic analysis will assess if the biological effect
produced by a combination of TDIQ (6) and clonidine (7) is greater than, equal to, or
smaller than, the sum of the individual effects of the component drugs.
Furthermore, if antinociception is observed with the above agents [mCPBG (20),
SR57227A (22), and TDIQ (6)] in the tail-flick assay, then analgesic actions will be
analyzed in a second nociceptive mouse model, the hot-plate assay. Both of these
assays model acute thermal pain, but hot-plate latencies are thought to reflect
supraspinal responses, whereas tail-flick latencies generally reflect spinal responses.143
The reflexes produced in the tail-flick assay may not always be entirely due to spinal
responses; they may be affected by supraspinal structures, too.143 In addition, it is
possible that there is a learned response related to both of these animal models (i.e.,
reiteration of the test can lead to false antinociceptive observations). 143 Therefore, it is
important to subject the animals to the assay conditions sparingly. Drugs examined in
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the hot-plate assay will include mCPBG (20), SR57227A (22), and TDIQ (6) alone and
in combination with clonidine (7). These combined results should provide information
related to possible novel mechanisms for pain therapy.
And, lastly, a mouse locomotor activity assay is often conducted to evaluate the
sedative/locomotor properties of antinociceptive agents. If it is found that an agent (or
combination of agents) produces a hypolocomotor (or depressant) or a hyperlocomotor
(or stimulant) action, it is difficult to interpret antinociceptive assay results. Moreover,
data are easier to interpret when it is known that the antinociceptive effect is not
associated with sedation or general behavioral depression (or stimulation), as these
adverse effects could alter the behavioral interpretation of the mouse assay in a way
that would emulate analgesic actions. For example, the hot-plate assay measures the
time it takes a mouse to jump from a heated surface (or another behavioral response).
If an agent produces decreased motor activity (i.e., depressed locomotor action), then
increased jump latency could be erroneously interpreted as an antinociceptive effect. 144
In addition, clonidine (7) produces sedative effects, so it is important to determine if
potentiation of clonidine’s (7) antinociceptive actions by mCPBG (20) is a selective
effect. That is, does a potential adjuvant analgesic [e.g., mCPBG (20), SR57227A (22)
or TDIQ (6)] selectively potentiate the antinociceptive effects of clonidine (7) or does it
non-selectively potentiate the antinociceptive and sedative effects of clonidine (7)? For
these reasons, it will be valuable to examine the locomotor properties of agents that
produce an analgesia-potentiating effect in combination with clonidine (7).
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B. Exploration of conformationally-constrained rotamers of MD-354 (21)

Another objective of this study is to further investigate the role of 5-HT3 receptors
in analgesia by developing agents that retain 5-HT3 receptor character with reduced α2AR properties.

As already mentioned, the conformational requirements for the

interaction of imidazolines [e.g., clonidine (7)] with α2-ARs calls for a nearly
perpendicular plane between the aromatic rings and the imidazoline-containing
moiety.70

Therefore, if MD-354 (21) mimics the binding mode of clonidine (7),

conformational constraint, as with 26 (Figure 13), should result in retention of 5-HT3
receptor affinity but in a reduction of α2-AR affinity.
Because MD-354 (21) possesses a rotatable bond (bond between C1 and the
aniline N atom), it exists as an indefinite number of rotamers. Thus, introduction of
conformational constraint might enlighten the manner in which MD-354 (21) interacts
with 5-HT3 receptors. When MD-354 (21) is constrained into a quinazoline ring [e.g., 2amino-7-chloro-3,4-dihydroquinazoline

(26)

and

2-amino-5-chloro-3,4-

dihydroquinazoline (27)], two extreme rotamers are represented as illustrated in Figure
13.
And, indeed, it was determined in initial competitive binding assays that 26, not
27, has comparable binding affinity to MD-354 (21); 27 has decreased binding affinity at
5-HT3 receptors relative to 26 (Table 7).140,145 Due to these initial results, 26 seems to
be the conformationally-constrained analog that best mimics MD-354 (21) and,
therefore, will be used as the parent compound in subsequent structure-affinity
relationship studies.
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Figure 13. Structures of rotamers of MD-354 (21) and related conformationallyconstrained analogs 26 and 27 (quinazoline numbering indicated in red).

Table 7. Receptor affinity (Ki, nM) for MD-354 (21) and conformationally-constrained
MD-354 (21) analogs 26 and 27.
Ki (nM)
5-HT3

α2A-AR

α2B-AR

α2C-AR

MD-354 (21)

35a

825d

25d

140d

MKD-65 (26)

34b

1384c

555c

1328c

SY-70 (27)

1021c

1305c

984c

2270c

a

Ref. 32, bRef. 140, cRef. 145, and dRef. 33.
Role of the ring nitrogen atoms. In order to determine the role of quinazoline ring

nitrogen atoms in the binding at 5-HT3 receptors, des-nitrogen analogs of 26 will be
prepared and evaluated (Figure 14).

In other words, nitrogen atoms of 26 will be
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systematically replaced one by one with an sp 2 hybridized carbon atom [e.g., 2-amino7-chloroquinoline

(28),

3-amino-6-chloroisoquinoline

(29),

and

2-amino-7-

chloronaphthalene (30); Figure 14]. For example, compound 28 does not contain the 3position nitrogen atom of 26, and 29 lacks the 1-position N atom found in 26.
Compound 30 lacks both of these N atoms. Compounds 31-33 will evaluate the role of
saturation/unsaturation on the binding of 28-30 at 5-HT3 receptors.
NH2

NH2

N

NH2

NH2
HN

N

Cl

Cl
28

Cl

Cl
29

NH2
NH

Cl
31

30

NH2

Cl
32

33

Figure 14. Structures of MD-354 (21)-related analogs 28-30 and their reduced forms
(31-33).

Structure-affinity relationship studies of arylguanidines, such as MD-354 (21),
have been previously conducted.32,114 It was found that if one of the terminal amine
nitrogen atoms of MD-354 (21) was replaced by a carbonyl group or H atom (e.g., 34
and 35), 5-HT3 receptor affinity was abolished (i.e., Ki > 10,000 nM; Figure 15).32 But,
34 is no longer basic. Furthermore, it might not be the lack of the N atom that accounts
for the decreased affinity of 35; rather it might be a lack of electrons associated with the
amine. Hence, it would be difficult to predict the affinity of 28 a priori. Nevertheless,
based on these studies, if 26 has the same binding mode as MD-354 (21), as 5-HT3
receptor binding affinity seems to indicate, then 28 might have little to no affinity at 5HT3 receptors. When the aniline nitrogen atom of MD-354 (21) was replaced with an
sp3 C atom in the arylguanidine SAFIR studies, 5-HT3 receptor affinity was reduced by
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approximately 35-fold (36; Figure 15).32 Compound 37 also lacked affinity. But, here
too, the electronic character of the chain has been altered. Compounds 28-30 will be
prepared and evaluated to address this issue.

NH2
HN

NH2

O

Cl

N

H

Cl
34

Ki: 5-HT3 > 10,000 nM

NH

NH2

NH2

Cl

35
> 10,000 nM

Cl
36
1,200 nM

37
> 10,000 nM

Figure 15. MD-354 (21) structure-affinity relationship results; 5-HT3 receptor binding
affinity reported as Ki values (nM).32

In addition to MD-354 (21) analogs 28-30, the reduced form of each, will be
synthesized to give 2-amino-7-chloro-1,2,3,4-tetrahydroquinoline (31), 3-amino-6chloro-1,2,3,4-tetrahydroisoquinoline
respectively (Figure 14).

(32),

and

2-amino-7-chlorotetralin

(33),

This will, in effect, modulate the basicities of the amine

functions in question. Although it is unknown if these novel agents will retain affinity for
5-HT3 receptors, it is difficult to predict the trend. If these nitrogen atoms are directly
implicated in interactions with the receptor (e.g., ionic or H-bond interactions between
the ligand and the receptor), then the increased basic property of compounds 31-33 will
be expected to increase 5-HT3 receptor affinity in comparison to compounds 28-30. For
example, compound 30 and 33 contain an aniline versus an aliphatic sp3 hybridized
amine moiety, which have approximate pKa values of 4.6 and 10.6, respectively.148
Therefore, compound 33 has increased basic character that may improve the strength
of the interactions with 5-HT3 receptors in comparison with 30. That is, if the strength of
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the interactions between the ligand and receptor is enhanced, receptor binding affinity
will increase (or produce a lower Ki value). In the case of the modification of 32 to 29,
as well as 31 to 28, the s character of the ring nitrogen atom (sp3 to sp2 hybridization) is
increased, which localizes the nitrogen lone electron pair closer to the nitrogen nucleus
and, therefore, reduces its ability to donate an electron pair (or, in other words, reduces
its Lewis basicity). This principle is supported by pKa values for piperidine (11.3) and
pyridine (5.2).146

Role of the chloro substituent. It is proposed to prepare the dichloro- and unsubstituted analogs, 2-amino-5,7-dichloro-3,4-dihydroquinazoline (38) and 2-amino-3,4dihydroquinazoline (39), respectively (Figure 16).
NH2
N

Cl

NH2

NH

N

NH

Cl
38

39

Figure 16. Structures of conformationally-constrained MD-354 (21) analogs 38 and 39.

In addition to SAFIR studies involving modification to the guanidine moiety of
MD-354 (21)-related compounds, extensive aryl substitution was also evaluated. For
example, the des-chloro analog of MD-354 (21) had reduced 5-HT3 receptor binding
affinity (phenylguanidine: Ki = 2,340 nM) by approximately 70-fold.32 Also, although mchlorophenylguanidine [MD-354 (21): Ki = 35 nM)] possessed the highest binding affinity
of all the monochlorinated aryl guanidines (e.g., o-chlorophenylguanidine and pchlorophenylguanidine: Ki = 190 and 320 nM, respectively), the 3,4-dichloro (Ki = 3.1
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nM) analog of MD-354 (21) displayed an even higher 5-HT3 receptor binding
affinity.32,114 Therefore, if it is assumed that the MD-354 (21) conformationallyconstrained analogs bind in a similar manner to MD-354 (21), it might be expected that
38 and 39 will possess increased and decreased 5-HT3 receptor binding affinity,
respectively, in comparison to the parent compound, 26.

C. MD-354 (21) binding mode at α2-adrenoceptors

MD-354 (21), an agent that binds with varied affinity at all three α2-ARs, has been
found to potentiate the antinociceptive effects of clonidine (7) due, at least in part, to an
α2-AR mechanism.31 In fact, competitive binding studies indicated that MD-354 (21)
binds at the low-affinity states of α2A/2B/2C-ARs (Ki = 110, 220, and 4,700 nM,
respectively) and at the high-affinity states of α2A/2B/2C-ARs (Ki = 825, 25, and 140 nM,
respectively).31,34 Furthermore, functional assays show that MD-354 (21) is a weak
partial agonist at α2A-ARs, but an antagonist at α2B/2C-ARs.31
A goal of the current studies is to explain the binding affinity and functional
activity of MD-354 (21) via examination of its binding mode to graphic receptor models
of low- and high-affinity states for α2A-, α2B-, and α2C-ARs. Since there are no current
high-resolution structures available for α2-ARs, a model of each subtype of the α2-ARs
will be generated using the inactive β2-AR crystal structure as a template (pdb = 2RH1;
Sybyl 8.1).57 These three models of α2A/2B/2C-ARs mimic the low-affinity state because
an inverse agonist is bound to the β2-AR in the crystal structure (i.e., an inverse agonist
binds preferentially to the inactive conformation of the receptor).57
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There are also no high-resolution structures of the active state of α2-ARs or the
similar β2-ARs. Therefore, the active or high-affinity state of the α2-ARs will be modeled
by modifying the low-affinity state models. The main modifications include: (a) rotation
of TM6, (b) tilting the TM5 extracellular portion into the binding pocket, and (c) “turning
on” the toggle switch by modifying the χ1 rotameric state of C6.47, W6.48, and F6.52.
These modifications will be made and will be assumed to simulate an active state
because they have been observed in other active-state structures of GPCRs.61-63 To
validate these α2-AR models, the endogenous ligands NE (1) and EPI (2) will be docked
(Gold 4.0) and their resulting docked poses will be compared to other homology models
reported in the literature as well as considering available site-directed mutagenesis
data.
Since MD-354 (21) contains rotatable bonds (Figure 13), before docking MD-354
(21) a systematic search will be conducted to identify its low-energy rotamers (Sybyl
8.1). These low-energy rotamers will be docked (Gold 4.0) to all six models (i.e., the
low- and high-affinity states of α2A-, α2B-, and α2C-AR models) to determine binding
modes. Results from this study will provide homology models of all three subtypes of
α2-ARs in both low- and high-affinity states based on a relatively new β2-AR crystal
structure.57 Also, more specifically, it will present potential binding modes of MD-354
(21) at all three receptors, which, in turn, might explain its variable binding and
functional activities at α2A-, α2B-, and α2C-ARs.
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Summary of the studies involved in the specific aims:
A. Investigation of the mechanism of action of the analgesia-potentiation effect of
clonidine (7) by MD-354 (21):


Examine clonidine (7) alone in the tail-flick and hot-plate assays.



Examine mCPBG (20) alone in the tail-flick and hot-plate assays.



Combination #1: examine mCPBG (20) + clonidine (7) in the tail-flick and hotplate assays.



Examine the mouse brain-penetrant 5-HT3 receptor agonist SR57227A (22)
alone in the tail-flick and hot-plate assays.



Combination #2: examine SR57227A (22) + clonidine (7) in the tail-flick and hotplate assays.



Examine a non-selective adrenoceptor agent lacking 5-HT3 receptor properties,
TDIQ (6), alone in the tail-flick and hot-plate assays.



Combination #3: examine TDIQ (6) + clonidine (7) in the tail-flick and hot-plate
assays.



If any of the above treatments produce antinociceptive effects in either assay,
sedative effects will be analyzed in the locomotor activity assay.



If analgesic potentiation is observed in any of the combinations (#1-3),
mechanistic studies will be conducted in the same nociceptive assay.


For

combinations

#1

and

2:

examine

5-HT3

receptor

antagonists

[ondansetron (23), tropisetron (25), or tropisetron methiodide] + combination.


For combinations #1-3: examine α2-AR antagonists [yohimbine (11),
BRL44408 (15), imiloxan (12), or ARC-239 (14)] + combination.
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B. Exploration of conformationally-constrained rotamers of MD-354 (21):


To determine the role of the nitrogen atoms of 26, des-amino analogs (28-30)
and the corresponding reduced forms (31-33) will be synthesized.



To determine the role of the chloro substituent of conformationally-constrained
analogs of MD-354 (21), 38 and 39 will be synthesized.

C. Study the MD-354 (21) binding mode at α2-ARs:


Construct α2A-, α2B-, and α2C-AR homology models of the inactive state based on
the inactive β2-AR crystal structure template.



Modify the α2A-AR inactive model to generate the α2A-AR active model; α2B- and
α2C-AR active models will be generated using the α 2A-AR active model as a
template.



Dock endogenous ligands [NE (1) and EPI (2)] in the 6 models.



Conduct a low-energy conformational search of MD-354 (21).



Dock low-energy conformers of MD-354 (21) in the 6 models.
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IV. Results and discussion

A. Pharmacological studies: Nociceptive and locomotor activity animal models
and binding assays

Pharmacological assays conducted in this project assessed the potential
attenuation or potentiation of the antinociceptive effect of the α 2-AR agonist clonidine (7)
by prospective adjuvant agents. First, the effects of clonidine (7) were evaluated when
administered alone in all assays utilized in the succeeding combination studies (mouse
tail-flick, hot-plate, and locomotor assays; control: saline). Pre-injection times employed
for clonidine (7) were those previously determined in our laboratory and, therefore, were
not necessary to re-establish.33,147,148 On the other hand, when evaluating agents in
behavioral assays such as tail-flick and hot-plate assays, it is best to keep the
environment constant, which includes the animal “handler”. Therefore, it was necessary
to repeat these assays with administration of clonidine (7) using the predetermined preinjection times to establish a new dose-response curve for the present studies. The
data from these clonidine (7) dose-response curves were used to calculate ED50 values
and were utilized in statistical analysis of subsequent combination studies.
In

the

mouse

tail-flick

and

hot-plate

assays,

clonidine

(7)

produced

antinociceptive effects in a dose-dependent manner (Figures 17 and 18, respectively).
A low dose of clonidine (7; 0.25 mg/kg) produced saline-like effects, but as the dose
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was increased (up to 2.0 mg/kg), the observed antinociceptive effect increased (tailflick: % MPE = 62-82; ED50 = 0.4 ± 0.07 mg/kg and hot-plate: % MPE = 27-73; ED50 =
0.9 ± 0.06 mg/kg) in both assays (Figures 17 and 18, respectively). These ED50 values
are very similar to previously reported values [clonidine (7) ED50 = 0.5 and 0.8 mg/kg for
tail-flick and hot-plate assays, respectively].33
Effect of Clonidine
in the Mouse Tail-Flick Assay
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Figure 17. Antinociceptive effect (± S.E.M.) of clonidine (7; 0.25-2.0 mg/kg, s.c.) in the
mouse tail-flick assay (n = 8-24 mice/treatment). Asterisks denote a significant
difference compared to the control group (saline); **P < 0.01, ***P < 0.001, one-way
ANOVA (F4,59 = 9.399) followed by Dunnett’s post hoc test.
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Effect of Clonidine
in the Mouse Hot-Plate Assay
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Figure 18. Antinociceptive effect (± S.E.M.) of clonidine (7; 0.25-2.0 mg/kg, s.c.) in the
mouse hot-plate assay (n = 9-10 mice/treatment). Asterisks denote a significant
difference compared to the control group (saline); **P < 0.01, ***P < 0.001, one-way
ANOVA (F4,42 = 11.94) followed by Dunnett’s post hoc test.

Since clonidine (7) has been previously reported to produce sedative effects, its
central depressant properties (e.g., the locomotor actions: movement episodes,
movement time, movement distance, and vertical entries) were evaluated in mouse
locomotor activity assays (Figure 19).29 Subcutaneous administration of a 0.25 mg/kg
dose of clonidine (7) [i.e., a dose of clonidine (7) shown to be statistically inactive in the
tail-flick and hot-plate assays] was analyzed in the locomotor activity assay because this
dose will be used in subsequent combination studies.
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Figure 19. Effect (± S.E.M.) of s.c. administered clonidine (7; pre-injection time: 5 min,
0.25 mg/kg) on (a) total movement episodes, (b) total movement time, (c) total
movement distance, and (d) vertical entries with a 15-min recording time in the mouse
locomotor activity assay (n = 8-10 mice/treatment). Asterisks denote a significant
difference compared to the control group (saline); **P < 0.01, ***P < 0.001, Student’s ttest.

Results from the locomotor activity assay indicated a general hypolocomoter
action of clonidine (7). That is, s.c. administration of clonidine (7; 0.25 mg/kg) produced
a significant reduction in locomotor actions in all four parameters compared to saline
vehicle (Figure 19); total movement episodes (60.2 ± 7.1, P < 0.001), total movement
times (352.9 ± 60.5 s, P < 0.001), total movement distance (1,414.7 ± 280.9 cm, P <
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0.01), and vertical entries (15.5 ± 5.2, P < 0.001). This is a clonidine (7) dose that
produced saline-like effects in both mouse antinociceptive assays (tail-flick and hotplate: Figures 17 and 18, respectively). Since there was a 5-min pre-injection time for
clonidine (7), sedative properties were measured for 15 min, which corresponds to the
pre-injection time in the antinociceptive assays (20 min).

1. Ondansetron (23)

In previous MD-354/clonidine (21/7) combination studies, the analgesic
potentiation (depicted by Peak A; Figure 12) was blocked by a 5-HT3 receptor
antagonist [tropisetron (25)]. Due to differences in actions of various 5-HT3 receptor
antagonists, a second agent was studied.115

Previously, ondansetron (23; 0.02-2.0

mg/kg, s.c.) showed no effect in the mouse tail-flick assay (% MPE = 1-4).29
Ondansetron (23; 0.01-1.0 mg/kg) failed to affect the antinociceptive effects of the Peak
A MD-354/clonidine (21; 1.0 mg/kg + 7; 0.25 mg/kg) combination (Figure 20).
Ondansetron (23; 0.01-1.0 mg/kg) was also found to neither attenuate nor potentiate the
analgesic actions of the Peak B combination [6.0 mg/kg dose of MD-354 (21) + 0.25
mg/kg dose of clonidine (7); Figure 21].
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Figure 20. Effect (± S.E.M.) of ondansetron (23; 0.01-1.0 mg/kg, s.c.) on the
antinociceptive action of the MD-354 (21; 1.0 mg/kg, s.c.)/clonidine (7; 0.25 mg/kg, s.c.)
combination in the mouse tail-flick assay (n = 8-23 mice/treatment). No significant
difference (P > 0.05) compared to the control group [MD-354/clonidine (21/7)
combination] was detected; one-way ANOVA (F3,43 = 0.1831) followed by Dunnett’s post
hoc test.
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Figure 21. Effect (± S.E.M.) of ondansetron (23; 0.01-1.0 mg/kg, s.c.) on the
antinociceptive action of the MD-354 (21; 6.0 mg/kg, s.c.)/clonidine (7; 0.25 mg/kg, s.c.)
combination in the mouse tail-flick assay (n = 8-19 mice/treatment). No significant
difference (P > 0.05) compared to the control group [MD-354/clonidine (21/7)
combination] was detected; one-way ANOVA (F3,39 = 1.381) followed by Dunnett’s post
hoc test.

The results presented in Figure 20 differ from the mechanistic studies using
tropisetron (25), which indicated a 5-HT3 receptor agonist mechanism for the
potentiating activity of a low dose of MD-354 (21; 1.0 mg/kg) in combination with an
“inactive” dose of clonidine (7; 0.25 mg/kg) depicted by Peak A.34

However,

ondansetron’s (23) failure to attenuate the effect (Figure 21) of the high-dose
combination [depicted by Peak B; MD-354 (21; 6.0 mg/kg) + clonidine (7; 0.25 mg/kg)]
is similar to the mechanistic studies with zacopride (24) and tropisetron (25). 29,33
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2. meta-Chlorophenylbiguanide (20; mCPBG)

a) Tail-flick assay

In the present study, the more established 5-HT3 receptor agonist mCPBG (20)
was evaluated alone and in combination with clonidine (7) to examine its possible
potentiation of clonidine (7)-induced analgesia. After comparing antinociceptive effects
produced by mCPBG (20) with a 20- and 45-min pre-injection time, it was determined
that 45 min was optimal (Figure 22). Nevertheless, as illustrated by the dose-response
curves, mCPBG (20; 0.3-10 mg/kg, s.c.) failed to produce significant antinociception (%
MPE < 36) when administered alone
(Figureof22).
Time Course
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Figure 22. Antinociceptive effect (± S.E.M.) of mCPBG [20; 0.3-10 mg/kg, s.c., 20-min
(orange squares) or 45-min (green triangles) pre-injection times] in the mouse tail-flick
assay (n = 7-9 mice/treatment). No significant difference (P > 0.05) compared to the
control group (saline) was detected; one-way ANOVA (F5,41 = 1.079 and F5,44 = 0.6228,
respectively) followed by Dunnett’s post hoc test. Saline data not shown.
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mCPBG (20; 0.3-10 mg/kg, s.c.), although inactive when administered alone,
potentiated an “inactive” dose of clonidine (7; 0.25mg/kg, s.c.) dose-dependently in the
mouse tail-flick assay (ED50 = 1.6 ± 0.14 mg/kg; Figure 23a). In fact, the potentiating
effect observed by the mCPBG/clonidine (20/7) combination persisted for at least 120
min (Figure 23b).
Since mCPBG (20) was found to potentiate the antinociceptive effect of an
“inactive” dose of clonidine (7; Figure 23), the effect of 5-HT3 receptor and α2-AR
antagonists on the effect of mCPBG (20)/clonidine (7) was examined.149 Ondansetron
(23), which has been used clinically to treat chemotherapy-induced nausea and
vomiting, is a 5-HT3 receptor antagonist. When ondansetron (23; 0.00001-2.0 mg/kg)
was co-administered with the mCPBG/clonidine (20/7) combination, neither attenuation
nor potentiation was observed in comparison to the effect produced by mCPBG (20; 6.0
mg/kg) and clonidine (7; 0.25 mg/kg) in the tail-flick assay (Figure 24).
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Figure 23. (a) Antinociceptive effect (± S.E.M.) of mCPBG (20; 0.3-10 mg/kg, s.c., 45min pre-injection time) in combination with clonidine (7; 0.25 mg/kg, s.c.) in the mouse
tail-flick assay (n = 8-24 mice/treatment). Asterisks denote a significant difference
compared to the control group (0.25 mg/kg dose of clonidine; 7); **P < 0.01, ***P <
0.001, one-way ANOVA (F5,88 = 5.002) followed by Dunnett’s post hoc test. (b)
Antinociceptive effect (± S.E.M.) of mCPBG (20; 10 mg/kg) in combination with clondine
(7; 0.25 mg/kg) at variable mCPBG (20) pre-injection times (20-120 min) in the mouse
tail-flick assay (n = 8-17 mice/treatment).
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Effect of Ondansetron on the mCPBG/Clonidine
Combination in the Mouse Tail-Flick Assay
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Figure 24. Effect (± S.E.M.) of ondansetron (23; 0.00001-2.0 mg/kg, s.c.) on the
antinociceptive action of the mCPBG (20; 6.0 mg/kg, s.c.)/clonidine (7; 0.25 mg/kg, s.c.)
combination in the mouse tail-flick assay (n = 8-16 mice/treatment). No significant
difference (P > 0.05) compared to the control group [mCPBG/clonidine (20/7)
combination] was detected; one-way ANOVA (F7,66 = 0.3224) followed by Dunnett’s post
hoc test.

The second 5-HT3 receptor antagonist examined was tropisetron (25) because
previously reported studies have shown opposing effects among 5-HT3 receptor
antagonists [e.g., ondansetron (23) and tropisetron (25)].115 Although tropisetron (25;
0.0000001-1.0 mg/kg, s.c.) showed no effect when administered alone (% MPE < 10;
data not shown), tropisetron (25; 0.00001-0.1 mg/kg) attenuated the antinociceptive
effect of the mCPBG/clonidine (20/7) combination as illustrated by a U-shaped doseresponse curve (Figure 25).29,150 The results indicate that a 0.0001 mg/kg dose of
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tropisetron (25) significantly blocked the potentiating effect of clonidine (7) by mCPBG
(20; Figure 25).
Effect of Tropisetron on the mCPBG/Clonidine
Combination in the Mouse Tail-Flick Assay
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Figure 25. Effect (± S.E.M.) of tropisetron (25; 0.00001-0.1 mg/kg, s.c.) on the
NOTE: SIGNIFICANCE BASED ON DUNNETT'S
antinociceptive action of the mCPBG (20; 6.0 mg/kg, s.c.)/clonidine (7; 0.25 mg/kg, s.c.)
combination in the mouse tail-flick assay (n = 8-16 mice/treatment). Asterisks denote a
significant difference compared to the control group [mCPBG/clonidine (20/7)
combination]; *P < 0.05, one-way ANOVA (F5,50 = 2.866) followed by Dunnett’s post hoc
test.

Since tropisetron (25) studies indicated involvement of a 5-HT3 receptor
mechanism, the quaternized analog of tropisetron (tropisetron methiodide) was
examined in combination studies. Tropisetron methiodide behaves as a 5-HT3 receptor
antagonist, but does not readily cross the BBB. 116

As a result, the analyses of

tropisetron (25) and tropisetron methiodide not only examine the receptor mechanism,
but also can support or refute a centrally-mediated effect. In other words, tropisetron
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methiodide acts as a control because it will only produce peripheral effects (if any).
Tropisetron methiodide (0.00001-0.1 mg/kg) did not alter the antinociception produced
Effect of Tropisetron Methiodide on the

by the combination in themCPBG/Clonidine
mouse tail-flick assay
(Figurein26).
Combination
the Mouse
Tail-Flick Assay
100

% MPE

80

60

40

20

0

Saline

mCPBG 0.00001
0.0001
0.1
6.0 mg/kg
Tropisetron Methiodide
+ Clonidine
Dose (mg/kg)
0.25 mg/kg

Figure 26. Effect (± S.E.M.) of tropisetron methiodide (0.00001-0.1 mg/kg, s.c.) on the
antinociceptive action of the mCPBG (20; 6.0 mg/kg, s.c.)/clonidine (7; 0.25 mg/kg, s.c.)
combination in the mouse tail-flick assay (n = 8-17 mice/treatment). No significant
difference (P > 0.05) compared to the control group [mCPBG/clonidine (20/7)
combination] was detected; one-way ANOVA (F3,45 = 0.9382) followed by Dunnett’s post
hoc test.

And finally, to determine if there is an α2-AR component associated with the
potentiation of clonidine (7) by mCPBG (20; Figure 23), the non-selective α2-AR
antagonist yohimbine (11) was examined. When administered alone, yohimbine (11;
0.1-1.0 mg/kg, s.c.) produced saline-like effects in the mouse tail-flick assay (% MPE <
1).31,150
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Effect of Yohimbine on the mCPBG/Clonidine
Combination in the Mouse Tail-Flick Assay
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Figure 27. Effect (± S.E.M.) of α2-AR antagonist yohimbine (11; 0.01-6.0 mg/kg, s.c.)
NOTE: SIGNIFICANCE BASED ON DUNNETT'S
on the antinociceptive action of the mCPBG (20; 6.0 mg/kg, s.c.) and clonidine (7; 0.25
mg/kg, s.c.) combination in the mouse tail-flick assay (n = 8-16 mice/treatment).
Asterisks denote a significant difference compared to the control group
[mCPBG/clonidine (20/7) combination]; *P < 0.05, **P < 0.01, ***P < 0.001, one-way
ANOVA (F6,62 = 6.525) followed by Dunnett’s post hoc test.

Yohimbine (11; 0.01-6.0 mg/kg), however, attenuated the potentiating effect of
the mCPBG/clonidine (20/7) combination in a dose-dependent manner in the mouse
tail-flick assay (AD50 = 0.04 mg/kg, 95% CL = 0.006-0.2 mg/kg; Figure 27).

b) Hot-plate assay

Before any combination studies were conducted, the antinociceptive effect of the
agents when administered alone was examined in the mouse hot-plate assay. In prior
hot-plate studies, clonidine (7) displayed reduced analgesic potency (ED50 = 0.9 mg/kg;
Figure 18) in comparison to the tail-flick assay (ED50 = 0.4 mg/kg; Figure 17). And
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similar to the tail-flick results (Figure 22), mCPBG (20; 0.3-10 mg/kg) failed to produce
any significant analgesic effects in the hot-plate assay (% MPE = 3-14; Figure 28).
Effect of mCPBG
in the Mouse Hot-Plate Assay
100

% MPE

80

60

40

20

0

Saline

0.3

1.0

3.0

6.0

10

mCPBG Dose (mg/kg)

Figure 28. Antinociceptive effect (± S.E.M.) of mCPBG (20; 0.3-10 mg/kg, s.c.) in the
mouse hot-plate assay (n = 8 mice/treatment). No significant difference (P > 0.05)
compared to the control group (saline) was detected; one-way ANOVA (F5,42 = 1.212)
followed by Dunnett’s post hoc test.

In the present investigation, clonidine (7; 1.0 mg/kg dose, which approximately
equals the calculated ED50 dose, and which produced about 50% MPE) was coadministered with mCPBG (20; 0.3-10 mg/kg, s.c.). And while 0.3-1.0 mg/kg doses of
mCPBG (20) only slightly attenuated (% MPE = 27-32; P > 0.05) the antinociceptive
effect of clonidine (7), significant attenuation (% MPE = 13.5 ± 4.9; P < 0.01) was
observed when 3.0 mg/kg of mCPBG (20) was co-administered (Figure 29).
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Figure 29. Antinociceptive
(± S.E.M.)
of mCPBG
(20; 0.3-10 mg/kg, s.c.) in
combination with clonidine (7; 1.0 mg/kg, s.c.) in the mouse hot-plate assay (n = 8-10
mice/treatment). Asterisks denote a significant difference compared to the control
group (1.0 mg/kg dose of clonidine; 7); **P < 0.01, one-way ANOVA (F4,45 = 2.844)
followed by Dunnett’s post hoc test.

The attenuating effect of clonidine (7)-induced antinociception by mCPBG (20;
0.3-3.0 mg/kg) seemed to be dose-dependent (AD50 = 0.8 mg/kg, 95% CL = 0.25-2.6
mg/kg). However, a higher dose of mCPBG [(20): 10 mg/kg] only slightly antagonized
(P > 0.05) the effect [i.e., the effect produced by clonidine (7; 1.0 mg/kg) alone was not
significantly different than that of the co-administration of mCPBG (20; 10 mg/kg) and
clonidine (7; 1.0 mg/kg); Figure 29]. It is important to note, there was a rather large
standard error in this combination (% MPE = 31.4 ± 9.7; Figure 29).
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c) Locomotor activity assay

Analgesic actions were observed when mCPBG (20) was co-administered with
clonidine (7; 0.25 mg/kg dose) in the mouse tail-flick assay (Figure 23a).

It was

necessary to determine if this antinociceptive potentiation was a selective potentiation.
In other words, does mCPBG (20) only potentiate the analgesic actions of clonidine (7)
and not its sedative properties? Also, because clonidine (7) has already been reported
to display hypolocomotor effects, the dose used in the tail-flick assay [0.25 mg/kg
clonidine (7)] should be evaluated in the same species (male ICR mice) and should be
used as a control for the combination treatment group. 29 A low dose of clonidine (7;
0.25 mg/kg), which showed no analgesic effects in the tail-flick and hot-plate assays,
produced hypolocomotor actions (Figure 19).
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Figure 30. Effect (± S.E.M.) of the co-administration of mCPBG (20; 6.0 mg/kg, s.c.,
pre-injection time: 30 min) and clonidine (7; 0.25 mg/kg, s.c., pre-injection time: 5 min)
on (a) total movement episodes, (b) total movement time, (c) total movement distance,
and (d) vertical entries with a 15-min recording time in the mouse locomotor activity
assay (n = 10 mice/treatment). No significant difference (P > 0.05) compared to the
control group [clonidine (7) 0.25 mg/kg] was detected; Student’s t-test.

The doses selected for the locomotor activity combination studies [6.0 mg/kg
mCPBG (20) + 0.25 mg/kg clonidine (7)] were those that produced a statistically
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significant increase in antinociceptive effects (% MPE = 68.0 ± 9.3; P < 0.01) in the tailflick assay (Figure 23a). As illustrated in Figure 30, mCPBG (20; 6.0 mg/kg) did not
alter the locomotor effects of clonidine (7; 0.25 mg/kg) in any of the four parameters
measured (P > 0.05).

d) Summary

The antinociceptive effects of the more established and selective 5-HT3 receptor
agonist mCPBG (20) administered alone and combination with an “inactive” dose of
clonidine (7) was examined in the mouse tail-flick assay because a structurally similar
agent, MD-354 (21), has been shown to potentiate the analgesic actions of clonidine (7)
in a biphasic manner (Figure 12).34 Previous mechanistic studies suggested that the
first potentiation peak (Peak A in Figure 12), which is produced by a low dose of MD354 (21; 1.0 mg/kg) and clonidine (7; 0.25 mg/kg) is, at least in part, due to a 5-HT3
receptor agonist mechanism and involvement of an α2-AR mechanism.34 To date, it is
unclear which α2-AR subtype is involved.34 As for the mechanism of action underlying
Peak B [6.0 mg/kg MD-354 (21) + 0.25 mg/kg clonidine (7)], 5-HT3 receptor antagonism
and α2-AR involvement seems to play a role. 29,31
In the present investigation, similar to results obtained with MD-354 (21),
mCPBG (20; 0.3-10 mg/kg) displayed no antinociceptive effects when administered
alone (Figure 22), but potentiated the analgesic actions of an “inactive” dose of
clonidine (7; 0.25 mg/kg) in the mouse tail-flick assay (Figure 23a).

In fact, this

potentiation was observed over the course of 2 hours (Figure 23b). On the other hand,
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unlike the biphasic curve observed with the co-administration of MD-354 (21) and
clonidine (7; 0.25 mg/kg), the dose-response curve illustrating the potentiation by
mCPBG (20) was monophasic (Figures 12 and 21a).
In the second nociceptive animal model (hot-plate assay), mCPBG (20; 0.3-10
mg/kg) also showed no analgesic effects when administered alone (Figure 28), but
contrary to the tail-flick assay, mCPBG (20) dose-dependently attenuated clonidine’s (7;
1.0 mg/kg) effect (Figure 29). Although it was found to be statistically insignificant,
antagonistic behavior was also observed when MD-354 (21) was co-administered with
clonidine (7) in the mouse hot-plate assay.33
And lastly, locomotor effects were evaluated in the analgesia producing
combination [6.0 mg/kg mCPBG (20) + 0.25 mg/kg clonidine (7); tail-flick assay]. The
results indicated that even though mCPBG (20) potentiated the antinociceptive effects
of a low dose of clonidine (7) in the mouse tail-flick assay, it did not alter clonidine’s (7)
locomotor properties (Figure 30).

3. SR57227A (22)

a) Tail-flick assay

Thus far, MD-354 (21) and mCPBG (20) have been examined in combination
studies with clonidine (7), and analgesic potentiation of an “inactive” dose of clonidine
(7) was observed with both of these agents. Mechanistically, this potentiation effect
seemed to be, at least in part, due to a 5-HT3 receptor action. There is question as to
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whether MD-354 (21) and mCPBG (20) penetrate the mouse BBB.

In contrast,

SR57227A (22) has been demonstrated to be brain penetrant. Therefore, the analgesic
properties of the centrally-acting 5-HT3 receptor agonist SR57227A (22) was examined
both alone and in combination with clonidine (7).

If potentiation is observed when

SR57227A (22) is co-administered with clonidine (7), then mechanistic studies involving
5-HT3 receptor antagonists will be conducted.
In the tail-flick assay, SR57227A (22; 0.3-10 mg/kg) showed saline-like effects
(i.e., the antinociceptive effect produced by SR57227A (22) was not statistically different
than saline; Figure 31). At the highest dose (30 mg/kg) evaluated, SR57227A (22)
produced an increase in antinociception and even though there was a relatively large
standard error, statistical analysis (one-way ANOVA followed by Dunnett’s post hoc
Effect ofthe
Clonidine
and and
SR57227A
test) verified a difference between
treatment
controlalone
group (P < 0.05; Figure 31).
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Figure 31. Antinociceptive effect (± S.E.M.) of SR57227A (22; 0.3-30 mg/kg, s.c.) in
the mouse tail-flick assay (n = 8 mice/treatment). Asterisks denote a significant
difference compared to the control group (saline); *P < 0.05, one-way ANOVA (F6,49 =
4.344) followed by Dunnett’s post hoc test.
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Tail-flick latency, which is the time delay between the onset of intense light and
the tail-flick response, is a second way of measuring tail-flick results. When the results
from SR57227A (22) administered alone were analyzed in this way, there was no
significant difference between the high dose of SR57227A (22; 30 mg/kg) and saline in
the Dunnett’s post hoc test (P > 0.05) but, interestingly, it was determined as being
significantly different in the Newman-Keuls multiple comparison test (P < 0.05; Figure
32).
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Figure 32. Antinociceptive effect (± S.E.M.) of SR57227A (22; 0.3-30 mg/kg, s.c.) in
the mouse tail-flick assay (n = 8 mice/treatment). No significant difference (P > 0.05)
compared to the control group (saline) was detected; one-way ANOVA (F6,49 = 4.574)
followed by Dunnett’s post hoc test.

Although not significantly different from saline, lower doses of SR57227A (22;
0.3-10 mg/kg) showed reduced tail-flick latency (Figures 31 and 32).

Therefore,

hyperalgesia was examined in a modified tail-flick assay (radiant heat was adjusted so
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that pre-treatment tail-flick latencies were 5-7 s). Dose-dependent hyperalgesic effects
Effect mg/kg)-treated
of SR57227A
were observed in the SR57227A (22; 1.0-10
mice (Figure 33).
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modified mouse tail-flick assay (n = 6-8 mice/treatment). For each treatment group,
bars on the left depict the pre-treatment tail-flick latency. Asterisks denote a significant
difference compared to the control group (pre-treatment tail-flick latency); ***P < 0.001,
Student’s t-test.

Because MD-354 (21) and mCPBG (20) both potentiated the antinociceptive
actions of an “inactive” dose of clonidine (7; 0.25 mg/kg), this same dose of clonidine (7)
was co-administered with the selective 5-HT3 receptor agonist SR57227A (22). In the
mouse tail-flick assay, SR57227A (22; 0.3-10 mg/kg, s.c.) did not alter the analgesic
properties of a saline-like dose of clonidine (7; Figure 34).
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Effect of SR57227A in Combination with Clonidine (0.25 mg/kg)
in the Mouse Tail-Flick Assay
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Figure 34. Antinociceptive effect (± S.E.M.) of SR57227A (22; 0.3-10 mg/kg, s.c.) in
combination with clonidine (7; 0.25 mg/kg, s.c.) in the mouse tail-flick assay (n = 8-24
mice/treatment). No significant difference (P > 0.05) compared to the control group
[0.25 mg/kg dose of clonidine (7)] was detected; one-way ANOVA (F5,58 = 0.6047)
followed by Dunnett’s post hoc test.

Since no potentiation was observed in the previous combination, a higher, more
effective dose of clonidine (7; calculated ED50 = 0.5 mg/kg) was selected to determine if
SR57227A (22) blocks the antinociceptive effect of clonidine (7; Figure 35).
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Effect of SR57227A in Combination with Clonidine (0.5 mg/kg)
in the Mouse Tail-Flick Assay
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Figure 35. Antinociceptive effect (± S.E.M.) of SR57227A (22; 0.3-10 mg/kg, s.c.) in
combination with clonidine (7; 0.5 mg/kg, s.c.) in the mouse tail-flick assay (n = 8-24
mice/treatment). No significant difference (P > 0.05) compared to the control group [0.5
mg/kg dose of clonidine (7)] was detected; one-way ANOVA (F5,66 = 0.4993) followed by
Dunnett’s post hoc test.

Similar to Figure 34, this combination [0.3-10 mg/kg doses of SR57227A (22) +
0.5 mg/kg dose of clonidine (7)] produced clonidine (7)-like effects (Figure 35). That is,
the antinociceptive effects of clonidine (7) were neither potentiated nor attenuated by
SR57227A (22).

b) Hot-plate assay

In the hot-plate assay, s.c. administration of SR57227A (22; 0.3-10 mg/kg)
produced no antinociception (compared to saline control) but, just as before (i.e., similar
to the tail-flick assay results), a higher dose (30 mg/kg) produced analgesic actions
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(Figure 36). This high dose of SR57227A (22; 30 mg/kg) was significantly different than
the saline control (P < 0.001; Figure 36).
Effect of SR57227A
in the Mouse Hot-Plate Assay
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Figure 36. Antinociceptive
effect (± S.E.M.)
SR57227A
the mouse hot-plate assay (n = 8-9 mice/treatment). Asterisks denote a significant
difference compared to the control group (saline); ***P < 0.001, one-way ANOVA (F5,47
= 5.322) followed by Dunnett’s post hoc test.

In combination studies, SR57227A (22; 0.3-10 mg/kg) neither potentiated nor
attenuated the antinociceptive effect of clonidine (7; 1.0 mg/kg; Figure 37).

90

Effect of SR57277A in Combination with Clonidine (1.0 mg/kg)
in the Mouse Hot-Plate Assay
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Figure 37. Antinociceptive
effect (± S.E.M.)
combination with clonidine (7; 1.0 mg/kg, s.c.) in the mouse hot-plate assay (n = 9-20
mice/treatment). No significant difference (P > 0.05) compared to the control group
[SR57227A/clonidine (22/7) combination] was detected; one-way ANOVA (F4,53 =
0.4547) followed by Dunnett’s post hoc test.

In summary, SR57227A (22; 0.3-10 mg/kg) produced no analgesic properties in
both examined antinociceptive assays (tail-flick and hot-plate assays) when
administered alone and in combination with clonidine (7), but a higher dose (30 mg/kg),
this 5-HT3 receptor agonist (22) showed augmented antinociceptive effects in the
mouse tail-flick and hot-plate assays (P < 0.05 and P < 0.001, respectively).

c) Locomotor activity assay

In the mouse locomotor activity assay, a 30 mg/kg dose of SR57227A (22; dose
that produced antinociceptive effects; Figures 32 and 36) was administered s.c. and
compared to a s.c. saline treatment group (Figure 38).
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Statistical analysis of the

examined locomotor parameters (e.g., total movement episodes, total movement time,
total movement distance, and total vertical entries) indicated a significant hypolocomotor
action of SR57227A (22; 30 mg/kg) in comparison to saline (P < 0.01; Figure 38). That
is, the only SR57227A (22) dose that produced antinociceptive effects in the tail-flick
and hot-plate assays, also, produced sedative effects in mice.
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Figure 38. Effect (± S.E.M.) of SR57227A (22; 30 mg/kg, s.c., pre-injection time: 0 min)
on (a) total movement episodes, (b) total movement time, (c) total movement distance,
and (d) vertical entries with a 45-min recording time in the mouse locomotor activity
assay (n = 8 mice/treatment). Asterisks denote a significant difference compared to the
control group (saline); **P < 0.01, ***P < 0.001, Student’s t-test.
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Potentiation of clonidine’s (7) analgesic properties by SR57227A (22) was not
observed in either nociceptive animal model (Figures 34, 35 and 37) and therefore, the
locomotor activity of the combination was not examined.

d) Summary

In summary, SR57227A (22; 0.3-10 mg/kg, s.c.) produced saline-like effects in
both antinociceptive assays (P > 0.05; Figures 31 and 34). Conversely, a higher dose
(30 mg/kg) of SR57227A (22) showed a significant increase in analgesic actions in
comparison to saline in the tail-flick and hot-plate assays (P < 0.05 and P < 0.001,
respectively; Figures 31 and 36). However, SR57227A (22; 30 mg/kg, s.c.) showed
decreased motor activity in all locomotor parameters (movement episodes, movement
time, movement distance, and vertical entries) in the mouse locomotor activity assay
(Figure 38).

Because low doses of SR57227A (22; 0.3-10 mg/kg) showed slight

analgesic attenuation in the tail-flick assay, a modified tail-flick assay was conducted to
detect hyperalgesia. Indeed, SR57227A (22) produced hyperalgesic effects (P < 0.001)
in the modified tail-flick assay (Figure 33).
In the tail-flick combination studies, SR57227A (22; 0.3-10 mg/kg, s.c.) neither
potentiated nor attenuated the antinociceptive effect of clonidine (7; 0.25 or 0.5 mg/kg,
s.c.; Figures 34 and 35). Similar to the tail-flick results, SR57227A (22; 0.3-10 mg/kg,
s.c.) did not alter the antinociception produced by clonidine (7; 1.0 mg/kg, s.c.) in the
hot-plate assay (Figure 37).
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4. TDIQ (6)

a) Tail-flick assay

An α2-AR role in the potentiation of clonidine (7; 0.25 mg/kg) by MD-354 (21) was
proposed because previous mechanistic studies showed analgesic attenuation of the
MD-354/clonidine (21/7) combination by the following α2-AR antagonists: yohimbine (11;
non-selective

α2-AR

antagonist),

imiloxan

(12;

preferentially selective

antagonist), and BRL44408 (15; preferentially selective

α2B-AR

α2A-AR antagonist).31

Therefore, the α2-AR agonist TDIQ (6) was selected to further examine the mechanism
of action. Although TDIQ (6) acts nonselectively at all three subtypes of α2-ARs, it is
devoid of 5-HT3 receptor activity.72
TDIQ (6; 0.3-10 mg/kg), when administered alone in the tail-flick assay, showed
no analgesic properties (% MPE = 1-10; Figure 39). However, when TDIQ (6; 0.3-3.0
mg/kg) was co-administered with clonidine (7; 0.25 mg/kg), potentiation of the
antinociceptive effect was observed (ED50 = 0.6 mg/kg, 95% CL = 0.2-1.3 mg/kg; Figure
40). That is, TDIQ (6) potentiated the antinociceptive effect of an “inactive” dose of
clonidine (7) in a dose-dependent manner (Figure 40).
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Effect of TDIQ in the
Mouse Tail-Flick Assay
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Figure 39. Antinociceptive effect (± S.E.M.) of TDIQ (6; 0.3-10 mg/kg, s.c.) in the
mouse tail-flick assay (n = 8 mice/treatment). No significant difference (P > 0.05)
compared to the control group (saline) was detected; one-way ANOVA (F4,35 = 0.6850)
followed by Dunnett’s
post
hoc test.
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Figure 40. Antinociceptive effect (± S.E.M.) of TDIQ (6; 0.3-3.0 mg/kg, s.c.) in
combination with clonidine (7; 0.25 mg/kg, s.c.) in the mouse tail-flick assay (n = 8-24
mice/treatment). Asterisks denote a significant difference compared to the control
group (0.25 mg/kg dose of clonidine; 7); *P < 0.05, **P < 0.01, one-way ANOVA (F3,51 =
10.19) followed by Dunnett’s post hoc test.
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Since 1.0 and 3.0 mg/kg doses of TDIQ (6) potentiated the antinociceptive
actions of clonidine (7; 0.25 mg/kg), TDIQ (6) in combination with a lower dose of
clonidine (7) was investigated. TDIQ (6) did not significantly alter the effect of the lower
dose (0.1 mg/kg) of clonidine (7; Figure 41).
Effect of TDIQ in Combination with Clonidine (0.1 mg/kg)
in the Mouse Tail-Flick Assay
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Figure 41. Antinociceptive effect (± S.E.M.) of TDIQ (6; 0.3-10 mg/kg, s.c.) in
combination with clonidine (7; 0.1 mg/kg, s.c.) in the mouse tail-flick assay (n = 8-16
mice/treatment). No significant difference (P > 0.05) compared to the control group [0.1
mg/kg dose of clonidine (7)] was detected; one-way ANOVA (F4,51 = 1.579) followed by
Dunnett’s post hoc test.

Since TDIQ (6) was found to potentate the analgesic action of clonidine (7; 0.25
mg/kg) in the mouse tail-flick assay (Figure 40), additional combination studies were
conducted to investigate the mechanism of action (Figure 40). The following α2-AR
antagonists were selected for mechanistic studies: BRL44408 (15; preferentially
selective at α2A-ARs), imiloxan (12; preferentially selective at α2B-ARs), and ARC-239
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(14; preferentially selective at α2B/2C-ARs).

All three α2-AR antagonists lacked

antinociceptive effects when administered alone in the mouse tail-flick assay (% MPE =
0-5).31,150 When BRL44408 (15; 0.03-3.0 mg/kg, s.c.) was co-administered with the
combination, attenuation of the antinociceptive effect of the combination [3.0 mg/kg
dose of TDIQ (6) + 0.25 mg/kg dose of clonidine (7)] was observed (AD50 = 0.2 mg/kg,
95% CL = 0.05-0.5 mg/kg; Figure 42).
Effect of BRL-44408 on the TDIQ/Clonidine Combination
in the Mouse Tail-Flick Assay
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Figure 42. Effect (± S.E.M.) of BRL44408 (15; 0.03-3.0 mg/kg, s.c.) on the
antinociceptive action of the TDIQ (6; 3.0 mg/kg, s.c.)/clonidine (7; 0.25 mg/kg, s.c.)
combination in the mouse tail-flick assay (n = 8-15 mice/treatment). Asterisks denote a
significant difference compared to the control group [TDIQ/clonidine (6/7) combination];
*P < 0.05, ***P < 0.001, one-way ANOVA (F6,59 = 9.751) followed by Dunnett’s post hoc
test.

Imiloxan (12; 0.1-3.0 mg/kg, s.c.) only attenuated (P < 0.05) the analgesic effect
of the TDIQ/clonidine (6/7) combination at a medium dose (0.3 mg/kg; Figure 43). That
is, lower (0.1 mg/kg) and higher (1.0-3.0 mg/kg) doses of imiloxan (12) did not alter (P >
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0.05) the antinociception produced by the combination [3.0 mg/kg TDIQ (6) + 0.25
mg/kg clonidine (7); Figure 43].
Effect of Imiloxan on the TDIQ/Clonidine Combination
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Figure 43. Effect (± S.E.M.) of imiloxan (12; 0.1-3.0 mg/kg, s.c.) on the antinociceptive
action of the TDIQ (6; 3.0 mg/kg, s.c.)/clonidine (7; 0.25 mg/kg, s.c.) combination in the
mouse tail-flick assay (n = 8-15 mice/treatment). Asterisks denote a significant
difference compared to the control group [TDIQ/clonidine (6/7) combination]; *P < 0.05,
one-way ANOVA (F4.45 = 3.223) followed by Dunnett’s post hoc test.
Finally, the α2B/2C-AR antagonist ARC-239 (14; 0.3-10 mg/kg, s.c.) blocked the
analgesic actions of the TDIQ/clonidine (6/7) combination in a dose-dependent manner
(AD50 = 0.6 mg/kg, 95% CL = 0.2-2.3 mg/kg; Figure 44).
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Effect of ARC-239 on the TDIQ/Clonidine Combination
in the Mouse Tail-Flick Assay
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Figure 44. Effect (± S.E.M.) of ARC-239 (14; 0.3-10 mg/kg, s.c.) on the antinociceptive
action of the TDIQ (6; 3.0 mg/kg, s.c.)/clonidine (7; 0.25 mg/kg, s.c.) combination in the
mouse tail-flick assay (n = 8-15 mice/treatment). Asterisks denote a significant
difference compared to the control group [TDIQ/clonidine (6/7) combination]; *P < 0.05,
**P < 0.01, ***P < 0.001, one-way ANOVA (F4,44 = 7.435) followed by Dunnett’s post
hoc test.

Clearly, TDIQ (6) potentiates the antinociceptive action of clonidine (7). If both
clonidine (7) and TDIQ (6) are non-selective (among α2-ARs) α2-AR agonists, TDIQ’s
(6) potentiation of clonidine (7)-induced antinociception might simply be an additive
effect of the two agents. To further characterize the analgesic potentiation of clonidine
(7; 0.25 mg/kg) produced by TDIQ (6; Figure 40), an isobolographic analysis was
conducted. An isobolographic analysis is a method that assesses if a biological effect
produced by a combination of drugs is greater than, equal to, or smaller than, the sum
of the individual effects of the component drugs. Specifically, does TDIQ (6) behave in
a synergistic or simply additive manner when co-administered with clonidine (7) in the
mouse tail-flick assay?
99

In an isobolographic analysis, synergism is evaluated by comparing the
experimental ED50mix of a fixed-ratio of TDIQ (6) and clonidine (7) to the theoretical
ED50add of a simply additive mixture having the same proportions. Since TDIQ (6) does
not produce antinociception when administered alone, the ED 50add will only be
dependent on clonidine’s (7) effect.

First, co-administration of fixed ratios of the

TDIQ/clonidine (6/7) combination were examined in the tail-flick assay; the coadministration of the 3:1 and 12:1 fixed-ratios of TDIQ (6) and clonidine (7) resulted in a
leftward shift compared to the clonidine (7) dose-response regression line (Figure 45).
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Figure 45. Dose-response lines determined by regression analysis for clonidine (7)
alone (red squares) and the co-administration of TDIQ (6) and clonidine (7) given in a
3:1 (green circles) and 12:1 (blue triangles) fixed-ratio in the mouse tail-flick assay (n =
8-24 mice/treatment), plotted as log clonidine (7) dose.
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Next, a regression analysis of % MPE vs. log total dose graphically presented
ED50clonidine (0.44 mg/kg), ED50mix (0.79 mg/kg) for the 3:1 fixed-ratio, and ED50mix (1.64
mg/kg) for the 12:1 fixed-ratio (Figure 46). ED50add values for both fixed-ratios can be
calculated: ED50add = ED50clonidine/P = 0.44/(1/4) = 1.76 mg/kg for the 3:1 fixed ratio and
ED50add = ED50clondine/P = 0.44/(1/13) = 5.72 mg/kg for the 12:1 fixed ratio.
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Figure 46. Dose-response lines determined by regression analysis for clonidine (7)
alone (red squares) and co-administration of TDIQ (6) and clonidine (7) given in a 3:1
(green circles) and 12:1 (blue triangles) fixed-ratio in the mouse tail-flick assay (n = 8-24
mice/treatment), plotted as log total administered dose.

The line of additivity is based solely on ED50clonidine because TDIQ (6) was found
to be inactive when administered alone in the mouse tail-flick assay (Figure 39).
Because both ED50mix values are plotted significantly below the line of additivity, the 3:1
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and 12:1 fixed ratios of TDIQ (6) and clonidine (7) behaved in a synergistic manner (P <
0.5 and P < 0.01, respectively; Figure 47).
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Figure 47. The isobologram shows the line of additivity (broken gray line), ED 50mix for
the 3:1 (green circles) and 12:1 (blue triangles) fixed-ratios of TDIQ (6) and clonidine
(7), and ED50add (red squares) from the mouse tail-flick results (n = 8-24
mice/treatment). Asterisks denote a significant difference compared to the control
(ED50add values); *P < 0.05, **P < 0.01, Student’s t-test.

Since the experimental ED50mix for a 3:1 and 12:1 fixed-ratio of TDIQ (6) and
clonidine (7) was statistically different than the theoretical ED50add of a simply additive
mixture having the same proportions, TDIQ (6) potentiates the analgesic actions of
clonidine (7) in a synergistic (or super-additive) manner [i.e., the isobologram (Figure
47) suggests that the biological effect (antinociception) produced by the combination of
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TDIQ (6) and clonidine (7) is greater than the sum of the individual effects of the
component drugs].

b) Hot-plate assay

The analgesic properties of TDIQ (6) administered alone and in combination with
clonidine (7) in a second nociceptive animal model, the hot-plate assay, were examined.
When TDIQ (6) was s.c. administered in mice, no antinociception was observed in the
hot-plate assay (Figure 48). This lack of antinociception is similar to the tail-flick results
for TDIQ (6; Figure 39).
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Figure 48. Antinociceptive effect (± S.E.M.) of TDIQ (6; 0.3-10 mg/kg, s.c.) in the
mouse hot-plate assay (n = 8-10 mice/treatment). No significant difference (P > 0.05)
compared to the control group (saline) was detected; one-way ANOVA (F4,41 = 0.2881)
followed by Dunnett’s post hoc test.
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In the tail-flick combination studies, TDIQ (6) potentiated a low, “inactive” dose of
clonidine (7; 0.25 mg/kg; Figure 40) and, therefore, the first hot-plate combination study
examined the co-administration of a low, “inactive” dose of clonidine (7; 0.25 mg/kg) and
TDIQ (6). Unlike in the tail-flick assay, TDIQ (6) did not potentiate the antinociceptive
effects of a low dose of clonidine (7) in the mouse hot-plate assay (Figure 49). In fact,
there seemed to be a slight attenuation of effect; this observed attenuation was not
significantly different from the control.
Effect of TDIQ in Combination with Clonidine (0.25 mg/kg)
in the Mouse Hot-Plate Assay
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Figure 49. Antinociceptive effect (± S.E.M.) of TDIQ (6; 0.3-10 mg/kg, s.c.) in
combination with clonidine (7; 0.25 mg/kg, s.c.) in the mouse hot-plate assay (n = 8-28
mice/treatment). No significant difference (P > 0.05) compared to the control group
[0.25 mg/kg dose of clonidine (7)] was detected; one-way ANOVA (F4,56 = 2.191)
followed by Dunnett’s post hoc test.

Due to slight attenuation observed in Figure 49, the dose of clonidine (7) was
increased so that significant attenuation by TDIQ (6) might be more readily observed.
TDIQ (6; 0.3-10 mg/kg) co-administered with a dose similar to the calculated ED50 (0.9
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mg/kg) of clonidine (7; 1.0 mg/kg) produced a significant decrease in antinociception
(AD50 = 1.4 mg/kg, 95% CL = 0.26-7.84 mg/kg) in comparison to clonidine (7; 1.0
mg/kg) alone (% MPE = 50.6 ± 6.2; Figure 50).

A similar analgesic attenuation (%

MPE = 32-36) by TDIQ (6; 0.3-10 mg/kg) was detected in an even larger dose of
EffectFigure
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Figure 50. Antinociceptive effect (± S.E.M.) of TDIQ (6; 0.3-10 mg/kg, s.c.) in
combination with clonidine (7; 1.0 mg/kg, s.c.) in the mouse hot-plate assay (n = 9-20
mice/treatment). Asterisks denote a significant difference compared to the control
group (1.0 mg/kg dose of clonidine; 7); *P < 0.05, **P < 0.01, one-way ANOVA (F4,53 =
3.927) followed by Dunnett’s post hoc test.
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Effect of TDIQ in Combination with Clonidine (2.0 mg/kg)
in the Mouse Hot-Plate Assay
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Figure 51. Antinociceptive effect (± S.E.M.) of TDIQ (6; 0.3-10 mg/kg, s.c.) in
combination with clonidine (7; 2.0 mg/kg, s.c.) in the mouse hot-plate assay (n = 11-19
mice/treatment). Asterisks denote a significant difference compared to the control
group (2.0 mg/kg dose of clonidine; 7); *P < 0.05, **P < 0.01, one-way ANOVA (F4,58 =
4.954) followed by Dunnett’s post hoc test.
In the mouse hot-plate assay, the non-selective α2-AR agonist TDIQ (6; 0.3-10
mg/kg) produced no antinociceptive effects when administered alone (Figure 48) and
interestingly, attenuated the analgesic actions of a 1.0 and 2.0 mg/kg dose of clonidine
(7; Figures 50 and 49, respectively). This attenuating effect produced by TDIQ (6)
differs from that observed in the tail-flick assay (Figure 40).

c) Locomotor activity assay

Locomotor activity of TDIQ (6; 0.3-3.0 mg/kg, s.c.) alone and in combination with
clonidine (7; 0.25 mg/kg, s.c.) has been previously examined in our laboratory. 151 TDIQ
(6; 0.3-3.0 mg/kg, s.c.) did not significantly differ from saline in the mouse locomotor
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activity assay in all four stimulant parameters (P > 0.05) with one exception (Figure 52).
A 3.0 mg/kg dose of TDIQ (6) did show decreased vertical entries (P < 0.05; data not
shown).
(a)
Total Movement Episodes

500
TDIQ alone
400

300
TDIQ + Clonidine (0.25 mg/kg)
200

100

0
Saline Clonidine
0.25 mg/kg

0.3

1.0

3.0

TDIQ Dose (mg/kg)

(b)
Total Movement Time (s)

2700

TDIQ alone
1800

TDIQ + Clonidine (0.25 mg/kg)
900

0
Saline Clonidine
0.25 mg/kg

0.3

1.0

3.0

TDIQ Dose (mg/kg)

Figure 52. Effect (± S.E.M.) of TDIQ (6; 0.3-3.0 mg/kg) alone and in combination with
clonidine (7; 0.25 mg/kg) on (a) total movement episodes and (b) total movement time
with a 45-min recording time in the mouse locomotor activity assay (n = 8
mice/treatment). No significant difference (P > 0.05) compared to the control group
[saline and clonidine (7; 0.25 mg/kg), respectively] was detected; one-way ANOVA (F3,22
= 0.4039 and F3,20 = 0.3899) followed by Dunnett’s post hoc test.151
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In the combination studies, co-administration of TDIQ (6; 0.3-3.0 mg/kg) and
clonidine (7; 0.25 mg/kg) produced locomotor activity similar to the effect observed by
the s.c. administration of clonidine (7; 0.25 mg/kg) alone (Figure 52).

d) Summary

Briefly, when TDIQ (6) was administered alone, it produced no antinociceptive
effects in the tail-flick (Figure 39) and hot-plate (Figure 48) assays. And since MD-354
(21) potentiated clonidine’s (7) antinociceptive effect, at least in part, by an α 2-AR
mechanism, the effect of the co-administration of the α2-AR agonist TDIQ (6) and
clonidine (7) was also examined. Indeed, TDIQ (6) potentiated the analgesic effect of
an “inactive” dose of clonidine (7; 0.25 mg/kg) in the mouse tail-flick assay (Figure 40).
In contrast, although statistically non-significant, TDIQ (6) slightly attenuated the effect
of an even lower dose (0.1 mg/kg) of clonidine (7; Figure 41). To further characterize
the analgesic potentiation observed in Figure 40, an isobolographic analysis was
conducted. These studies indicated that 3:1 and 12:1 fixed ratios of TDIQ (6) and
clonidine (7) behave synergistically in the mouse tail-flick assay (Figure 47).
To investigate the mechanism of action, α2-AR antagonists were co-administered
with the TDIQ/clonidine (6/7) combination. More specifically, the preferentially selective
α2A-AR antagonist BRL44408 (15; 0.03-3.0 mg/kg), α2B-AR antagonist imiloxan (12; 0.13.0 mg/kg), and α2B/2C-AR antagonist ARC-239 (14; 0.3-10 mg/kg) significantly
attenuated the analgesic potentiation of clonidine (7; 0.25 mg/kg) produced by TDIQ (6)
in the mouse tail-flick assay (Figures 42, 43, and 44, respectively).
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In the hot-plate assays, TDIQ (6) initially seemed to have no effect on the
antinociceptive actions of clonidine (7; 0.25 mg/kg; Figure 49), but the effect of higher
doses (1.0 and 2.0 mg/kg) of clonidine (7) was significantly attenuated by TDIQ (6;
Figures 50 and 49, respectively).
In the final pharmacological studies, the locomotor activity of TDIQ (6) alone and
in combination with clonidine (7) was assessed. In the mouse locomotor activity assay,
s.c. administration of TDIQ (6; 0.3-3.0 mg/kg) produced saline-like effects (Figure 52).
But more importantly, the TDIQ/clonidine (6/7) combinations that produced enhanced
antinociceptive effects in the tail-flick assay (Figure 40) were examined in the mouse
locomotor activity assay; results indicated that the co-administration of TDIQ (6; 0.3-3.0
mg/kg) and clonidine (7; 0.25 mg/kg) was not statistically different than control [clonidine
(7); Figure 52].
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Table 8. Summary of the pharmacological assays; the dose of clonidine (7; where employed) in all
combination studies is 0.25 mg/kg.

Treatment
MD-354 (21; up to a 30 mg/kg dose)
Clonidine (7)
+ MD-354 (21)

Mouse tail-flick assay
inactive

33

Mouse hot-plate
inactive

assay

ED50 = 0.9 mg/kg

ED50 = 0.4 mg/kg
biphasic potentiation

33

34

33

no potentiation

MD-354 (21; 1.0 mg/kg) + clonidine (7)
+ ondansetron (23)

failed to attenuate

+ tropisetron (25)

AD50 = 0.00047 mg/kg

+ yohimbine (11)

AD50 = 0.33 mg/kg

+ BRL44408 (15)

AD50 = 2.1 mg/kg

+ imiloxan (12)

AD50 = 0.17 mg/kg

34

31

31
31

MD-354 (21; 6.0 mg/kg) + clonidine (7)
+ ondansetron (23)
+ zacopride (24)
+ tropisetron (25)

failed to attenuate
failed to attenuate

33,29

failed to attenuate

29

+ yohimbine (11)

AD50 = 2.3 mg/kg

+ imiloxan (12)

attenuated (s.c.)

+ imiloxan (12)
mCPBG (20; up to a 10 mg/kg dose)

failed to attenuate (i.p.)

33

inactive

AD50 = 0.8 mg/kg

mCPBG (20) + clonidine (7; ED50 dose)
mCPBG (20) + clonidine (7)
+ ondansetron (23)
+ tropisetron (25)

ED50 = 1.6 mg/kg
failed to attenuate
attenuated

+ tropisetron methiodide

failed to attenuate

+ yohimbine (11)

AD50 = 0.04 mg/kg

SR57227A (22; 0.3-10 mg/kg)
+ clonidine (7)

inactive

inactive

inactive

failed to potentiate

+ clonidine (7; ED50 dose)

failed to potentiate/attenuate

failed to potentiate/attenuate

TDIQ (6; up to a 10 mg/kg dose)

inactive

inactive
attenuated

TDIQ (6) + clonidine (7; ED50 dose)
TDIQ (6) + clonidine (7)

ED50 = 0.6 mg/kg

+ BRL44408 (15)

AD50 = 0.2 mg/kg

+ imiloxan (12)

AD50 = 0.2 mg/kg

+ ARC-239 (14)

AD50 = 0.6 mg/kg
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failed to potentiate

5. Binding assays

Various agents [(-)NE (1), TDIQ (6), clonidine (7), and MD-354 (21)] were
evaluated in α2A-, α2B-, and α2C-AR binding assays: [35S]GTPγS and competitive
radioligand binding assays (conducted Dr. Scheinin’s Laboratories at University of
Turku, Turku, Finland). In the [35S]GTPγS binding assays, activity was analyzed under
low salt conditions (i.e., low concentration of NaCl and GDP in the buffer solutions) that
favor the detection of partial agonism.152

In general, partial agonists do not show

activity in high salt conditions.
(-)NE (1), considered as a full agonist, was analyzed as control [i.e., (-)NE’s (1)
intrinsic activity at each receptor subtype was normalized to 100%]. As depicted in the
graph (Figure 53a), (-)NE (1) displayed greater efficacy at α2A- and α2B-ARs (Emax ≈
150% over basal levels) in comparison to α2C-ARs (Emax ≈ 75% over basal levels;
Pohjanoksa and Scheinin, unpublished data). Similarly, the potency of (-)NE (1) is
greater at α2A/2B-ARs (EC50 = 106 and 145 nM, respectively) than α2C-ARs (EC50 = 612
nM; Pohjanoksa and Scheinin, unpublished data; Table 9).
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Figure 53. Effectslog[MD-354]
of α2-AR agents [a) (-)NE (1), b) TDIQ (6), c) clonidine (7),
and d)

Alfa2A
Alfa2B
Alfa2C

TDIQ
MD-354 (21)] on [35S]GTPγS
binding (incubation buffer containing low Na+ and GDP
concentrations)
in CHO cell membranes expressing human α2-ARs (α2A: ●; α2B: ■; α2C:
200
Alfa2A
▲). Data points represent the mean ± S.E.M. (each dose examined in triplicate).
Alfa2B
Alfa2C

150
100

TDIQ (6), clondine (7), and MD-354 (21) were of lower efficacy than the full

agonist
(-)NE (1; IA = 100%) at all three α2-AR subtypes in the [35S]GTPγS binding
50
assays;
that is, intrinsic activity was less than 100% (Figure 53; Pohjanoksa and
0
-12

-10

-8

-6

-4

-2

Scheinin, unpublished
data). Table 9 summarizes the potency (EC50) and efficacy [%IA
log[TDIQ]
of (-)NE (1)] of the agents examined at α2A-, α2B-, and α2C-ARs (Pohjanoksa and
Scheinin, unpublished data).
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Table 9. Characterization of [35S]GTPγS binding to CHO cell membranes expressing
human α2A-, α2B-, or α2C-ARs in low salt conditions. Potency is represented as EC 50
values (nM) with the 95% CI in parenthesis. Efficacy (or maximal stimulation over
basal) is expressed as intrinsic activity (IA) compared to (-)NE (1; Pohjanoksa and
Scheinin, unpublished data).
α2A

α2B

α2C

EC50
(nM)
106
(74-152)

IA [% of
(-)NE (1)]
100

EC50
(nM)
145
(94-223)

IA [% of
(-)NE (1)]
100

1,312
(382-4,503)

22

>10,000

18

6,233

22

Clonidine (7)

23
(16-35)

62

220
(82-587)

36

>10,000

37

MD-354 (21)

1,588
(757-3,333)

36

>10,000

31

>10,000

41

(-)NE (1)
TDIQ (6)

EC50
IA [% of
(nM)
(-)NE (1)]
612
100
(276-1,358)

Affinity at α2-AR subtypes (α2A, α2B, and α2C) was examined for the abovementioned agents via competitive ligand binding assays employing the α2-AR
antagonist radioligand [ethyl-3H]RS-79948-197 (Table 10). The binding affinity for the
full agonist (-)NE (1) and (as subsequently determined) the partial agonists TDIQ (6),
clonidine (7) and MD-354 (21) was measured in CHO cells expressing recombinant
human α2A-, α2B-, and α2C-ARs (Table 10, unpublished data).

Binding affinity for

SR57227A (22) at α2-AR subtypes was also examined via competitive radioligand
binding assays employing the human α2-AR agonist radioligand [3H]clonidine (Table
11).145
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Table 10. Competitive binding affinity at human α2-ARs expressed in CHO cells
employing [ethyl-3H]RS-79948-197 radioligand (α2-AR antagonist). Binding affinity is
expressed as Ki values (nM) with the 95% CI in parenthesis (Pohjanoksa and Scheinin,
unpublished data).31
Ki (nM)
α2A

α2B

α2C

(-)NE (1)

405 (284-578)

579 (421-798)

417 (333-524)

TDIQ (6)

598 (478-749)

1,183 (904-1,547)

Clonidine (7)

35 (28-45)

98 (81-118)

MD-354 (21)

110 (70-190)

220 (170-280)

Ligand

1,782 (1,538-2,065)
287 (234-353)
4,700 (2,800-7,800)

Table 11. Competitive binding affinity at human α2-ARs expressed in CHO cells
employing [3H]clonidine radioligand (α2-AR agonist). Binding affinity is expressed as Ki
values ± S.E.M. (nM; unpublished data). 145
Ki (nM)
Ligand
SR57227A (22)

α2A

α2B

α2C

6,653 ± 665

4,990 ± 709

8,222 ± 658

TDIQ (6) shows a slight binding preference for α2A-ARs (2- and 3-fold over α2Band α2B-ARs, respectively) but, in general, has relatively low binding affinity at α2-ARs.
Similarly, clonidine (7) displays higher affinity at α2A-ARs versus α2B- and α2C-ARs (3and 8-fold difference, respectively). MD-354 (21) binds at α2A- and α2B-ARs with similar
affinity (Ki = 110 and 220 nM), but with significantly lower binding affinity at α 2C-ARs (Ki
= 4,700 nM). SR57227A (22), which has been described in the literature as a selective
5-HT3 receptor agent, displayed negligible binding affinity at human α 2A-, α2B-, and α2CARs (Ki > 1,000 nM; Table 11).145
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6. Discussion

Pharmacological studies were conducted to further characterize the biphasic,
analgesic potentiation observed when MD-354 (21; 0.3-10 mg/kg) is co-administered
with an “inactive” dose of clonidine (7; 0.25 mg/kg) in the mouse tail-flick assay (Figure
12).135 Since MD-354 (21) binds to 5-HT3 receptors and α2-ARs (Table 5), it is likely
that each peak (Figure 12) depicts a unique mechanism of action. For example, the
potentiation depicted by Peak A could be due to 5-HT3 receptor agonism, whereas Peak
B potentiation could be due to α2-AR antagonism. In general, the Peak A and/or B
potentiating effects could involve: (a) 5-HT3 receptor agonism or antagonism, (b) α2-AR
(one or more of the receptor subtypes) agonism or antagonism, (c) a combination of the
above, or (d) neither 5-HT3 receptor nor α2-AR action (i.e., that is, some other, yet
unidentified, receptor mechanisms might be involved). Previously reported mechanistic
studies on MD-354 (21) potentiation of the antinociceptive effect of clonidine (7) might
provide some insight on Peak A and Peak B potentiation (summarized in Table 12).
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Table 12. Summary of the previously reported mechanistic studies associated with the
analgesic potentiation of clonidine (7; 0.25 mg/kg) by MD-354 (21; 0.3-10 mg/kg).
Mechanistic study results

Comments
Peak A

 Tropisetron (25) attenuated the
antinociceptive effect of the MD-354
(21; 1.0 mg/kg)/clonidine (7; 0.25
mg/kg) combination.34

 This suggests a 5-HT3 receptor agonist
mechanism; but not all 5-HT3 receptor
antagonists [e.g., ondansetron (23)]
blocked the effect.

 Yohimbine (11), imiloxan (12), and
BRL44408
(15) attenuated
the
antinociceptive effect of the MD-354
(21; 1.0 mg/kg)/clonidine (7; 0.25
mg/kg) combination.31

 This suggests an α2-AR agonist
mechanism (but, it is unclear which α2AR subtype is involved).

Peak B
 Ondansetron (23), zacopride (24), and
tropisetron (25) failed to attenuate the
antinociceptive effect of the MD-354
(21; 6.0 mg/kg)/clonidine (7; 0.25
mg/kg) combination.33,29
 Yohimbine (11) and imiloxan (12)
attenuated the antinociceptive effect
of the MD-354 (21; 6.0 mg/kg)/
clonidine (7; 0.25 mg/kg) combination
(unpublished data).

 This suggests that 5-HT3 receptor
agonism is not the mechanism of action.

 This suggests an α2-AR agonist
mechanism (but, it is unclear which α2AR subtype is involved).

Peak A or B
 Ondansetron (23), zacopride (24), and
tropisetron (25) potentiated the
antinociceptive effect of clonidine (7;
0.25 mg/kg).29

 This suggests that 5-HT3 receptor
antagonists
can
potentiate
the
antinociceptive effects of clonidine (7).

 Imiloxan
(12)
potentiated
the
antinociceptive effects of clonidine (7;
0.25 mg/kg).31

 This suggests an α2-AR antagonist can
potentiate the antinociceptive effects of
clonidine (7).

116

Although numerous mechanistic studies have been conducted, the mechanism of
action of the potentiation of clonidine’s (7) antinociceptive effect by MD-354 (21)
remains elusive. As summarized in Table 12, 5-HT3 receptors and α2-ARs both seem to
be involved in both Peak A and B. For example, a low dose of MD-354 (21; 1.0 mg/kg)
appears to potentiate the antinociceptive effects of clonidine (7) via a 5-HT3 receptor
agonist mechanism (Peak A), whereas a higher dose of MD-354 (21; 6.0 mg/kg) might
be acting as a 5-HT3 receptor antagonist (Peak B).

29,34

The latter mechanism is

speculative; MD-354 (21) shows partial agonist activity at 5-HT3 receptors and,
therefore, can behave functionally as an agonist or antagonist. 113 Also, as shown in our
laboratory, three structurally diverse 5-HT3 receptor antagonists [ondansetron (23),
zacopride (24), and tropisetron (25)] enhanced the analgesic actions of an “inactive”
dose of clonidine (7) in the tail-flick assay.29 This observed potentiation is unlikely due
to a central depressant effect because co-administration of these 5-HT3 receptor
antagonists [e.g., zacopride (24; 0.01 mg/kg) or tropisetron (25; 0.2 mg/kg)] and the α2AR partial agonist clonidine (7; 0.25 mg/kg) produced results similar to that of control
[0.25 mg/kg dose of clonidine (7); P > 0.05] in mouse locomotor activity assays.29 This
provides evidence that antagonism at 5-HT3 receptors augments the antinociceptive
effects of clonidine (7), but does not necessarily indicate a 5-HT3 receptor antagonist
role for MD-354 (21) in its analgesic potentiation of clonidine (7) in the moue tail-flick
assay.
In the present investigation, the role of 5-HT3 receptor involvement in the
potentiation of clonidine (7)-induced analgesia was further evaluated.

A more

established 5-HT3 receptor agonist, mCPBG (20), and a known centrally-acting 5-HT3
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receptor agonist, SR57227A (22), were examined to help clarify the mechanism of
action.

In the mouse tail-flick assay, no antinociception was observed with s.c.

administration of either mCPBG (20; 0.3-10 mg/kg; Figure 22) or SR57227A (22; 0.3-10
mg/kg; Figure 31) alone.

However, a high dose (30 mg/kg) of SR57227A (22),

administered alone, produced a significant effect (P < 0.05; Figure 31).

Dose-

dependent antinociception by SR57227A (22, doses of up to 20 mg/kg; ED50 = 6.5
mg/kg) has been previously observed in the mouse-tail flick assay but, as opposed to
the current study (which employed a s.c. route of administration), SR57227A (22) was
administered via i.p. injection.27 It is possible that the observed antinociceptive effect
described in the literature is due to route of administration; furthermore, the
hypolocomotor effects produced by this dose of SR57227A (22), as shown herein, might
have interfered with interpretation of its antinociceptive actions. But, two prior studies
showed no effect in the mouse locomotor assay when low doses (1.0-10 mg/kg) of
SR57227A (22) were administered i.p., whereas only a high dose (30 mg/kg) showed
hypolocomotor actions.153,154 This is similar to the results obtained in our laboratory;
SR57227A (22) elicited saline-like effects when low doses (1.0-10 mg/kg, i.p.) were
administered, but sedative-like effects were observed when a high dose of SR57227A
(22; 30 mg/kg) was administered s.c. in the mouse locomotor activity assay (P < 0.01;
Figure 38).155

It is difficult to reconcile differences between the published

antinociceptive actions of SR57227A (22) with the present investigation, and even more
difficult to explain its actions as resulting from sedation, given its lack of effect in
locomotor assays (except at a very high dose). But, it might be noted that the single
report showing that SR57227A (22) possesses antinociceptive action was published
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only as an abstract and that various details (e.g., mouse strain and gender, pre-injection
times, time of measurement, and apparatus) were not described.

Nevertheless,

antinociceptive effects have been produced by other 5-HT3 receptor agonists [5-HT
(16), 2-methyl-5-HT (17), and mCPBG (20)] in various animal models (tail-flick, paw
pressure, and formalin assays; refer to Table 4).28,127,128,131-133

Therefore, the

antinociceptive effects produced by SR57227A (22) are plausible, but inconsistent with
the present results.
In the combination studies, albeit mCPBG (20; 0.3-10 mg/kg) augmented the
antinociceptive effects of an “inactive” dose of clonidine (7; 0.25 mg/kg) in a dosedependent manner (Figure 23), SR57227A (22; 0.3-10 mg/kg) had no effect on
clonidine’s (7) analgesic properties in the mouse tail-flick assay (Figure 31).

It is

doubtful that the observed antinociception in the mCPBG/clonidine (20/7) treatment
group is due to the hypolocomotor effects of mCPBG (20); the analgesia-producing
combination [mCPBG (20; 6.0 mg/kg) + clonidine (7; 0.25 mg/kg)] showed clonidine (7)like effects in the mouse locomotor activity assay (Figure 30). In addition, both i.p. and
i.c.v. administration of mCPBG (20), alone, elicited saline-like effects in rat locomotor
activity assays.156,157
mCPBG (20) and SR57227A (22) have slightly different receptor binding profiles;
mCPBG (20) binds with high affinity at 5-HT3 receptors (Ki = 17 nM) and with low affinity
at α2-ARs (Ki = 1,445 or 3,800 nM), 5-HT2A receptors (Ki = 5,700 nM), and 5-HT2C
receptors (Ki = 1,400 nM), and according to the current literature, SR57227A (22) binds
with high affinity only at 5-HT3 receptors (Ki = 103 nM).111,115,149,158

It seems that

SR57227A (22) is relatively selective for 5-HT3 receptors; however, its affinity for other
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receptors was simply reported as >1,000 nM and specific Ki values were not provided
(that is, its affinity for these other receptors might be only slightly greater than 1,000
nM). Bachy and co-workers described SR57227A (22) as a highly potent and selective
5-HT3 receptor agonist; depending on the assay conditions, its Ki value at 5-HT3
receptors was approximately 100 nM (IC50 = 199-258 nM).115

In the same study,

SR57227A (22) did not bind to other 5-HT receptors (5-HT1A, 5-HT1B, 5-HT1C, 5-HT1D, 5HT2, and 5-HT4; IC50 > 1,000 nM, exact Ki values were not reported).115

Since

SR57227A (22) binding affinity at α2-ARs was ambiguous, our laboratory submitted a
sample to the PDSP for binding affinity analysis. Using an α2-AR agonist radioligand
[3H]clonidine, SR57227A (22) showed little to no affinity for α2-ARs (Ki: α2A = 6,653, α2B
= 4,990, and α2C = 8,222 nM; Roth, unpublished data; refer to Table 11).145
In general, both of these agents [mCPBG (20) and SR57227A (22)] bind
selectively at 5-HT3 receptors, but it is possible that the behavioral activity of mCPBG
(20) involves α2-ARs and/or 5-HT2A/2C receptors. This is unlikely because the affinity of
mCPBG (20) at 5-HT3 receptors is at least 100 times greater than that for the other
receptors. Likewise, the lower-affinity 5-HT3 receptor agent SR57227A (22) binds to
other receptors, such as α2B-ARs, but with very low affinity (Ki ≈ 5,000 nM).145 This
binding profile indicates moderate binding selectivity at 5-HT3 receptors (50-fold
difference compared to α2B-ARs).
The differences observed in the analgesia-potentiating activity of clonidine (7) by
mCPBG (20) and SR57227A (22) combination studies might be due to species
difference.

For example, mCPBG (20) binds at rat 5-HT3 receptors with 100-times

greater affinity than at human 5-HT3 receptors.159 Also, the 5-HT3 receptor efficacy of
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mCPBG (20) is species dependent: ferret (53%), mouse (91%), rat (100%), and human
(79-99%).97,159-162

Most in vitro and in vivo pharmacological assays indicate that

mCPBG (20) is a full 5-HT3 receptor agonist, however, mCPBG (20) exhibited partial
agonist character in an electrophysiological assay employing NG108-15 cells.163 More
specifically, the mCPBG (20) response was 54% of the maximal response produced by
5-HT (16).163 Similar to most other pharmacological studies, mCPBG (20) exhibited a
full agonist response in a second electrophysiological study (i.e., utilizing N1E-115
cells).164 To the best of our knowledge, similar studies have not been conducted with
SR57227A (22), but it is possible that this agent also has variable binding affinity and/or
efficacy at 5-HT3 receptors in different species.
Another explanation for the analgesic potentiation observed when mCPBG (20),
but not SR57227A (22), is co-administered with clonidine (7) is its selectivity for 5-HT3
receptor subpopulations. That is, action at 5-HT3AB receptors, but not 5-HT3A
receptors, might cause a potentiation in clonidine’s (7) antinociceptive effects. If this is
the case, then it is plausible that mCPBG (20) might act at 5-HT3AB receptors whereas
SR57227A (22) activates 5-HT3A receptors. This remains to be investigated.
To the best of our knowledge, binding affinities (under the same conditions) at
each human receptor subtype (i.e., 5-HT3A vs. 5-HT3AB) are unknown for mCPBG (20)
and SR57227A (22). As reported in the Background section, mCPBG (20; Ki = 17 nM)
binds at 5-HT3 receptors (mixture of 5-HT3A and 5-HT3AB receptors) with higher affinity
than SR57227A (22; Ki = 103 nM).111,115 To date, 5-HT3A receptor affinity for these two
agents have been reported, but the experimental conditions, as well as the species, are
different. Ito and co-workers reported binding affinity for 5-HT (16; Ki = 339 nM) and
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mCPBG (20; Ki = 224 nM) at cloned human 5-HT3A receptors transfected in COS-1
cells employing [3H]ramosetron (5-HT3 receptor antagonist) as a radioligand.165
Because our laboratory was analyzing the mouse functional activity of SR57227A (22),
investigation of the binding affinity at 5-HT3A receptors was of interest to us.
SR57227A’s (22; Ki = 357 ± 44 nM) binding affinity at recombinant mouse 5-HT3A
receptors was evaluated using [3H]LY 278,584 (5-HT3 receptor antagonist; unpublished
data).145 Unfortunately, these values are meaningless without the 5-HT3AB binding
affinities of both agents. It is also difficult to compare the 5-HT3A receptor binding
affinities of these two agents due to dissimilar experimental conditions.
Although, binding affinity has not been reported for each receptor subtype,
mCPBG’s (20) functional activity has been evaluated both at 5-HT3A and 5-HT3AB
receptors. Two electrophysiological studies were performed and they both suggest that
mCPBG (20) has similar potencies at human 5-HT3A and 5-HT3AB receptors (e.g., EC50
= 2.5 and 2.1 μM, respectively).97,98 But, interestingly, mCPBG (20) showed greater
efficacy at the homomeric 5-HT3 receptors [5-HT3A receptors: 134%, 5-HT3AB
receptors: 79%; efficacy is expressed as % of 5-HT (16) effect].97 Assuming that this is
how mCPBG (20) behaves in mice, it seems reasonable that mCPBG (20) produces a
greater pharmacological effect via 5-HT3AB receptors than at 5-HT3A receptors.
Therefore, 5-HT3AB, rather than 5-HT3A, receptor agonism might be responsible for the
analgesic potentiation observed in the mCPBG/clonidine (20/7) combination (Figure
23a). If this is the case, it is possible that the lack of analgesic potentiation of clonidine
(7) by SR57227A (22) is due to negligible 5-HT3AB receptor activity.

122

Both mCPBG (20) and the structurally-related analog MD-354 (21) were inactive
(i.e., both agents produced saline-like effects) in the tail-flick assay (Figure 22).33 On
the other hand, the 5-HT3 receptor agonist SR57227A (22) exhibited pronociceptive
effects in the mouse tail-flick assay (Figure 33). That is, SR57227A (22)-treated mice
showed hyperalgesic effects (or increased sensitivity to pain). There are other reports
for the hyperalgesic actions of 5-HT3 receptor agonists. For example, when 5-HT (16)
or 2-methyl-5-HT (17) was applied to human blisters, a hyperalgesic effect resulted.110
The pain-producing effect evoked by 5-HT (16) was inhibited by the 5-HT3 receptor
antagonist tropisetron (25).110 However, a hyperalgesic effect for SR57227A (22) has
not been previously reported.
Since involvement of α2-ARs seems to play a role in the potentiation of the
antinociceptive actions of clonidine (7) by MD-354 (21), it was initially thought that the
potentiating effect observed with mCPBG (20) but not SR57227A (22) in the tail-flick
assay might be due to the difference in receptor binding selectivity [i.e., mCPBG (20)
may be acting via an α2-AR and not a 5-HT3 receptor mechanism, which would explain
why a 5-HT3 receptor agent such as SR57227A (22) that lacks α2-AR affinity would not
potentiate the antinociceptive effects of clonidine (7)]. Hypothetically, if this was correct,
a 5-HT3 receptor antagonist should not attenuate the antinociceptive effects of the
mCPBG/clonidine (20/7) combination.

In contrast, the 5-HT3 receptor antagonist

tropisetron (25; 0.00001-0.1 mg/kg) attenuated the antinociceptive effect of the
mCPBG/clonidine (20/7) combination, which resulted in a U-shaped dose-response
curve (Figure 25). Although it is possible that this type of antagonism (i.e., antagonist
effect that produces a U-shaped dose-response curve) is sometimes not detected when
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a full range of doses is not examined, U-shaped dose-response curves are observed
with many 5-HT3 receptor antagonists [e.g., ondansetron (23)].166,167 Blockade of the
effect of the mCPBG/clonidine (20/7) combination by the 5-HT3 receptor antagonist
tropisetron (25) indicates that mCPBG (20) may be potentiating clonidine’s (7) analgesic
effects via a 5-HT3 receptor agonist mechanism.
If a 5-HT3 receptor agonist mechanism is involved with the potentiating effect of
clonidine (7) by mCPBG (20), then it would be expected that a 5-HT3 receptor
antagonist [e.g., ondansetron (23)] would block the effect of the combination.
Ondansetron (23) did not alter the antinociceptive effect of the mCPBG/clonidine (20/7)
combination (Figure 24). It is important to note that previous pharmacological assays
involving ondansetron (23) and tropisetron (25) have produced contradictory
results.168,169

For example, tropisetron (25), but not ondansetron (23), improved

phencyclidine-induced cognitive deficits in mice.168

And, most analogous to the

mCPBG (20) studies, our laboratory showed analgesic attenuation in the mouse tail-flick
assay by tropisetron (25), but not by ondansetron (23), in the low-dose (1.0 mg/kg) MD354/clonidine (21/7) combination (Figure 20).34 Therefore, literature precedent suggests
that ondansetron’s (23) lack of effect in our combination studies does not necessarily
disprove a 5-HT3 receptor agonist mechanism proposed from the tropisetron (25)
results.
Moreover,

a

locomotor

suppressant

effect

could

alter

the

observed

antinociceptive effect in the tail-flick assay. When administered alone, tropisetron (25;
0.2 mg/kg, s.c.) and ondansetron (23; 0.1-1.0 mg/kg, i.p.) showed saline-like effects in
the mouse locomotor activity assay.29,155,170
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Tropisetron (25; 0.2 mg/kg) co-

administered with clonidine (7; 0.25 mg/kg) showed slightly reduced locomotor activity.29
However, this attenuation was not statistically different from control [0.25 mg/kg dose of
clonidine (7)].29
To date, it is unknown if mCPBG (20) crosses the BBB; there is contradictory
literature data (summarized in Table 6). Although it is unclear if mCPBG (20) behaves
as a central agent, mechanistic studies suggest that potentiation of the antinociceptive
effects of clonidine (7) by mCPBG (20) in the mouse tail-flick assay is due to a central 5HT3 receptor agonist mechanism because tropisetron (25), but not tropisetron
methiodide, attenuated this effect (Figures 24 and 24). Results from this in vivo assay
provide an indication that mCPBG (20) can cross the BBB. Similarly, a 5-HT3 receptor
agonist mechanism was postulated for the analgesic potentiation depicted by Peak A in
the MD-354/clonidine (21/7) combination studies (Table 12). There is some indication
from previous in vivo studies that MD-354 (21) acts as a central agent; MD-354 (21)
neither substituted for nor antagonized, but enhanced the stimulus effects of
(+)amphetamine in a rat drug discrimination study.135

Thus far, although a central

mechanism has also been implied in the mouse tail-flick studies, it is unknown if the
agonistic behavior of MD-354 (21) is due to central or peripheral activation of 5-HT3
receptors.

Additional mechanistic studies are required (e.g., pretreatment with

tropisetron methiodide).
In summary, the tail-flick assay results with mCPBG (20) provide evidence for 5HT3 receptor agonist potentiation of an “inactive” dose of clonidine (7). This was the
same conclusion that was reached from the tail-flick assay results with MD-354 (21;
Peak A).34 However, the SR57227A (22; 0.3-10 mg/kg) results (Figure 34) indicate that
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not all 5-HT3 receptor agonists augment the analgesic properties of clonidine (7).
Possible explanations for the lack of potentiation observed upon co-administration of
SR57227A (22) and clonidine (7) include: (a) lower 5-HT3 receptor binding affinity of
SR57227A (22; Ki = 103 nM) in comparison to mCPBG (20; Ki = 17 nM), (b) action at
different 5-HT3 receptor subtypes (e.g., 5-HT3A or 5-HT3AB receptors), (c) possible
offsetting behavioral activity [e.g., pronociceptive effects of SR57227A (22)] due to
unknown activity at other receptors, (d) species difference, and that (e) unexamined,
higher doses of SR57227A (22; >10 mg/kg) or temporal parameters might
produce/influence potentiating activity. The latter explanation is plausible, but it would
be difficult to understand if the analgesic potentiation was due to antinociceptive or
sedative effects because a 30 mg/kg dose of SR57227A (22) was found to produce
hypolocomotor effects in the present investigation (Figure 38). In fact, in a previously
reported study, lower i.p. doses of SR57227A (22; 3-10 mg/kg) exhibited saline-like
effects, whereas a 30 mg/kg dose (i.p.) significantly reduced locomotor activity (P <
0.001) in the mouse locomotor activity assay.154
The role of 5-HT3 receptors in potentiating the analgesic effects of clonidine (7)
was evaluated in a second nociceptive mouse model, the hot-plate assay. Similar to
the results in the tail-flick assay, when administered alone, both mCPBG (20; 0.3-10
mg/kg) and SR57227A (22; 0.3-10 mg/kg) showed no antinociceptive effects in the hotplate assay (Figures 28 and 36, respectively); however, a higher, sedative-producing
dose of SR57227A (22; 30 mg/kg) showed significant antinociceptive effects in the
mouse hot-plate assay (Figure 36). Hence, these “antinociceptive” effects might be
attributed to the sedative effect of SR57227A (22).
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In combination studies, MD-354 (21) was found to potentiate the antinociceptive
effect of clonidine (7) in the tail-flick assay, but not in the hot-plate assay.33 Reports of
contrasting results in tail-flick and hot-plate assays have been documented in the
literature; for example, gabapentin attenuated the analgesic actions of the non-selective
COX inhibitor metamizol in the mouse tail-flick assay, but did not affect the
antinociceptive effects of metamizol in the mouse hot-plate assay.171

The different

effects observed in the tail-flick and hot-plate assays can be explained by different
receptor subpopulations (spinal versus supraspinal, respectively) or different receptor
mechanisms.143 In the current study, the ED50 dose of clonidine (7; 1.0 mg/kg) was
selected so that potentiation or attenuation could be observed when clonidine (7) was
co-administered with varying doses of the 5-HT3 receptor agents mCPBG (20) and
SR57227A (22) in the hot-plate assay.

mCPBG (20; 0.3-10 mg/kg) significantly

attenuated the antinociceptive effect (AD50 = 0.8 mg/kg) of clonidine (7; Figure 29), but
SR57227A (22; 0.3-10 mg/kg) failed to potentiate or attenuate the actions of clonidine
(7; Figure 37) in the hot-plate assay. Different pharmacological effects were observed
among these three 5-HT3 receptor agents; in combination studies with clonidine (7; 1.0
mg/kg), the antinociceptive effect was not significantly attenuated (i.e., not statistically
significant) by MD-354 (21), significantly attenuated by mCPBG (20), and not affected
by SR57227A (22).33
A high dose of MD-354 (21; 30 mg/kg) slightly antagonized the analgesic action
of the ED50 dose of clonidine (7) in the hot-plate assay.33 Therefore, the results in the
mCPBG [20; structurally similar to MD-354 (21)]/clonidine (7) combination studies were
not completely unexpected (Figure 29). MD-354 (21) behaves as a partial agonist at 5127

HT3 receptors and, therefore, could be producing its inhibitory actions via an agonist or
antagonist mechanism. In contrast, mCPBG (20) displays full agonist action at 5-HT3
receptors (mouse and human).160 As a result, it is likely that the inhibitory action of
clondine’s (7) antinociceptive effects by mCPBG (20) and MD-354 (21) in the hot-plate
assay is mediated by 5-HT3 receptor agonism.
If mCPBG (20) attenuates the analgesic actions of clonidine (7) in the mouse hotplate assay via a 5-HT3 receptor agonist mechanism, why doesn’t administration of
SR57227A (22) also inhibit the analgesic effect of clonidine (7) in the same assay?
Even though inhibition by SR57227A (22) would further support a 5-HT3 receptor
agonist mechanism, the lack of attenuation by SR57227A (22) was not too surprising
because, as discussed in the Background section, 5-HT3 receptor agonists have
notoriously produced varying results in nociceptive animal models (Table 4).

For

example, mCPBG (20; i.t.) produced saline-like effects, whereas a second 5-HT3
receptor agonist 2-methyl-5-HT (17; i.t.) produced antinociceptive effects in the tail-flick
assay.26,28

The reason for these varying effects among 5-HT3 receptor agonists

remains unclear.

It is possible that 5-HT3 receptor subtype selectivity alters the

pharmacological effects of these agents. Two known functional 5-HT3 receptor types
have been identified: homopentameric 5-HT3A receptors and heteropentameric 5HT3AB receptors, which are composed of two 5-HT3A and three 5-HT3B receptor
subunits.21,97-101 Also, there are three other known 5-HT3 receptor subunits (5-HT3C, 5HT3D, and 5-HT3E) but, to date, they have unknown function. Unfortunately, the lack
of information regarding 5-HT3 receptors, and the affinity of agents at each of those
populations, might lead to ambiguous interpretation of pharmacological results.
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Following the combination studies that examined the role of 5-HT3 receptors in
the analgesia potentiation of clonidine (7), the role of α2-ARs was investigated. It was
already determined in mechanistic studies that mCPBG (20)-potentiation of the
antinociceptive effect of an “inactive” dose of clonidine (7) in the tail-flick assay, at least
in part, involves a 5-HT3 receptor agonist mechanism.

Next, mechanistic studies

involving α2-AR antagonists were conducted in the mouse tail-flick assay. The nonselective α2-AR antagonist yohimbine (11; 0.01-6.0 mg/kg) blocked the antinociceptive
potentiation of clonidine (7) by mCPBG (20) in a dose-dependent manner (Figure 27).
This suggests that the combination is not only acting via a central 5-HT3 receptor
agonist mechanism, but also affects the analgesic properties of clonidine (7) via α2-ARs.
α2-AR involvement was also observed in the potentiation of clonidine (7) by MD354 (21); the non-selective, α2A-, and α2B-AR preferential antagonists [yohimbine (11),
BRL44408 (15), and imiloxan (12), respectively] blocked the analgesia-potentiating
effect produced by MD-354 (21).31 MD-354 (21) binds to all three α2-AR subtypes with
variable affinity (Ki = 25-4,700 nM; refer to Table 5) and functionally behaves as a partial
agonist at α2A-ARs [IA = 36% of NE (1) activity; EC50 = 1,588 nM].31 Additionally, MD354 (21) seems to behave as a partial agonist at α2B- and α2C-ARs [IA = 31 and 41% of
NE (1) activity, respectively], but its potency is very low (EC50 > 10,000 nM for both
subtypes).31

On the other hand, although subtype selectivity was not examined,

mCPBG (20) has low affinity at α2-ARs (Ki = 1,445 nM) and seems to behave as an α 2AR antagonist.149 In this study, mCPBG (20) binding affinity was based on rat brain
cortex homogenates and the functional data was based on ex vivo mouse studies, in
which mCPBG (20) facilitated NE (1) release in mouse cerebral cortex.149 Although
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mCPBG (20) did produce α2-AR antagonist actions at high doses, its potency was
rather low compared to the yohimbine (11) stereoisomer rauwolscine (i.e., rauwolscine
had 340-fold greater potency than mCPBG (20)].149
There are two possible ways of interpreting the mechanistic studies involving α 2AR antagonists co-administered with the MD-354/clonidine (21/7) combination. The
analgesic attenuation could be due to blocking the effect of clonidine (7) or MD-354
(21). Conversely, since mCPBG (20) seems to behave as an α2-AR antagonist, the
analgesic attenuation observed in mechanistic studies utilizing the non-selective α2-AR
antagonist yohimbine (11) in combination with mCPBG (20) and clonidine (7) is most
likely due to blocking the effect of clonidine (7). mCPBG (20) might potentiate the
antinociceptive effect of clonidine (7) in the hot-plate assay if clonidine (7) is able to act
at α2-ARs (i.e., it is essential for clonidine (7) to act at α2-ARs). In addition, because
mCPBG (20) has low binding affinity for α2-ARs (Ki = 1,445 nM) compared to its affinity
for 5-HT3 receptors (Ki = 17 nM), it is unlikely that the pharmacological effects of
mCPBG (20) are due to interaction at α2-ARs. Nevertheless, it is important to note that,
to the best of our knowledge, the binding affinity and functional activity of mCPBG (20)
at the three α2-AR subtypes have not been examined. It is possible that the low affinity
data obtained from rat brain cortex homogenates does not depict the affinity of mCPBG
(20) at all α2-AR subtypes (e.g., it is possible that mCPBG (20) displays high affinity at
α2A-AR, but not α2B- or α2C-ARs).149
Previous literature indicates that the antinociceptive effects of clonidine (7) are
due to an α2A-AR agonist mechanism.172,173 And although clonidine (7) binds to all three
subtypes of α2-ARs with similar affinity (refer to Table 2), it behaves as a partial agonist
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at α2A-ARs and as a very weak partial agonist at α2B- and α2C-ARs [%Emax = 62, 36, and
37% of NE (1) activity; EC50 = 23, 220, and >10,000 nM, respectively; Pohjanoksa and
Scheinin, unpublished data].
The non-selective α2-AR agonist TDIQ (6), which is devoid of 5-HT3 receptor
affinity, was evaluated in the mouse tail-flick assay. This agent produced no
antinociceptive effects when administered alone, but dose-dependently potentiated the
analgesic effect of an “inactive” dose of clonidine (7; Figures 39 and 38, respectively).
In fact, an isobolographic analysis of a 3:1 and 12:1 fixed ratio dose of TDIQ (6) and
clonidine (7) indicated a synergistic potentiation of the antinociceptive effect (Figure 47).
Activation of one receptor mechanism presumably produces a simply additive effect
(i.e., the co-administration of the combination should produce the theoretical effect
based on the individual potencies of the two drugs). 174,175

Most reports conclude

synergy is due to multiple mechanisms (i.e., two drugs acting via different sites, whether
that is different anatomical sites or different receptors); a recent study indicated that
clonidine (7) and dexmedetomidine produced antinociceptive synergy in mice via a dual
receptor mechanism (agonist action at α2A- and α2C-ARs).176 Therefore, the supraadditive effect (or synergistic effect) produced by TDIQ (6) in combination with clonidine
(7) suggests multiple mechanisms. For example, the analgesic synergy produced by
TDIQ (6) and clonidine (7) could be mediated by an α2A-AR agonism as well as either a
α2B- or α2C-AR agonism.
One therapeutic advantage to synergistic drug effects is a decrease in drug
doses. This reduced drug dose(s) can theoretically produce efficacy of the desired
effect, but reduce efficacy in producing side effects.
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In the abovementioned

combination studies [e.g., TDIQ (6) and clonidine (7)], a desired antinociceptive effect
occurred without affecting clonidine’s (7) sedative side effect. That is, a reduced dose
of clonidine (7; 0.25 mg/kg) in combination with TDIQ (6) produced analgesic actions
without influencing locomotor activity.
To further understand the mechanism(s) underlying these actions, combination
studies were conducted.

The mechanistic studies with TDIQ (6) produced similar

results compared to MD-354 (21); that is, the α2A-, α2B-, and α2B/2C-AR preferential
antagonists [BRL44408 (15), imiloxan (12), and ARC-239 (14), respectively] significantly
blocked the analgesia-potentiating effect of an “inactive” dose of clonidine (7) by TDIQ
(6) in the tail-flick assay (Figures 42, 43, and 44, respectively). In [35S]GTPγS binding
studies, TDIQ (6) behaved as a weak partial agonist at α2A-, α2B-, and α2C-ARs [IA =
22%, 18%, and 22% of NE (1) activity; EC50 = 1,300, >10,000, and 6,230 nM,
respectively; Pohjanoksa and Scheinin, unpublished data]. Although TDIQ (6) produces
partial agonist action at all three subtypes of α2-ARs, its efficacy (or intrinsic activity) is
lower than that of clonidine [7; IA = 62%, 36%, and 37% of NE (1) activity at α2A-, α2B-,
and α2C-ARs; Pohjanoksa and Scheinin, unpublished]. Due to its lower intrinsic activity,
TDIQ (6) may behave as an α2-AR antagonist when co-administered with clonidine (7).
In fact, previous imiloxan (12) studies suggest that α2B-AR antagonism might account
for the potentiation of the antinociceptive effects of clonidine (7) in the mouse tail-flick
assay (refer to Table 12).31
Based on these in vivo results, it is difficult to determine which α 2-AR subtype is
responsible for the analgesic potentiation observed in the TDIQ/clonidine (6/7)
combination. At this time, none of the α2-AR subtypes can be ruled out. It is possible
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that one or more of the receptor subtypes plays a role in this potentiating effect. The
results are difficult to interpret because the available α2-AR antagonists, to date, are
only preferentially selective.

For example, BRL44408 (15) binds to all three α2-AR

subtypes (Ki: α2A = 5.7, α2B = 651, and α2C = 150 nM). Even though BRL44408 (15)
shows preferential binding affinity at α2A-ARs (e.g., 26-fold over α2C-ARs), it is possible
that BRL44408 (15) behaves as an α2C-AR antagonist at the doses evaluated and,
therefore, is able to block the effect of an α2C-AR agonist.
Similar to the results obtained in the tail-flick study (Figure 39), TDIQ (6)
produced saline-like effects in the hot-plate assay when administered alone (Figure 48).
However, unlike the potentiating effect observed in the tail-flick assay (Figure 40), when
TDIQ (6) was co-administered with clonidine (7; 1.0 and 2.0 mg/kg doses), analgesic
attenuation occurred (Figures 50 and 51).

In summary, TDIQ (6) potentiated the

antinociceptive actions of clonidine (7) in the mouse tail-flick assay, but blocked
clonidine’s (7) effect in the hot-plate assay.
Opposing results in antinociceptive animal models have been previously
described; for example, gabapentin augmented the antinociceptive effects of morphine
in the hot-plate assay, but attenuated morphine’s effect in the tail-flick assay.171 As
discussed earlier, these contrasting results could be due to spinal versus supraspinal
receptor activation. It is generally thought that the tail-flick response is due to a spinal
response, whereas antinociceptive effects produced in the hot-plate assay are mostly
due to a supraspinal response.143 Therefore, it is possible that TDIQ (6) might attenuate
the antinociceptive effect of clonidine (7) in the mouse hot-plate assay via a supraspinal
mechanism, but its analgesia-potentiating effect in the tail-flick assay is mediated by
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spinal receptors. Conversely, there is some controversial data suggesting that this is
not the case (i.e., tail-flick responses may be due to both spinal and supraspinal
activation).143
mCPBG (20) and TDIQ (6) showed similar pharmacological effects in the two
thermal nociceptive animal models:

analgesic potentiation of an inactive dose of

clonidine (7; 0.25 mg/kg) in the tail-flick assay and analgesic attenuation of the ED50
dose of clonidine (7; 1.0 mg/kg) in the hot-plate assay. It seems unlikely that mCPBG
(20) and TDIQ (6) share the exact same mechanism of action because of a dissimilar
binding profile; mCPBG (20) binds with high affinity at 5-HT3 receptors (Ki = 17 nM),
whereas TDIQ (6) binds with high affinity at α2-ARs (Ki: α2A = 75, α2B = 97, α2C = 65
nM).53,111,113 On the other hand, the non-selective α2-AR antagonist yohimbine (11)
blocked the analgesic potentiation of clonidine (7) by mCPBG (20) which indicates α2AR involvement in the tail-flick assay (Figure 27).
In previously published hot-plate studies, clonidine’s (7) antinociceptive actions
were augmented by the α2-AR agonist guanabenz (9; s.c.) in rats and blocked by the α2AR antagonist idazoxan (i.p., i.c.v., or i.t) in mice.177,178 Therefore, it seems reasonable
that TDIQ (6) may be attenuating clonidine’s (7) analgesic actions in the hot-plate assay
via an α2-AR antagonist mechanism.
In summary, combination studies with clonidine (7) and various agents [MD-354
(21), mCPBG (20), SR57227A (22), and TDIQ (6)] have provided evidence of novel pain
mechanisms. Clonidine (7), which is a potent analgesic agent, also produces undesired
side effects such as sedation. Three of the four agents mentioned above [MD-354 (21),
mCPBG (20) and TDIQ (6), but not SR57227A (22)] were able to potentiate the
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antinociceptive effects of an “inactive” dose (i.e., a dose that does not produce
antinociceptive effects when administered alone) of clonidine (7) in the mouse tail-flick
assay. Furthermore, this analgesia-potentiating effect seems to be selective because
all three combinations failed to alter the sedative properties of clonidine (7).
Specifically, the locomotor “action” of the combinations was similar to that of clonidine
(7; 0.25 mg/kg) when administered alone. Not only does this provide support for a
selective potentiating effect, but it also indicates that the analgesic potentiation by MD354 (21), mCPBG (20) or TDIQ (6) is unlikely due to a central depressant effect. When
reviewing the mechanistic studies of all three agents, it seems that 5-HT3 receptor and
α2-AR agonism can potentiate the analgesic effects of clonidine (7) without affecting its
sedative properties. To date, it is unclear which α 2-AR subtype(s) is involved in this
potentiating effect. One major disadvantage of studying α2-AR agents is the lack of
subtype-selective agents; advancement in this area should enhance our current
understanding of α2-AR pharmacology.

B. Synthesis

1. meta-Chlorophenylbiguanide Hydrochloride (20)

The hydrochloride salt of mCPBG (20) was synthesized according to a previously
published procedure (Scheme 1).179

The free base of meta-chloroaniline (40) was

dissolved in absolute EtOH and the hydrochloride salt (41) precipitated upon addition of
a 35 M solution of HCl/Et2O.

Compound 41 was purified by recrystallization from
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acetone (3x); mp (compared to lit180 mp) and tlc analysis with an authentic sample
supported its identity and purity. Cyanoguanidine and m-chloroaniline hydrochloride
(41) were allowed to stir at reflux for 4 h and then cooled to 10 °C. The resulting
precipitate was collected by filtration, washed with Et2O, and recrystallized twice from
H2O to afford mCPBG hydrochloride (20). Product characterization of 20 (mp, 1H NMR,
and IR) corresponded to previously reported data.181
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Reagents and conditions: i) HCl/Et2O, absolute EtOH, -10 °C; ii) cyanoguanidine,
H2O, reflux for 4 h, 10 °C for 24 h.
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abovementioned pharmacological assays (tail-flick, hot-plate, and locomotor activity
assays).

2. 2-Amino-7-chloroquinoline Hydrochloride (28)

Compound 28 was prepared in a five-step synthesis starting with the
commercially available toluene analog 42 (Scheme 2). Partial dissociation of DMFDMA occurred in DMF and deprotonation of 42 occurred in the presence of pyrrolidine;
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the resulting N,N-dimethylimmonium ion and toluene (42) anion reacted and upon
elimination of a molecule of methanol, 43 was produced in quantitative yield. Oxidative
hydrolysis of enamine 43 using NaIO4 led to the formation of benzaldehyde 44.
Compound

44

was

converted

to

45

upon

addition

of

NaH,

diethyl

cyanomethylphosponate and anhydrous DMF. In the last step, 45 was cyclized with
SnCl2·2H2O in refluxing absolute EtOH; the resulting free base (28) was converted to a
hydrochloride salt.

Scheme 2.a
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Reagents and conditions: i) DMF·DMA, pyrrolidine, DMF, N2, 110 °C for 1h; ii) NaIO4,
H2O, DMF, rt for 1.5 h; iii) diethyl cyanomethylphosphonate, anhydrous DMF, 0 °C for 5
min; iv) SnCl2·2H2O, absolute EtOH, reflux for 2.5 h; v) HCl/Et2O, MeOH.

In the third step of Scheme 2, the isomers of 45 were not separated and purified
(i.e., the mixture of (E/Z)-45 was used in the final step without further purification). The
reaction (step iv; Scheme 2) was monitored by tlc analysis and once the starting
material disappeared, the reaction was worked-up.
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The resulting crude product

consisted of two compounds (Rf = 0.5 and 0.9; eluent: CH2Cl2/CH3OH/NH4OH =
9:1:0.1). Following column chromatography, both compounds were fully characterized.
Based on 1H NMR and IR analyses, only (Z)-45 cyclized to form the free base of 28 (Rf
= 0.5) as depicted in Scheme 3. Addition of Sn2Cl2·2H2O to (E)-45 simply reduced the
nitro group to an amine, which resulted in the formation of compound 46 (Rf = 0.9) as a
light-brown solid (Scheme 3).

Scheme 3.a
N

N

NO2

NH2

Cl

Cl
(E)-45
+

46
+

i

NH2

N
O2Na
N

N

Cl

Cl
(Z)-45

28

a

Reagents and conditions: i) SnCl2·2H2O, absolute EtOH, reflux for 2.5 h.

Although it was easy to separate 28 and 46 by column chromatography and to
subsequently characterize each compound, further analysis was necessary to explain
the reaction mechanism. In the first attempt to clarify the results, compound (E/Z)-45
was reacted with SnCl2∙2H2O in absolute EtOH at room temperature, rather than at
reflux.

It was thought that at the reduced temperature, (E/Z)-45 would be simply
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reduced into (E/Z)-3-(2-amino-4-chlorophenyl)acrylonitrile (46) isomers.

However,

based on tlc analysis, the same two compounds were produced (i.e., compounds that
fluoresced under UV light at Rf = 0.5 and 0.9, which corresponded to 28 and 46,
respectively). Also, time did not seem to play a role in the reaction because the reaction
mixture was allowed to stir for 1 week at room temperature followed by 2 days at reflux
and the tlc remained the same.
Since it was speculated that one isomer was reduced to an amine while the other
isomer was reduced and then cyclized, the mixture of 45 isomers were separated via
combi-flash chromatography (eluent: hexanes/EtOAc = 1:0 to 1:1 over 20 min).
Unfortunately, only the Z-isomer (45) was completely purified. In a small-scale reaction,
(Z)-45 reacted with SnCl2∙2H2O at room temperature to afford only one product (Rf =
0.5). That is, the Z-isomer was reduced and subsequently cyclized to form compound
28. Since two products (46 and 28) were formed when (E/Z)-45 was added to the
reaction, the E-isomer (compound 46) must be unable to cyclize under the experimental
conditions. IR analysis aided in the structural characterization; compounds 45 and 46
indicated a nitrile moiety (peak at 2215 cm-1) whereas compound 28 showed only a
baseline signal in the general nitrile region (2200-2300 cm-1).

3. 2-Amino-7-chloro-1,2,3,4-tetrahydroquinoline Hydrochloride (31)

When planning the synthesis of compound 31, it was thought that it could be
prepared from 28 via catalytic hydrogenation (Scheme 4). Careful attention was given
to the selection of catalyst because of the concern of dehalogenation of the 7-position
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chloro group. For example, palladium and nickel catalysts have previously been used
for the partial hydrogenation of quinolines to 1,2,3,4-tetrahydroquinolines.182,183
However, these catalysts have also been involved with dehalogenation of aryl
halides,184,185 such as the 7-chloro group in 28. Due to these concerns, platinum oxide
was chosen for the catalytic hydrogenation reaction (Scheme 4). In fact, the chemical
literature reported catalytic hydrogenation (conditions: PtO2, AcOH, H2, rt) of a similar
compound (5,6-dichloro-2-methylquinoline).186 Therefore, dehalogenation of 28 should
not occur under these experimental conditions (attempt #1; Scheme 4).

Scheme 4.a
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Reagents and conditions for attempts #1-3: 1) PtO2, AcOH, H2, 15 psi (18 h); 30 psi
(24 h); 45 psi (24 h); 60 psi (24 h); 2) PtO2, AcOH, HOCl4, H2, 60 psi (24 h); 3) Rh/Al2O3,
MeOH, H2, 50 psi (24 h).

The experimental procedure reported by Ishikawa and co-workers was first
employed in a trial reaction before attempting to hydrogenate 28.186

In the model

reaction, a solution of isoquinoline in AcOH was partially hydrogenated with PtO 2 under
H2 (50 psi) to afford 1,2,3,4-tetrahydroisoquinoline.

Both of these agents (starting

material and product) were available in our laboratory and therefore, the reaction was
monitored by tlc; tlc analysis suggested complete conversion within 18 h (i.e., UV light
detected only the product). Although other laboratories have successfully reduced the
140

pyridine ring of heterocyclic systems (e.g., quinoline and isoquinoline analogs) with
these conditions, attempts to reduce 28 to 31 were unsuccessful.
In the first attempt, 28 was subjected to H2 under atmospheric pressure (≈ 14.7
psi) for 18 h and no reaction occurred (i.e., tlc analysis indicated only starting material).
Subsequently, the pressure was altered to determine if it affected the reaction;
increased H2 pressure (30, 45, and 60 psi) on the Parr hydrogenator for 24 h also
resulted in no reaction.
Since time and pressure seemed to have no effect on the reaction, modifying the
reagents was considered. In the second attempt, a trace amount of perchloric acid was
added to the reaction mixture because strong protic acids can act as promoters
(substance that increases catalytic activity).187 The addition of perchloric acid had no
effect on the reaction (attempt #2; Scheme 4).
In the third attempt to reduce the pyridine ring of 28, the catalyst was changed to
Rh/Al2O3, which was based on a published experimental procedure for the selective
hydrogenation (i.e., selective reduction of the pyridine and not the benzene ring) of 6bromoquinoline as well as 2-substituted quinoline analogs such as 2-methylquinoline
with catalyst Rh/Al2O3 and solvent MeOH in the presence of H2 under increased
pressure (50 bar; ≈ 725 psi).188 These analogs were interesting cases because the
reaction worked in the presence of a halogen substituent and a substituent at the 2position of quinoline. It is important to note, that conversion of 2-methylquinoline to
1,2,3,4-tetrahydro-2-methylquinoline was only 40% in 22 h whereas after 1 h, 6bromoquinoline was consumed.188 Although there was 100% conversion observed in
the 6-bromoquinoline reaction, two products were formed: the desired product 6-bromo141

1,2,3,4-tetrahydroquinoline

(82%)

and

the

debrominated

product

1,2,3,4-

tetrahydroquinoline (18%).188 In our reaction, 28 was subjected to similar conditions
(Rh/Al2O3, MeOH, H2, 50 psi) for 24 hours, but only starting material was detected. It is
possible that 28 would undergo hydrogenation at increased pressure (e.g., 50 bar as in
the literature procedure), but unfortunately we do not have that capability in our
laboratory.
In addition to the PtO2 experimental (attempt #1; Scheme 4), Ishikawa and coworkers described the partial hydrogenation of the quinoline anolog, 6-fluoro-2-methyl5-(4-methyl-1-piperizinyl)quinoline, with 5% platinum on carbon under atmospheric H 2 in
high yield (91%).186 Since 28 was prepared in small quantity, trial reactions were first
done with the commercially available dechlorinated starting material (47; 2aminoquinoline). Unfortunately, when 47 was exposed to the same conditions, only
starting material fluoresced under UV light (attempt #1; Scheme 5).

Scheme 5.a
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a

Reagents and conditions for attempts #1 and 2: 1) 5% Pt/C, AcOH, H2, 15 psi (24 h);
2) NaCNBH3, BF3∙OEt2, MeOH, reflux.

There is another interesting hydrogenation reaction reported in the literature
which used NaCNBH3 in the presence of boron trifluoride etherate in refluxing MeOH to
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selectively reduce the nitrogen-containing ring in quinoline derivatives.189

In a last

attempt to convert 2-aminoquinoline (47) to 2-amino-1,2,3,4-tetrahydroquinoline (48),
the same conditions were applied to 47, but over the course of 9 h no appreciable
product formed (reaction monitored by tlc analysis: no products fluoresced under UV
light and only a very faint spot near the baseline appeared, but over time this spot did
not increase in intensity).
To our knowledge, there is no reported reactions involving the reduction of a 2aminoquinoline analog to its 1,2,3,4-tetrahydro derivative. However, Moon and Hsi tried
to directly hydrogenate 3-aminoquinoline.190
hydrogenation

of

3-aminoquinoline

to

Although it is stated that the direct

3-amino-1,2,3,4-tetrahydroquinoline

was

unsuccessful, no details of the reaction conditions (e.g., reagents, time, temperature,
etc.) were provided.190 On the other hand, they were able to selectively reduce the
pyridine ring following acylation of the amine in the 3-position.190 Subsequently, the
crude amide was hydrolyzed to afford 3-amino-1,2,3,4-tetrahydroquinoline.190 Due to
these results, attempts were made to reduce 7-chloro-2-formamidoquinoline (49) in the
same manner (Scheme 6).
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Reagents and conditions: i) Ac2O, AcOH, THF, N2; ii) PtO2, AcOH or MeOH, H2, 50 psi
(24-60 h); iii) HCl/EtOH, 70 °C.
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Compound 49 was synthesized by acylating 28 with acetic anhydride (Scheme
6). Unlike the reported results with the 3-formamido derivative, 49 did not reduce to 50.
Various experimental conditions were modified to determine if any affected the reaction
(e.g., solvents: AcOH and MeOH, time, and pressure).

Though most experimental

modifications did not seem to change the reaction progress as monitored by tlc analysis
(i.e., only starting material was detected), time appeared to alter the tlc. For example,
after 3 d on the Parr hydrogenator (50 psi), there were two faint product spots detected
on tlc [eluent: EtOAc/MeOH = 20:1; starting material 49 (Rf = 0.5) and products (Rf = 0.3
and 0.8)], but these spots did not increase in intensity and the starting material did not
decrease in intensity after an additional 4 d on the Parr hydrogenator. Therefore, the
reaction was stopped after a total of 7 d and the two minor products were purified by
preparative tlc (eluent: EtOAc/MeOH = 20:1). An insufficient amount was collected by
preparative tlc to characterize these compounds. The reaction was repeated on a larger
scale, but no products were formed. Synthesis of 31 was abandoned.

4. 3-Amino-6-chloroisoquinoline Hydrochloride (29)

Compound 29 was prepared in a three-step synthesis.

First, a nucleophilic

aromatic substitution of the commercially available starting material 4-chloro-2fluorobenzonitrile (51) occurred resulting in a substitution of the aryl halide with a
benzylic nitrile. Specifically, the sodium anion of ethyl cyanoacetate reacted with the 2fluoro group of 51 to produce an ester intermediate and upon refluxing the ester in
water, decarboxylation occurred to yield compound 52.
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The di-nitrile product was

purified by recrystallization from Et2O (identical mp compared to lit.191 mp). Cyclization
of 52 was achieved by adding a solution of HBr in AcOH, allowing the reaction mixture
to stir for 1 h and precipitating compound 53 with Et2O. The resulting crude product
was neutralized, dried and purified via column chromatography.
Scheme 7.a
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Reagents and conditions: i) ethylcyanoacetate, NaH, DMSO, 0 °C to rt, 30 min., 90 °C
for 90 h, water, reflux, 8 h; ii) HBr, AcOH, Et2O; iii) n-BuLi in hexanes, anhydrous THF,
N2, -70 °C, 30 min, absolute EtOH.

In the last step of Scheme 7, selective debromination in the 1-position was
attempted; such selective debromination has been previously done on a similar
compound, 3-amino-1,6-dibromoisoquinoline.192 However, when a mixture of 3-amino1-bromo-6-chloroisoquinoline,

ammonium

formate,

tetrakis(triphenyl

phosphine)

palladium and DMF was heated to 50 °C in a sealed tube, the tlc analysis after only 8
hours (literature procedure reported 48 hour reaction) displayed a very faint product
spot and approximately 8 additional spots. It was apparent that purification of each
product would be very difficult.
Therefore, in a second attempt, a known catalyst-free reaction was used to try to
synthesize 29. In this literature reported procedure, selective debromination of both 1bromo-3-chlorobenzene
(approximately 98%).193

and

1-bromo-4-chlorobenzene

occurred

in

high

yield

Nevertheless, when 53 was reacted with LiAlH4 in the
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presence of DME for 18 hours (submerged in a ultrasound cleaner), no reaction
occurred (only starting material fluoresced on the tlc plate and 1H NMR indicated
starting material only).
In the last attempt to selectively debrominate, compound 53 was reacted with nbutyllithium (2.5 M in hexanes) under a N2 atmosphere and followed by ethanolic
quenching. This reaction scheme was successfully used to selectively debrominate the
1-position bromo group of 1,3-dibromoisoquinoline.194

Successful synthesis of the

debrominated product 29 occurred when using the procedure of Muchowski et al.,194 but
the product was not without impurities. The tlc analysis showed two products; the major
spot was 29 and the minor spot was presumably the des-chloro analog of the the
product or the des-chloro analog of the starting material (i.e., either 3-aminoisoquinoline
or 3-amino-1-bromoisoquinoline, respectively).

Upon recrystallization from benzene,

pure product 29 as a free base was obtained (mp 232-234 °C) and confirmed by
elemental analysis. An attempt was made to convert the free base to an HCl salt,
however elemental analysis indicated that it was not a pure HCl salt of 29.

5. 3-Amino-6-chloro-1,2,3,4-tetrahydroisoquinoline hydrochloride (32)

Similar to the synthesis of 31, attempts to partially hydrogenate 32 were
unsuccessful.
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Even after reacting 29 with H2 (50
psi) in the presence
of a platinum catalyst for 3
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days, only starting material was detected in the reaction mixture based on tlc and 1H
Cl

NMR analyses. The route was abandoned.
54

Cl
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6. 2-Amino-7-chloronaphthalene Hydrochloride (30)

Compound 30 was prepared according to literature procedures for similar
compounds (Scheme 9).195-199
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Scheme 9.a
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Reagents and conditions: i) H2SO4, HNO3, 20 °C to 60 °C; ii) Cu, quinoline, reflux; iii)
MeOH, reflux, NaSH, MeOH/H2O (1:2), reflux; iv) NaNO2, H2SO4, AcOH, 0 °C; v)
Cu(I)Cl, HCl, 0 °C; vi) PtO2, H2, absolute EtOH, rt; vii) absolute EtOH, HCl (g), 0 °C.
Addition of nitric acid selectively nitrated the starting material 56 at the meta
positions to afford 3,6-dinitro-1,8-napthalic anhydride (57).

Decarboxylation of the

anhydride moiety in a quinoline solution with copper powder, as in step ii, was first
described by Shepard et al. in 1930.200 Although the mechanism is not completely
understood, the literature suggests that quinoline’s basicity and high boiling point
facilitates carboxylate anion formation by withdrawing d-electrons from the copper
catalyst.201,202 In the current case, the decarboxylated product 58 was partially reduced
to 2-amino-7-nitronaphthalene (59) by the addition of approximately one equivalent of
sodium hydrosulfide. In the fourth and fifth step of Scheme 9, the aryl amine was
converted to the aryl chloride via a Sandmeyer reaction. In the last step, reduction of 60
to 2-amino-7-chloronapthalene (30) occurred under mild conditions (PtO2, rt,
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atmospheric H2) in order to reduce the possibility of dehalogenation; subsequently the
free base was converted to a hydrochloride salt via the addition of HCl gas to an
ethanolic solution.

7. 2-Amino-7-chlorotetralin Hydrochloride (33)

Compound 33 was prepared according to a literature procedure for similar
compounds (Scheme 10).203,204,206

Scheme 10.a
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Reagents and conditions: i) SOCl2, CH2Cl2, reflux; ii) CH2Cl2, AlCl3, C2H4 (g), -10 °C
to 0 °C, H2O; iii) NaBH3CN, NH4OAc, MeOH, rt; iv) absolute EtOH, HCl/EtOH, 0 °C.
The commercially available phenylacetic acid 61 was converted to the
corresponding acid chloride 62 upon the addition of thionyl chloride and was
subsequently purified under reduced pressure distillation (0.5 Torr, bp 97-103 °C). In
the second step (Friedel-Crafts acylation-cycloaddition reaction207), purification of AlCl3
via prior sublimation improved the yield of the reaction. A methylene chloride solution of
compound 62 was added to a suspension of AlCl3 in CH2Cl2 at -10 to 0 °C under inert
conditions (Scheme 10, step ii); ethylene gas was bubbled into the reaction mixture for
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30 min, which caused the reaction temperature to slightly increase to 5-10 °C. Although
no starting material remained, two products were formed due to two possible cylclization
reactions (Scheme 11).

Scheme 11.a
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Reagents and conditions: i) CH2Cl2, AlCl3, C2H4 (g), -10 °C to 0 °C, H2O.

Column chromatography was performed to separate the two tetralones: 5-chloroβ-tetralone (64; 15%) and 7-chloro-β-tetralone (63; 10%); tlc eluent hexanes/EtOAc =
5:1 (Rf = 0.6, purple tlc stain and Rf = 0.5, beige tlc stain, respectively). There were
other minor differences between the two products such as 5-chloro-β-tetralone (64) was
an oil whereas 7-chloro-β-tetralone (63) was a low melting point solid (mp 37-38 °C).
Structural characterization of the two products was determined by H1 NMR. Although
both products showed three aromatic protons in the H1 NMR spectrum, there were
differences in the chemical shifts and splitting patterns.
To synthesize the desired target compound, 63 was converted to 33 via reductive
amination followed by hydrochloride salt formation (Scheme 10).
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8. 2-Amino-5-chlorotetralin Hydrochloride (65)

Compound 65 was prepared via the same synthetic route as 33 (Scheme 12).

Scheme 12.a
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Reagents and conditions:
HCl/EtOH, 0 °C.

i)

65

NaBH3CN, NH4OAc, MeOH, rt; ii)

absolute EtOH,

The starting material 64 was synthesized from the previous reactions (Schemes
10 and 11). And similar to the preparation of 2-amino-7-chlorotetralin (33), reductive
amination of β-tetralone 64 produced 2-amino-5-chlorotetralin hydrochloride (65;
Scheme 12).

9. 2-Amino-5,7-dichloro-3,4-dihydroquinazoline Hydrochloride (38)

Compound 38 was prepared according to a literature procedure for similar
compounds (Scheme 13).208-210
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Reagents and conditions: i) CrO3, gl. AcOH, Ac2O, 90 °C; ii) S-methylthioisourea
sulfate, Na2CO3, aq. MeCN (80%), reflux to rt, H2O; iii) BH3∙THF (1M), N2, reflux; iv)
absolute EtOH, HCl/EtOH, O °C.
The first step was based on a literature procedure,208 but unlike what was
suggested in the literature, the reaction did not go to completion and therefore, starting
material 66 and product 67 remained in the reaction mixture. Prehaps due to similar
chemical properties, purification via recrystallization (MeOH, isopropanol, or AcOH)
and/or chromatography (column or flash) of isatin 66 and isatoic anhydride 67 was not
successful. A second oxidation method was attempted in which a suspension of 4,6dichloroisatin (66) in glacial AcOH and concentrated H2SO4 was heated to 30 °C and
then an aqueous solution of H2O2 was added. However, this reaction did not go to
completion as well.
Therefore, the next step was attempted without further purification of 67 because
it was thought that it should be easy to purify the product by acid-base extraction.
Compound 68 (2-amino-5,7-dichloroquinazolin-4(3H)-one) was prepared by reacting
crude isatoic anhydride 67 with S-methylthioisourea sulfate (Scheme 13). An acid-base
extraction was used to purify the product 68 and recover the starting material (66) from
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the first step.

Reduction of the amide with borane resulted in final compound 38

(Scheme 13). The free base was converted to a hydrochloride salt.

10. 2-Amino-3,4-dihydroquinazoline Hydrochloride (39)

The des-chloro analog of 38, 2-amino-3,4-dihydroquinazoline (39), was
synthesized by the same procedure as described above (Scheme 14).
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Reagents and conditions: i) S-methylthioisourea sulfate, Na2CO3, aq. MeCN (80%),
reflux to rt, H2O; ii) BH3∙THF (1M), N2, reflux; iii) absolute EtOH, HCl/EtOH, O °C.
Commercially available isatoic anhydride 69 resulted in omission of the first step
described in the synthesis of 38.
Summary: compounds 20, 28, 29 (free base), 30, 33, 38, 39, and 65 were
successfully synthesized. Binding affinity at 5-HT3 receptors has been evaluated for
several of the abovementioned synthesized compounds. Compounds 28, 33 and 65
were found to lack affinity at 5-HT3 receptors; that is, Ki > 10,000 nM. These preliminary
binding affinity results indicate that the ring-nitrogen atoms are important for 5-HT3
receptor binding. 5-HT3 receptor binding affinity results of the remaining synthesized
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compounds will further evaluate the role of the nitrogen atoms and the chloro
substiutent in MD-354 (21) and conformationally-constrained analogs of MD-354 (21) in
5-HT3 receptor binding.

C. Molecular modeling

Although MD-354 (21) shows no antinociceptive effects when administered
alone, it potentiates the antinociceptive actions of the clinically used analgesic clonidine
(7; non-subtype selective α2-AR agonist) in a synergistic manner in the mouse tail-flick
assay due to an α2-AR mechanism (Table 8).31,34

Mechanisms underlying the

analgesia-potentiating effect are thought to involve at least an α2A-AR component.31
Radioligand binding assays indicate that MD-354 (21) binds at both low-affinity states
(antagonist [ethyl-3H]RS-79948-197) and high-affinity states (agonist [125I]clonidine) of
the three α2-AR subtypes (Table 5).31,34 Furthermore, functional assays show that MD354 (21) is a weak partial agonist at α2A-ARs, but an antagonist at α2B/2C-ARs.31 In an
attempt to explain the binding affinity and functional activity of MD-354 (21), molecular
models were constructed to allow an examination of its binding modes to low- and highaffinity states of α2A-, α2B-, and α2C-ARs.
The α2-ARs are G protein-coupled receptors (GPCRs) which are integral
membrane proteins that are structurally characterized by 7 transmembrane-spanning
(TM) helices connected by intra- and extracellular loops, an amino-terminal (Nt)
extracellular domain and a carboxyl-terminal (Ct) intracellular domain (Figures 3, 4 and
54). Interaction with agonists induces a conformational change in the receptor that
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allows the receptor to associate with G proteins and initiates a signaling cascade that
produces an effect. Due to this conformational change in the receptor, it was necessary
to model the “inactive” (or low-affinity) and “active” (or high-affinity) state of α2A-, α2B-,
and α2C- ARs.

Figure 54. X-Ray crystal structure of the β2-AR (2RH1): TM1 (red), TM2 (orange), TM3
(yellow), TM4 (green), TM5 (cyan), TM6 (blue), TM7 (magenta), intra- and extra-cellular
loops (tan) bound to the inverse agonist (carazolol; gray).57

There are no high resolution structures of α2A-, α2B-, or α2C-ARs. Among the
known GPCR crystal structures, the β2-AR X-ray crystal structure (pdb = 2RH1; 2.4-Å
resolution; Figure 54) has the greatest sequence similarity to the three subtypes of α2155

ARs.57 Therefore, this crystal structure, which is in the low-affinity state, was used as a
template to generate homology models of α2-ARs. This β2-AR X-ray crystal structure
mimics the low-affinity state because an inverse agonist (i.e., carazolol) is bound to the
receptor (i.e., an inverse agonist binds preferentially to the inactive conformation of the
receptor).57

1. MD-354 (21) rotamers

MD-354 (21) possesses a rotatable bond (bond between C1 and the aniline N),
and exists as an indefinite number of rotamers (Figure 13). Therefore, it was important
to first examine the likely conformations of MD-354 (21). There were two ways of
examining the possible conformation(s) of MD-354 (21): (a) a systematic conformation
search (SYBYL 8.1) and (b) determination of the conformations of arginine and
clonidine in their X-Ray crystal structures, both of which have a guanidine moiety.
A systematic search was conducted on MD-354 (21) to determine its lowestenergy rotamers (Tripos Force Field, AM1; SYBYL 8.1). The systematic search was
used to calculate the energy associated with the possible torsion angles of the rotatable
bond between C1 and the aniline N of MD-354 (21; Figure 55a). In general, syn (s)
torsion angles are those between 0 and ±90° whereas anti (a) correspond to torsion
angles between ±90 and 180°. Similarly, stereochemical conformations with a torsion
angle between ±30 and 50° are called clinal (c) and those between 0 and 30° or 150
and 180° are called periplanar (p). When these terms are combined the following
ranges of torsion angles are identified: synperiplanar (sp) = -30 to 30°, synclinal (±sc) =
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±30 to ±90°, anticlinal (±ac) = ±90 to ±150°, and antiperiplanar (ap) = ±150 to 180°
(Figure 55b).
(a)
red = TFF blue = AM1
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Figure 55. (a) Energy associated with the various torsion angles of the rotatable bond
in MD-354 (21) (red: TFF; blue: AM1); (b) the four lowest-energy rotamers of MD-354
(21); +/– synclinal (sc) and +/– anticlinal (ac).
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Coincidentally, the torsion angle of arginine (from the Cambridge Structural
Database) and clonidine crystal structures212 match one (i.e., the +sc) of the lowestenergy rotamers of MD-354 (21). Furthermore, the mCPBG crystal structure (57.4 and
301.9° torsion angles) displays similar torsion angles to +sc- and –sc-MD-354 (21) (65
and 295° torsion angles).213 Due to the results from both conformational analyses, the
four lowest-energy rotamers of MD-354 (21) were employed in the docking studies.

2. α2A-Adrenoceptor 3D models

In order to generate the inactive model of α2A-ARs, the sequences of various
GPCRs including the human α2A-AR and β2-AR were aligned using ClustalX (other
GPCR sequences: human muscarinic ACh M1 receptor, human vasopressin VIa
receptor, human dopamine D3 receptor, human δ-opioid receptor and bovine
rhodopsin) as described by Bissantz et al.214 This sequence alignment (Figure 56) is, in
general, based on aligning the highly conserved amino acids among GPCRs (e.g.,
D3.32).

When comparing the amino acid sequence of the transmembrane regions

(TM1-TM7) of α2A-ARs and β2-ARs, 41% are identical and 68% are similar (e.g., L and
V residues are similar, but not identical). Using the ClustalX alignment, the side chains
of amino acids within the transmembrane (TM) helices of the β2-AR crystal structure
(pbd ID: 2RH1) were mutated to mimic the α2A-AR (Sybyl 8.1). The intra- and
extracellular loops of the homology model were based on similar protein loops (Sybyl
8.1).
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Figure 56.
Amino acid sequence alignment of 6 GPCRs (human muscarinic
acetylcholine receptor M1, human vasopressin V1a receptor, human dopamine D3
receptor, human β2 adrenoceptor, human delta-type opioid receptor and bovine
rhodopsin receptor) and human α2A-AR (ADA2A_HUMAN); the 7 transmembrane
helices are highlighted in yellow and highly conserved amino acids amongst GPCRs are
highlighted in cyan.
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Protein side chains were optimized using a backbone-dependent rotamer library
(SCWRL4), and PROCHECK was performed to examine the stereochemistry of the
receptor. Protable (SYBYL 8.1) was utilized to check all amino acid bond angles, bond
lengths, and torsion angles.
Once the inactive α2A-AR homology model was energy minimized (Tripos Force
Field; Gasteiger-Hϋckel charges, distance-dependent dielectric constant = 4.0),
modifications to the receptor were made to mimic the active state: (a) rotating TM6 (30°; R6.29-V6.60), (b) tilting the extracellular portion of TM5 into the binding pocket (6°;
K5.36-A5.49), and (c) ‘turning on’ the toggle switch63 (i.e., modifying the χ1 rotameric
state of C6.47, W6.48 and F6.52 to g+, t and t, respectively). These modifications were
assumed to simulate an active state because they have been observed in other activestate structures of GPCRs.61-63

Tilting of TM5 brought residues S5.42 and S5.46

approximately 1 Å closer to D3.32. Rigid rotation of TM6 broke the ionic lock (R3.50–
E6.30 Cα distance = 12.9 Å) and enlarged the intracellular G protein binding cavity
consistent with experimental results.62 Side chain conformations of residues on TM5
and TM6 were adjusted using SCWRL4, and manually, to optimize side chain–side
chain interactions. PROCHECK was performed which resulted in a Ramachandran
plot. This plot indicates which amino acid residues are within the most favorable (red),
additional allowed (yellow), generously allowed (khaki), and disallowed (white) regions
(Figure 57). As depicted in Figure 57, 90.4% of the amino acids were within the most
favorable region (red), 8.8% in the allowed regions (yellow or khaki) and only two amino
acids (0.8%) showed disallowed stereochemistry (white): E237 and C401. However,
both of these latter two amino acids are located outside of the proposed binding pocket
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and, therefore, for our purposes, these imperfections were ignored and should not
impact the docking studies.

More specifically, E237, which was just outside the

allowable region (Figure 57), is part of IL-3, whereas C401 is part of EL-3.

Figure 57. A Ramachandran plot of the active α2A-AR homology model (generated by
PROCHECK; Sybyl 8.1).
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To validate the energy-minimized active α2A-AR homology model, the
endogenous ligands norepinephrine (NE; 1) and epinephrine (EPI; 2) were docked
(GOLD 4.0) into the binding pocket (15-18 Å sphere centered around the conserved
aspartate in TM3, D3.32). Since both NE (1) and EPI (2) have a stereocenter, all four
isomers were examined in the docking study (NE: (R)-1 and (S)-1; EPI: (R)-2 and (S)2). In the case of both phenylethylamines, the R-enantiomers are more active and have
higher affinity at α2-ARs than those with the S-configuration of the β-OH group.53
Additionally, N-methyl-substituted phenylethylamines, such as 2, have higher binding
affinity at α2-ARs than unsubstituted analogs, such as 1.53 Additional SAFIR studies,
including other analogs of 1 and 2, which were discussed in greater detail in the
Background section, have been published in the past two decades (Figure 5 and Table
1).
Due to extensive SAFIR studies, as well as site-directed mutagenesis studies, of
phenethylamines, much is known about the binding mode of these agents, which makes
phenethylamines a good tool to help validate the homology model. With support from
catecholamine molecular modeling studies, the Easson-Stedman hypothesis suggests a
three-point interaction between adrenoceptors and catecholamines [e.g., NE (1) and
EPI (2)]: (a) the protonated aliphatic amine, (b) the catecholic hydroxyl groups, and (c)
the β-hydroxyl group (see Table 13 for specific interactions).83,84
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Table 13. Interactions between α2-ARs and catecholamines.70,85,86
α2-AR residue

catecholamine moiety

ionic bond

D3.32

charged amine

hydrogen bond

S5.42

meta-hydroxyl

hydrogen bond

S5.46

para-hydroxyl

hydrogen bond

S2.61 or Y6.55

β-OH

Chemical interaction

When necessary, constraints were incorporated into the GOLD dockings of the
endogenous ligands: H-bond constraints with the highly conserved D3.32, and distance
constraints

with

S5.42

and

S5.46.

In

general,

data

from

site-directed

mutagenesis85,86,215 and structure-activity relationship (SAR)215 studies of epinephrine
(2) and its analogs were used to guide the docked poses into the models. In addition to
comparing results to the Easson-Stedman hypothesis (Table 13), various characteristics
were analyzed when examining the docking results, such as the GOLDscore (the higher
the score, the better the docking result is likely to be based on factors such as Hbonding energy, van der Waals energy and ligand torsion strain), potential “unfavorable”
interactions (e.g., the ligand is “too close” to the protein backbone; clashing), and
favorable bonding distances (e.g., hydrogen bond ≈ 3 Å).
Of the four isomers [i.e., (R) and (S) isomers of NE (1) and EPI (2)], (R)-EPI (2; Ki
= 13 nM) has the highest binding affinity at α2A-ARs (active state) and, therefore, should
display additional and/or stronger interactions with the receptor in comparison to the
remaining 3 isomers. As shown in Figure 58, the main ligand–receptor interactions of
(R)-EPI (2) observed in the active α2A-AR model were: (a) ionic: N+—D3.32; (b) HB: β163

OH—D3.32, m-OH—S5.42 and p-OH—S5.46; (c) π-π (edge-to-face): F6.51, Y6.55;
CH-π: V3.33; (d) π-cation: N+—F7.39.

The β-OH moiety of (R)-EPI (2) seems to

strongly interact (H-bond) with D3.32 whereas in the docking poses of (S)-EPI (2), the
additional H-bond interaction with D3.32 was absent (i.e., the distance between the
oxygen atoms of the β-OH and D3.32 side chain was > 5Å). This is consistent with the
lower binding affinity of (S)-EPI (2) at α2A-ARs (Ki = 687 nM; agonist radioligand).215
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Figure 58. Proposed binding mode of (R)-epinephrine (2) in the active α2A-AR model.
Amino acids within 4 Å are shown as capped sticks (grey) and distances (Å) of
favorable ionic and HB interactions are shown in orange.

The docked poses of the norepinephrine (1) isomers showed similar results (data
not shown). In general, the poses are consistent with binding affinity assay studies of
endogenous ligands (and their analogs) that indicate affinity is affected by: β-OH ((R)165

isomer > (S)-isomers by ≈ 20-fold; presence > absence by ≈ 8-fold), m-OH (presence >
absence by ≈ 100-fold); p-OH (presence > absence by ≈ 30-fold).86 These favorable
interactions have been suggested by site-directed mutagenesis studies and are
consistent with previous models.86,215,216
The four lowest-energy rotamers of MD-354 (21), as interpreted from both
conformational analyses, were docked in the abovementioned active model of the α2AAR (Figure 55). After the MD-354 (21) rotamers were docked, energy minimization was
implemented in order to optimize the bonding interactions between ligand and receptor.
The major bonding interactions observed in the docked poses of MD-354 (21) rotamers
include: (a) an ionic interaction between both the aniline and terminal nitrogens and
D3.32 and (b) hydrogen bonding between the m-Cl group and either S5.42 or S5.46,
with optimal bond distances (i.e., approximately 3 Å; Figure 59 and Table 14a). There
are, also, additional hydrophobic interactions observed in the proposed binding mode of
MD-354 (21) at the active α2A-ARs (e.g., V3.33, F6.51, F7.35 and F7.39; Figure 59).
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Table 14. Distances (Å) of favorable HB and ionic interactions observed in proposed
binding mode between ligands and the (a) active and (b) inactive α2A-ARs.
(a)
Ligand

D3.32

Y5.38

S5.42

S5.46

(R)-EPI (2)
terminal N

2.6

β-OH

2.6

m-OH

3.0

p-OH

2.9

3.2

+sc–MD-354 (21)
aniline N

2.8

terminal N

3.3

terminal N

3.8

m-Cl

3.0

-ac–MD-354 (21)
aniline N

2.8

terminal N

3.4

terminal N

3.9

m-Cl

(b)
Ligand

3.0

D3.32

Y6.55

S5.42

+sc–MD-354 (21)
aniline N

2.8

terminal N

3.0

terminal N

3.1

m-Cl

3.8
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Figure 59. Proposed binding mode of –ac- (magenta) and +sc- (orange) MD-354 (21)
in the active α2A-AR model. Amino acids within 4 Å are shown in capped sticks (grey)
and distances (Å) of favorable HB or ionic interactions are shown in orange.

168

Figure 60. Proposed binding mode of +sc-MD-354 (21) in the active α2A-AR model;
close-up of the interaction between the guanidine-D3.32 hydrogen bond network with
the aryl ring of F7.39. D3.32 and F7.39 are shown in capped sticks (grey) and distances
(Å) of favorable HB interactions are shown in orange whereas the centroid-to-centroid
distance between the aryl ring of F7.39 and the 6-membered ring formed between the
guanidine and D3.32 are shown by the black arrow.
In the inactive model of α2A-ARs, MD-354 (21) docked in a similar manner as
compared to the active-state docking pose.

Although the interaction with the TM5

residues was minimal (i.e., the distance between the m-Cl group and the serine
residues of TM5 was not optimal for halogen bonding; Table 14b), a more favorable
interaction with all three nitrogen atoms of the guanidine moiety was observed (Figure
61 and Table 14b).

Measurements between the heavy atoms indicate a favorable

bonding distance between the aniline N and D3.32, the terminal amine and D3.32, and
the other terminal amine and Y6.55.
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Figure 61. Proposed binding mode of +sc-MD-354 (21) in the inactive α2A-AR model.
Amino acids within 4 Å are shown in capped sticks (grey) and distances (Å) of favorable
HB or ionic interactions are shown in orange.
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Figure 62. Proposed binding mode of +sc-MD-354 (21) in the inactive α2A-AR model;
close-up of the interaction between the guanidine-D3.32 hydrogen bond network with
the aryl ring of F7.39. D3.32 and F7.39 are shown in capped sticks (grey) and distances
(Å) of favorable HB interactions are shown in orange whereas the centroid-to-centroid
distance between the aryl ring of F7.39 and the 6-membered ring formed between the
guanidine and D3.32 are shown by the black arrow.

Furthermore, the bonding network between the guanidine moiety of MD-354 (21)
and the aspartate carboxylate moiety (D3.32) is stacked over the aromatic ring of F7.39
in both the inactive and active α2A-AR models (Figures 60 and 62). The centroid-tocentroid distance, as shown in these figures, indicates that the 6-membered ring formed
by the hydrogen bonding network between the guanidine moiety of MD-354 (21) and the
carboxylate group of D3.32 has a slightly stronger parallel-stacking interaction with the
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aryl ring of F7.39 in the inactive state (3.6 Å) in comparison with the active state (4.0 Å)
of the α2A-AR models.217

3. α2B-Adrenoceptor 3D models

Since the sequence similarity within the TM regions is greater between α 2A- and
α2B-ARs (94%) compared to α2B-ARs and β2-ARs (66%), α2B-AR homology models were
generated based on the previously generated α2A-AR models. The “active” α2A-AR
model, which was previously supported by simulating the proposed binding mode of the
neurotransmitters (i.e., the binding mode based on site-directed mutagenesis results
and other homology models), was used as the template for the “active” α 2B-AR model.
First, the amino acid side chains among the transmembrane helices were mutated to
mimic the α2B-AR sequence. The intra- and extracellular loops were replaced by protein
loops with similar sequences and then the side chains were mutated if necessary (Sybyl
8.1).

All protein side chains were optimized using a backbone-dependent rotamer

library (SCWRL 4). As a final assessment, PROCHECK was performed to examine the
stereochemistry of the receptor and Protable was used to check all amino acid bond
angles, bond lengths, and torsion angles (SYBYL 8.1). Protein modifications were
manually made when necessary; for example, the χ1 torsion angle of S5.42, which has
been implicated in neurotransmitter binding, was modified so that the serine side chain
pointed into the binding pocket. Protein modifications were followed by energy
minimization in order to optimize ligand—receptor interactions.
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The two best binding modes of MD-354 (21) (i.e., those with the most optimal
bonding interactions) at the active α2B-ARs showed favorable ionic interactions with the
conserved D3.32 (bonding distance = 2.7-3.0 Å), as well as hydrogen bonding
interaction between the terminal amine of MD-354 (21) and Y5.38 (Table 15a and
Figure 63). Furthermore, only one MD-354 (21) rotamer displayed an interaction with
TM5. The proposed binding mode of the –ac-MD-354 (21) rotamer showed favorable
distance (approximately 3 Å) between the m-Cl moiety and a serine residue of TM5
(S5.46); that is, a halogen bond interaction was observed between the ligand and
receptor (Table 15a and Figure 63).
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Table 15. Distances (Å) of favorable HB and ionic interactions observed in proposed
binding mode between ligands and the (a) active and (b) inactive α2B-ARs.
(a)
Ligand
D3.32
Y5.38
S5.46
+sc–MD-354 (21)
aniline N
terminal N
terminal N
m-Cl
-ac–MD-354 (21)
aniline N
terminal N
terminal N
m-Cl
(b)
Ligand
+sc–MD-354 (21)
aniline N
terminal N
terminal N
m-Cl
+ac–MD-354 (21)
aniline N
terminal N
terminal N
m-Cl
-sc–MD-354 (21)
aniline N
terminal N
terminal N
m-Cl

2.9
3.0
2.8

2.8
2.9
2.7
3.2
D3.32

Y6.55

S5.42

2.6
2.8
3.4
2.7
2.7
3.1

3.4

2.8

3.9

3.2
3.2
3.0
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Figure 63. Proposed binding mode of –ac- (magenta) and +sc- (orange) MD-354 (21)
in the active α2B-AR model. Amino acids within 4 Å are shown in capped sticks and
distances (Å) of favorable HB or ionic interactions are shown in orange.

In the inactive model of α2B-ARs, three conformers of MD-354 (21) showed good
ionic interactions with the conserved asparate residue (D3.32), as well as, hydrogen
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bonding with Y6.55 and either the terminal amine or m-Cl group (dependent on the
rotamer; Table 15b and Figure 64).

Figure 64. Proposed binding mode of –sc- (green), +ac (magenta), and +sc- (orange)
MD-354 (21) in the inactive α2B-AR model. Amino acids within 4 Å are shown in capped
sticks and distances (Å) of favorable HB or ionic interactions are shown in orange.
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As in the active and inactive models of α2A-ARs, parallel stacking (i.e., a π-π
interaction) was observed between the bonding network of the amines in MD-354 (21)
and D3.32 with F7.39 in the inactive model only (i.e., not in the active model) of α 2B-ARs
(centroid-to-centroid distance = 3.6 Å; Figure 64).

4. α2C-Adrenoceptor 3D models

The active model of the α2C-AR was generated in a similar manner to that of the
α2B-ARs.

That is, the active α2A-AR model was mutated to simulate the α2C-AR

sequence, loopsearch was conducted to incorporate possible loop configurations,
SCWRL was conducted, protein modifications were made if necessary and the receptor
was energy minimized. Next, the NTs [(R)- and (S)-isomers of NE (1) and EPI (2)] were
docked and the resulting ligand—receptor complex was energy minimized (data not
shown). This model (with the ligand removed) was used for subsequent MD-354 (21)
dockings.
The two best binding modes of MD-354 (21) in the active α2C-AR model showed
favorable bonding distances for a halogen bond between the m-Cl group of 21 and
S5.46 (≈3.1 Å), as well as ionic interactions between the amines of 21 and D3.32 and
Y5.38 (≈2.7-3.0 Å) (Figure 65).
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Figure 65. Proposed binding mode of –ac- (purple) and +sc- (orange) MD-354 (21) in
the active α2C-AR model. Amino acids within 4 Å are shown in capped sticks (grey) and
distances (Å) of favorable HB or ionic interactions are shown in orange.
MD-354 (21) docking studies with the inactive α2C-AR model proved to be
difficult; MD-354 (21) did not seem to bind favorably into the binding pocket. That is,
MD-354 (21) would sometimes interact with the conserved aspartate D3.32, but would
never reach the other side of the binding pocket near TM5 regardless of which rotamer
of MD-354 (21) was utilized in the docking study (data not shown).
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Unsuccessful

attempts to influence the binding mode of MD-354 (21) in the inactive α2C-AR model
were made. Manually docking MD-354 (21) closer to TM5, as well as additional binding
constraints in GOLD (e.g., distance constrainsts between the m-Cl group of MD-354
(21) and the conserved TM5 serines), resulted in unfavorable interactions and therefore,
upon energy minimizations, 21 moved away from TM5.

5. Discussion

3D molecular modeling studies suggest that MD-354 (21) might bind to the
“active” α2A-AR model in a manner similar to that of epinephrine (2). More specifically,
when superimposing +sc-MD-354 (21) and (R)-EPI (2) docked poses, the terminal
amines, as well as the m-hydroxyl and chloro groups, overlap (Figure 66). In turn, these
functional groups appear to interact with the same amino acid residues (i.e., ionic: N +—
D3.32; HB: m-OH—S5.42 or m-Cl—S5.42; Figure 66). Although the aromatic moiety
and one of the terminal amines of –ac-MD-354 (21) does overlap with the docked pose
of (R)-EPI (2), the m-Cl group does not overlap with the m-OH of (R)-EPI (2) (Figure
66). Alternatively, this m-Cl group overlaps with the unsubstituted m-position of (R)-EPI
(2).

Therefore, the docked pose of –ac-MD-354 (21) does not display an optimal

interaction with S5.42, but may interact with S5.46 (bonding distance = 3.0 Å).
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Figure 66. Proposed binding mode of (R)-Epinephrine (2) (magenta), –ac- (orange)
and +sc- (green) MD-354 (21) in the active α2A-AR model. Key amino acids of α2A-ARs
are shown in capped sticks (grey).
Based on the molecular modeling studies, it is possible that MD-354 (21) has a
greater binding affinity at the low affinity state (i.e., inactive model of α 2A-ARs) in
comparison to the high affinity state because of increased interactions with the receptor.
In the proposed binding mode of MD-354 (21) at the inactive α2A-ARs, there were three
amine—receptor interactions (D3.32 and Y6.55), all of which were in optimal distance
from each other (i.e., approximately 3 Å), but no halogen bonding with TM5 (e.g., mCl—S5.42 or S5.46). When evaluating all docked poses of the four lowest-energy
rotamers of MD-354 (21) in the inactive α2A-AR model, the closest measurement
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between the m-Cl group and the TM5 serine residues was 3.8 Å, which is not optimal
for a halogen bond. In general, a halogen bond, which is a short interaction between a
carbon-bonded halogen [e.g., the m-Cl moiety of MD-354 (21)] and a carbonyl,
hydroxyl, charged carboxylate, or phosphate group (e.g., S5.42 or S5.46 of α2A-ARs), is
optimally less than 3.3 Å when chlorine is the halogen. 218 In general, the binding mode
of MD-354 (21) contains three strong amine—receptor interactions in the inactive state,
whereas it contains only 2 amine—receptor interactions and a relatively weak halogen
bond in the active state. It is hypothesized that this difference in interactions provides
support for the MD-354’s (21) greater binding affinity (less than 10-fold difference
between the “active” and “inactive” α2A-ARs; see Table 5 for Ki values) at the “inactive”
state.
The π-π stacking interaction (i.e., the bonding network between the guanidine
moiety of MD-354 (21) and the aspartate carboxylate moiety (D3.32), which is stacked
over the aromatic ring of F7.39) has been previously found between the H-bonding
network between R (the guanidinium moiety) and E or D (the carboxylate moiety) and
the aromatic moiety of a tyrosine residue.217 In this particular example, the distance
between the center of the hydrogen bonding network and the center of the aromatic
residue was 3.7 Å.217 This additional interaction in the proposed binding mode of MD354 (21) in the inactive state of α2A-ARs may be one of the factors involved with
increased binding affinity as compared to the active state (Figures 60 and 62).
It was not obvious as to how MD-354 (21) could behave as a weak partial agonist
at α2A-ARs, while having a greater binding affinity to the low-affinity state of the receptor.
However, it is noted, that the docking studies described above do indicate that MD-354
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(21) only interacts with the conserved TM5 serines (S5.42 or S5.46) when α 2A-AR is in
an active conformation. That is, modifications to the inactive α2A-AR model brought the
top portion of TM5 further into the binding pocket, which allowed the m-Cl group of MD354 (21) to get close enough to either S5.42 or S5.46 for a favorable halogen bond. As
it has been previously proposed that the movement of TM5 is an important
conformational change in GPCR activity, the interaction of the ligand and the TM5
residues might be key in keeping a receptor in its active state. Therefore, the agonist
activity of MD-354 (21) at α2A-ARs may be due to its halogen bonding with S5.42 or
S5.46. Further, it is proposed that MD-354 (21) does not produce full agonist activity
because halogen bonds are not extremely strong.
When comparing the proposed binding modes of MD-354 (21) in the active and
inactive α2B-AR models, one difference is that the four lowest-energy conformers of MD354 (21) do not get close enough to TM5 to have favorable bonding distances between
the m-Cl group of 21 and the conserved serines, S5.42 and/or S5.46, in the inactive
model (Table 15). Secondly, in the active α2B-AR model, F7.39 was positioned too far
away (>5 Å) from the guanidine moiety of MD-354 (21) to provide a parallel-stacking
interaction. Furthermore, the hydrogen bonding interactions between the guanidine of
21 and the carboxylate group of D3.32 were not optimal; that is, they did not form a 6membered ring parallel to the aryl ring of F7.39 (as shown in Figure 63). It is possible
that the additional parallel stacking interaction of MD-354 (21) in the inactive α2B-AR
model with the TM7 phenylalanine (F7.39), prevents the ligand from strongly interacting
with the other side of the binding pocket, specifically with the TM5 serines (S5.42 and
S5.46).
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When comparing the two α2B-AR models, it is proposed that the approximately
10-fold difference in binding affinity of MD-354 (21) at the “active” and “inactive” α2BARs (Ki = 25 and 220 nM at agonist [125I]clonidine and antagonist [3H]RX 821002 sites;
Table 5) may be due to the halogen bond interaction between the m-Cl group and S5.46
observed in the –ac-MD-354 (21) binding mode in the active α2B-AR model (Figure 63).
As for the antagonist functional data for MD-354 (21) at α2B-ARs, it is possible that the
parallel-stacking interaction (between F7.39 and the hydrogen bonding network of the
guanidine moiety of MD-354 (21) and the carboxylate group of D3.32) reduces
interaction with TM5 and therefore, affects MD-354’s (21) activity at α2B-ARs.
In the docking studies for the active α2C-AR model, the four lowest-energy
conformers of MD-354 (21) showed favorable bonding distances to indicate ionic
interactions between amines of 21 and D3.32 and Y5.38, as well as halogen bonding
interactions between the m-Cl group of 21 and S5.46 (Figure 65). On the other hand,
the conformers of MD-354 (21) did not show optimal interactions when docked to the
inactive α2C-AR model; in fact, MD-354 (21) did not always reach the binding pocket
(i.e., it did not always interact with the conserved aspartate D3.32). Although not too
much can be concluded, these types of results in a docking study are indicative of a
relatively low binding affinity.
In summary, the homology modeling results indicate that the difference in binding
affinity of MD-354 (21) at the low- and high-affinity states of α2A-ARs may be due to the
amine—receptor interactions, which are stronger in the inactive α2A-AR model than in
the active α2A-AR model, whereas the binding affinity difference of MD-354 (21) at the
low- and high-affinity states of α2B-ARs seem to be due to the additional halogen bond
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interaction between the m-Cl group of 21 and the conserved TM5 serine (S5.46) in the
active α2B-ARs. The inability of the lowest-energy conformer of MD-354 (21) to always
bind in the binding pocket (i.e., the pocket centered around the conserved D3.32) of the
inactive α2C-AR model correspond to the low binding affinity. Overall the above results
are only speculative, and remain to be further investigated (or documented) by
mutagenesis studies.
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V. Conclusions

One goal of the current project was to further investigate the mechanism of
action of the selective analgesia-potentiating effect of clonidine (7) by MD-354 (21). As
previously reported, co-administration of MD-354 (21) and clonidine (7) produces a
biphasic analgesic effect in the mouse tail-flick assay (Peaks A and B, Figure 12) and
mechanistic studies suggested that the analgesic potentiation is due, at least in part, to
a 5-HT3 receptor and an α2-AR mechanism.29,33,34
In the present investigation, the structurally similar, yet more established, 5-HT3
receptor agonist mCPBG (20), also produced saline-like effects when administered
alone (Figure 22), but potentiated the antinociceptive effect of an “inactive” dose of
clonidine (7) in the mouse tail-flick assay (Figure 23a). Similar to the MD-354/clondine
(21/7) mechanistic studies,31,34 attenuation of the antinociceptive effect of the
mCPBG/clonidine (20/7) combination by the 5-HT3 receptor antagonist tropisetron (25;
Figure 25), as well as the non-selective α2-AR antagonist yohimbine (11; Figure 27),
indicated that 5-HT3 receptors and at least some subtypes of the α2-AR are involved in
mCPBG’s (20) potentiating effect in the mouse tail-flick assay. Furthermore, since the
5-HT3 receptor antagonist tropisetron methiodide, that does not readily cross the
BBB,116 failed to block the analgesic effect produced by the mCPBG/clonidine (20/7)
combination (Figure 26), it seems that the role of 5-HT3 receptors in the potentiating
mechanism may be centrally-mediated. Similar to the MD-354 (21) results presented in
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previous investigations,29,33 mCPBG’s (20) potentiation of the antinociceptive effects of
clonidine (7) is a selective effect; that is, a dose combination of mCPBG (20, 6.0 mg/kg)
and clonidine (7; 0.25 mg/kg), which produce a statistically significant increase in
antinociceptive effects (% MPE = 68.0) in the tail-flick assay, did not affect the
locomotor effects of clonidine (Figure 30).
Unlike the potentiation effect observed in the mouse tail-flick assay, mCPBG (20)
attenuated clonidine’s (7) antinociceptive effect in the mouse hot-plate assay (Figure
29). This result was also observed when the structurally similar 5-HT3 receptor agonist
MD-354 (21) is co-administered with clonidine (7) in the mouse hot-plate assay.33
The previous MD-354 (21)34 and current mCPBG (20) studies both indicate that
5-HT3 receptors play a role in the analgesia-potentiating effect of clonidine (7).
Furthermore, the tropisetron (25) and tropisetron methiodide mechanistic studies
suggest that mCPBG (20) potentiates the antinociceptive effects of clonidine (7), at
least in part, due to a central 5-HT3 receptor mechanism. Therefore, SR57227A (22), a
known centrally-acting 5-HT3 receptor agonist, was selected as a pharmacological tool
to evaluate central versus peripheral activity.

When SR57227A (22; 0.3-10 mg/kg

doses) was administered alone, saline-like effects were observed in the mouse tail-flick
(Figure 31) and hot-plate (Figure 36) assays.

In fact, in a modified tail-flick assay

wherein radiant heat is adjusted, dose-dependent hyperalgesic effects were produced in
SR57227A (22)-treated mice (Figure 33). At higher doses, SR57227A (22; 30 mg/kg)
produced antinociceptive effects in the mouse tail-flick (Figure 31) and hot-plate (Figure
36) assays.

However, locomotor activity results indicated that this high dose also,

produces significant hypolocomotor actions in comparison to saline (Figure 38), which
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can misleadingly suggest that a high dose of SR57227A (22; 30 mg/kg) produces
antinociceptive effects.
Unlike the other 5-HT3 receptor ligands studied [MD-354 (21) and mCPBG (20)],
SR57227A (22) did not attenuate or potentiate the antinociceptive actions of an
“inactive” dose (Figure 34) or an ED50 dose (Figure 35) of clonidine (7). SR57227A
(22), also, had no effect on the antinociceptive effects of clonidine (7) in the mouse hotplate assay (Figure 36). Because it has been previously shown that SR57227A (22)
behaves as an agonist at central 5-HT3 receptors115 and the abovementioned results
indicate that SR57227A (22) does not alter the antinociceptive effects of clonidine (7), it
might be speculated that MD-354 (21) potentiates the analgesic actions of clonidine (7)
via a peripheral 5-HT3 receptor mechanism, but this is highly unlikely as already
described above and in the Discussion.
Since previous mechanistic studies of the analgesia-potentiating effect of
clonidine (7) by MD-354 (21) also suggest a role for α2-ARs (e.g., an α2-AR agonist
mechanism in Peak A),31 TDIQ (6), a non-selective α2-AR agonist devoid of 5-HT3
receptor activity, was selected as a pharmacological tool to examine the potential α 2-AR
mechanism. In both antinociceptive assays, TDIQ (6) showed saline-like effects when
administered alone (tail-flick assay: Figure 39; hot-plate assay: Figure 48). However,
studies with co-administration of TDIQ (6) and clonidine (7; “inactive” dose) in the
mouse tail-flick assay indicated potentiation of the antinociceptive effects of clonidine (7)
in a dose-dependent manner (Figure 40). This is analogous to the MD-354/clonidine
(21/7) results previously reported.31
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Furthermore, since both clonidine (7) and TDIQ (6) are non-selective α2A/2B/2C-AR
agonists, TDIQ’s (6) potentiation of clonidine (7)-induced antinociception might simply
be an additive effect of the two agents. However, an isobolographic analysis indicated
that TDIQ (6) potentiates the analgesic actions of clonidine (7) in a synergistic (or superadditive) manner in the mouse tail-flick assay [3:1 and 12:1 fixed ratios fo TDIQ (6) and
clonidine (7), Figure 47]; that is, the isobologram suggested that the antinociception
produced by the combination of drugs [TDIQ (6) and clonidine (7)] is greater than the
sum of the individual effects of the component drugs.
In order to determine the mechanism of action associated with TDIQ’s (6)
potentiating effect of the antinociceptive actions of an “inactive” dose of clonidine (7),
various α2-AR antagonists were co-administered with the TDIQ/clonidine (6/7)
combination.

Since the selected α2-AR antagonists, BRL44408 (15; preferentially

selective at α2A-ARs), imiloxan (12; preferentially selective at α2B-ARs) and ARC-239
(14; preferentially selective at α2B/2C-ARs), produced saline-like effects when
administered alone, but blocked the antinociceptive effect of the TDIQ/clonidine (6/7)
combination (Figures 42, 43 and 44), there is support for an α2A- and α2B-AR role in the
mechanism and, further, a role for α2C-AR cannot be ruled out. These results support
the hypothesis that MD-354 (21) could be potentiating the analgesic actions of clonidine
(7) via an α2-AR agonist mechanism.
Thus, potentiation of the analgesic actions of clonidine (7) by MD-354 (21) might
be attributed to its unique 5-HT3 receptor/α2-AR character (Peak A, Figure 12)
As indicative of the abovementioned pharmacological studies, there is support for
a 5-HT3 receptor mechanism in the selective potentiation of the antinociceptive actions
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of clonidine (7) by MD-354 (21), which leads to the next goal of the present
investigation: the exploration of conformationally-constrained rotamers of the 5-HT3
receptor agonist MD-354 (21). Preliminary results indicated that when MD-354 (21) was
constrained into a quinazoline ring to form two MD-354 (21) rotamers, 2-amino-7-chloro3,4-dihydroquinazoline (26) and 2-amino-5-chloro-3,4-dihydroquinazoline (27), 26 more
closely mimics the binding profile of MD-354 (21) (Figure 13 and Table 7). Therefore,
26 was used as the parent compound in the present investigation which explored the
role of the ring nitrogen atoms and the chloro substituent in binding at 5-HT3 receptors.
In order to explore the role of the ring nitrogen atoms, procedures to synthesize
compounds 28-33 (Figure 14) were developed, but only compound 28, 29, 30 and 33
were successfully synthesized (Schemes 2, 7, 9 and 10). Additionally, compound 65
was also synthesized because its precursor was a minor product in the reaction scheme
to synthesize 33 (Schemes 11 and 12).

Compounds 38 and 39 (Figure 16) were

successfully prepared in order to study the role of the chloro substituent (Schemes 13
and 14). Binding affinity at 5-HT3 receptors have been evaluated for compounds 28, 33
and 65, all of which lacked affinity at 5-HT3 receptors (Ki > 10,000 nM). Due to these
preliminary binding results, it is evident that the nitrogen atoms of the conformationallyconstrained analogs of MD-354 (21) are important for 5-HT3 receptor binding. The
conformationally-constrained MD-354 (21) analog 28 is missing one of the two terminal
amines of MD-354 (21) or when comparing to 26, it is missing the 3-position amine.
Both MD-354 (21) and 26 display high affinity at 5-HT3 receptors (Ki = 35 and 34 nM,
respectively, Table 7) whereas the des-amino anolog 28 lacks 5-HT3 receptor binding
affinity (Ki > 10,000 nM), which suggests that at least one, if not both, of the MD-354
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(21) terminal amines is necessary for 5-HT3 receptor binding. Furthermore, no matter
which meta-position the chloro substituent is in, when the aniline and 3-position nitrogen
atoms are missing, 5-HT3 receptor binding is abolished. For example, when comparing
compunds 26 (Ki = 34 nM) with 33 (Ki > 10,000 nM), and 27 (Ki = 1021 nM) with 65 (Ki >
10,000 nM), 5-HT3 receptor binding affinity is reduced by at least 300- and 10-fold,
respectively (Table 7).

5-HT3 receptor binding affinity results of the remaining

synthesized compounds will further evaluate the role of the nitrogen atoms and the
chloro substiutent in MD-354 (21) and conformationally-constrained analogs of MD-354
(21) in 5-HT3 receptor binding.
Just as the present investigation showed that various 5-HT3 receptor [e.g.,
mCPBG (20) and SR57227A (22)] and α2-AR [e.g., TDIQ (6)] ligands potentiated the
antinociceptive actions of clonidine (7) via 5-HT3 receptor or α2-AR mechanisms,
previous pharmacological studies indicated that there was a 5-HT3 receptor and α2-AR
mechanism involved in clonidine’s (7) analgesic potentiation by MD-354 (21) in the
mouse tail-flick assay. Since MD-354 (21) shows varied binding affinities and functional
activity at the α2-AR subtypes, the final goal of the current studies was to explain these
subtype differences via examination of the binding mode of MD-354 (21) to graphic
receptor models of low- and high-affinity states of α2A-, α2B- and α2C-ARs.
In order to examine the binding mode of MD-354 (21) at α2A-, α2B- and α2C-ARs in
their inactive and active states, it was first necessary to identify the lowest-energy
conformers of MD-354 (21) as these conformers should mimic the likely conformations
of MD-354 (21) in its binding mode. A systematic conformation search conducted in
SYBYL identified the four lowest-energy rotamers of MD-354 (21; Figure 55), which
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coincidentally, matched the torsion angles found in arginine, clonidine (7) and mCPBG
(20) crystal structures.
The inactive state of α2A-ARs was modeled by mutating the β2-AR crystal
structure (pbd ID: 2RH1) and the active state of α2A-ARs was modeled by modifying the
inactive α2A-AR homology model in a manner observed in other active-state structures
of GPCRs. Due to extensive SAFIR studies and site-directed mutatgeneis studies of
phenethylamines, endogenous ligands including NE (1) and EPI (2), were docked into
the binding pocket to help validate the active α2A-AR homology model. Similar to the
support in the literature, the docking studies indicated ligand—receptor interactions of,
for example, (R)-EPI (2) in the active α2A-AR model: (a) ionic: N+—D3.32; (b) HB: βOH—D3.32, m-OH—S5.42 and p-OH—S5.46; (c) π-π (edge-to-face): F6.51, Y6.55;
CH-π: V3.33; (d) π-cation: N+—F7.39 (Figure 58). The lower binding affinity of (S)-EPI
(2) in comparison to (R)-EPI (2) may be due to the decreased ligand—receptor
interactions such as the H-bond interaction between the conserved D3.32 and the β-OH
moiety of (S)-EPI (2).
Upon docking the four lowest-energy rotamers of MD-354 (21) based on the
conformational analyses in the active model of α 2A-AR, the major bonding interactions
observed included: (a) an ionic interaction between both the aniline and terminal
nitrogens and D3.32; (b) hydrogen bonding between the m-Cl group and either S5.42 or
S5.46; (c) hydrophobic interactions with V3.33, F6.51, F7.35 and F7.39 (Figure 59 and
Table 14a). In general, these docking studies suggest that MD-354 (21) might bind to
the active α2A-AR model in a manner similar to that of EPI (2) (Figure 66).
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Furthermore, when comparing the proposed binding modes of MD-354 (21) at
the inactive and active α2A-ARs, it is possible that MD-354 (21) has a greater binding
affinity at the low-affinity state because of increased interactions with the receptor.
Specifically, the binding mode of MD-354 (21) contains three strong amine—receptor
interactions in the inactive state, whereas it contains only 2 amine—receptor
interactions and a relatively weak halogen bond in the active state.
Upon a comparison between the proposed binding modes of MD-354 (21) at the
inactive and active α2B-AR models, it is proposed that the approximately 10-fold
difference in binding affinity of MD-354 (21) at the low- and high-affinity state α2B-ARs
(Ki = 25 and 220 nM, respectively; Table 5) may be due to the halogen bond interaction
between the m-Cl group and S5.46 observed in the –ac-MD-354 (21) binding mode in
the active α2B-AR model (Figure 63). With regards to the antagonist functional data for
MD-354 (21), it is possible that the additional parallel-stacking interaction (between
F7.39 and the hydrogen bonding network of the guanidine moiety of MD-354 (21) and
the carboxylate group of the conserved D3.32) dimishes the interaction with TM5
residues and therefore, affects MD-354’s (21) ability to “hold” the α2B-AR in an active
state.
As the lowest-energy conformers of MD-354 (21) did not show optimal
interactions in the inactive α2C-AR model, low binding affinity is not surprising. Similar to
proposed binding mode of MD-354 (21) at active α2A-AR models, favorable bonding
distances for a halogen bond between the m-Cl group of 21 and S5.46, as well as ionic
interactions between the amines of 21 and D3.32 and Y5.38 was observed in the active
α2C-AR docking results.
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To conclude, the pharmacological studies indicated that arylguanidines represent
a novel class of analgesic adjuvants with a dual mechanism of action (i.e., the
mechanism involves both 5-HT3 receptors and α2-adrenoceptors). The proposed
docking modes of MD-354 (21) at high-affinity states of α2A- and α2B-AR models display
a halogen bond interaction between the chloro group of MD-354 (21) and conserved
TM5 serines. Since the tilting of TM5 into the binding pocket has been implicated in the
GPCR activation process, it seems possible that this halogen bond interaction observed
in the α2A- and α2B-AR models might account for its partial agonist activity. Furthermore,
on the basis of available binding affinity data of conformationally-constrained MD-354
(21) analogs, the nitrogen atoms seem to be necessary for 5-HT3 receptor binding
affinity.
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VI. Experimental

A. Pharmacological studies

1. Animals

Male ICR mice (Harlan Laboratories; Indianapolis, IN; 19-30 g) were housed in
groups of 5-6, with free access to food and water. The housing rooms were under a
temperature- (22 °C) and humidity- (≈50%) controlled environment and a standard
12:12 h light/dark cycle starting at 7:00 a.m. The experiements were conducted in
accordance to protocols set by the Institutional Animal Care and Use Committee
(IACUC) of Virginia Commonwealth University (IACUC protocol # AM10339). On the
experiment day, mice were first acclimated to the testing environment for at least one
hour and weighed prior to any treatment.

2. Drugs

The hydrochloride salts of MD-354 (21; meta-chlorophenylguanidine) and
mCPBG (20) were synthesized in our laboratory. Ondansetron hydrochloride (Zofran®,
Lot CO99723; GlaxoSmithKline) was purchased from the MCVH-Pharmacy (Richmond,
VA).

Imiloxan hydrochloride (12), ARC-239 (14; 2-[2-(4-(2-Methoxyphenyl)piperazin194

1-yl)ethyl]-4,4-dimethyl-1,3-(2H,4H)-isoquinolindione dihydrochloride), BRL44408 (15;
2-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-2,3-dihydro-1-methyl-1H-isoindole), SR57227A
hydrochloride (22; 1-(6-chloro-2-pyridyl)-4-piperidinylamine) and Zacopride (24) were
purchased from Tocris (Ballwin, MO).

TDIQ (6; 5,6,7,8-tetrahydro-1,3-dioxolo[4,5-

g]isoquinoline) hydrochloride was synthesized in our laboratory.

Clonidine (7),

tropisetron (25) and yohimbine (11) were purchased from Sigma-Aldrich Chemicals
(Milwaukee, WI).

Tropisetron methiodide was purchased from RBI (Research

Biochemicals Inc; Natick, MA).

Drug solutions were prepared daily; all drugs were

dissolved in 0.9% saline and administered to mice in a total volume of 10 mL/kg body
weight by subcutaneous (s.c.) or intraperitoneal (i.p.) injections. Each dose of drug (or
combination of drugs) was studied in at least 8 mice (i.e., n ≥ 8 mice/treatment).

3. Behavioral assays

a) Tail-Flick assay

Antinociception was assessed by the tail-flick method of D’Armour and Smith219
as modified by Dewey et al.220 using a Columbus Tail-Flick Analgesia Meter (Columbus
Instruments, Columbus, Ohio).

Determination of qualifying mice was conducted by

screening each mouse before the treatment (qualifying control response time between
1.7 and 4.0 s; in hyperalgesic studies: radiant heat was modified so that qualifying
control response time was between 5 and 7 s). Test latency was determined after drug
administration. In order to minimize tissue damage, a maximum latency of 10 s was
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imposed. The antinociceptive response was calculated as percent maximum possible
effect (%MPE), where %MPE = [(test latency – control latency)/(cutoff time – control
latency)] x 100.
The experimental protocol for testing the antinociceptive effects of drugs was as
follows: 15 min prior to s.c. administration of drugs, baseline tail-flick latency was
determined for each mouse. Drugs were administered either alone or in combination
with other drugs with the following pre-injection times (i.e., injection time prior to test):
TDIQ (6; 45 minutes), clonidine (7; 20 minutes), yohimbine (11; 60 minutes), imiloxan
(12; 55 minutes), ARC-239 (14; 50 minutes), BRL-44408 (15; 50 minutes), mCPBG (20;
45 minutes), MD-354 (21; 45 minutes), SR57227A (22; 45 minutes), ondansetron (23;
50 minutes) and tropisetron/tropisetron methiodide (25; 50 minutes).

b) Hot-Plate assay

The hot-plate method is a modification of that described by Eddy and
Leimbech221 and Atwell and Jacobson.222 Mice were placed onto a hot-plate (Columbus
Hot-plate Analgesia Meter) and covered with a 10 cm-wide glass cylinder, wherein the
temperature was maintained at 55 °C. Determination of qualifying mice was conducted
by screening each mouse before the treatment (qualifying mouse displays a control
response time between 6 and 10 s).

Test latency was determined after drug

administration. In order to prevent any paw damage, 30 s was used as the cutoff time.
The antinociceptive response was calculated as percent maximum possible effect

196

(%MPE), where %MPE = [(test latency – control latency)/(cutoff time – control latency)]
x 100.
The experimental protocol for testing the antinociceptive effects of drugs was as
follows: 15 min prior to s.c. administration of drugs, baseline latency was determined for
each mouse. Drugs were administered either alone or in combination with other drugs
with the following pre-injection times (i.e., injection time prior to test): TDIQ (6; 45
minutes), clonidine (7; 30 minutes), mCPBG (20; 45 minutes) and SR57227A (22; 45
minutes).

c) Locomotor activity assay

Mice were placed into individual Tru Scan Infrared Locomotor Activity System
(Coulbourn Instruments, Allentown, PA) photocell activity cages (40 cm cube) after s.c.
(or i.p.) administration of drugs or combination of drugs (mice were only tested once).
Ambulatory movement was measured by the number of times the animal interrupted the
infrared beams traversing the cage for a period of 15 minutes; measurements were
taken 15, 30 and 45 minutes following the start of the assay. The behavioral analysis
examined nine measures of activity: movement episodes, movement time (s),
movement distance (cm), vertical entries, margin distance (cm), margin time (s), center
distance (cm), center time (s) and center entries.
Drugs were administered either alone or in combination with other drugs with the
following pre-injection times (i.e., injection time prior to test): TDIQ (6; 30 minutes),
clonidine (7; 5 minutes), mCPBG (20; 30 minutes) and SR57227A (22; 0 minutes).
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4. Statistical analysis

Data were analyzed statistically by an analysis of variance (ANOVA) followed by
the Dunnett’s post-hoc test. A measure of significant difference between two groups
was analyzed using a Student’s t-test. The null hypothesis was rejected at the 0.05
level.

5. Isobolographic analysis

Synergism was assessed by the isobolographic analysis method described by
Tallarida.223 In order to assess if a biological effect produced by a combination of drugs
is greater than, equal to, or samller than the sum of the individual effects of the
component drugs, an isobolographic analysis was performed.

The representative

graph, an isobologram, compares the experimental ED50 of the combination of drugs
(ED50mix) to the theoretical additive combination (ED50add).

ED50add is based on the

individual potencies of the components (e.g. drug 1 and 2) in the combination. If only
drug 2 is active when administered alone then, the ED50add is based on the ED50 of drug
2 and its proportion in the combination.

To evaluate synergism, the experimental

ED50mix of a fixed-ratio of TDIQ (6) and clonidine (7) is compared to the theoretical
ED50add of a simply additive mixture having the same proportions, wherein ED 50add =
(ED50clonidine) / Pclonidine (P = proportion). ED50mix and ED50clonidine were obtained from the
regression analysis of the % MPE against log total dose. The difference between the
two ED50 values with its corresponding standard error was statistically tested with a
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Student’s t-test.

Evaluation of results: a super-additive effect (exaggerated effect)

occurs when ED50mix < ED50add, an additive effect (theoretical effect) occurs when ED50mix =
ED50add and a sub-additive effect (attenuated effect) occurs when ED50mix > ED50add.

B. Synthesis

Reactions were monitored by thin layer chromatography (tlc) on silica gel GHLF
plates (250 μ, 2.5 x 10 cm, Analtech Inc.). Some compounds were purified via column
chromatography (silica gel 62, 60-200 mesh, Sigma-Aldrich) or flash chromatography
(CombiFlash Companion/TS, Teledyne Isco Inc.). All solid products were characterized
by melting point on a Thomas-Hoover mp apparatus (and are uncorrected).

1

H NMR

spectra were obtained on either a Varian 300 MHz spectrometer or a Bruker 400 MHz
spectrometer with tetramethylsilane as internal standard. Nicolet Avatar 360 FT-IR or
Nicolet 52DX FT-IR spectrophotometers were used to obtain IR spectra for all
compounds. Combustion analysis of carbon, hydrogen, and nitrogen was conducted by
Atlantic Microlab Inc. (Norcross, GA) on all unknown target compounds. Calculated
values were +/- 0.4 % of the theoretical values.

m-Chlorophenylbiguanide Hydrochloride (20).

Compound 20 was prepared

according to a literature procedure for a similar compound.179 Compound 41 (6.83 g,
41.64 mmol) was added to a stirred mixture of cyanoguanidine (3.50 g, 41.64 mmol) in
H2O (10 mL) and heated at reflux for 4 h. The reaction mixture was allowed to cool to
10 C for 24 h. The precipitated salt was collected by filtration, washed with Et 2O (6 x 5
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mL), and recrystallized from H2O (2 x) to afford 4.46 g (22%) of 20 as white crystals: mp
195.5-196.5 C (lit.181 mp 197-198 C); 1H NMR (DMSO-d6) δ 7.00-7.15 (m, 3H, ArH
and NH, D2O ex), 7.22-7.30 (m, 2H, ArH and NH, D2O ex), 7.32 (t, 1H, ArH), 7.44 (br s,
3H, NH, D2O ex), 7.59 (s, 1H, ArH), 9.92 (br s, 1H, NH+, D2O ex); IR (diamond, cm-1)
3303, 3129, 2962, 1629, 1596.

2-Amino-7-chloroquinoline Hydrochloride (28).

Compound 28 was prepared

according to a literature procedure for a similar compound. 224 A solution of 45 (1.54 g,
7.40 mmol) and SnCl2·2H2O (16.66 g, 7.40 mmol) in absolute EtOH (100 mL) was
heated at reflux for 2.5 h.

The reaction mixture was allowed to cool to room

temperature and poured into ice-water (75 mL). The solution was made slightly basic
(pH ≈ 8-9) by the addition of saturated NaHCO3 solution. Solid NaCl (≈ 2-3 g) was
added to the solution, and the solution extracted with EtOAc (5 x 200 mL).

The

combined organic extract was dried (Na2SO4) and the solvent was removed under
reduced pressure. The mixture of products (Rf = 0.5 and 0.9; CH2Cl2/MeOH/NH4OH;
9:1:0.1) was purified by column chromatography (silica gel; CH 2Cl2/MeOH/NH4OH;
9:1:0.1) to afford the free base (Rf = 0.5) of 28 as an off-white solid (0.20 g; 15%): mp
237-240 °C; 1H NMR (DMSO-d6) δ 7.11 (d, 1H, ArH), 7.40 (dd, 1H, ArH), 7.51 (br s, 2H,
NH2, D2O ex); IR (diamond, cm-1) 3300, 3075, 2915, 1645, 1608.
A saturated solution of HCl (g)/Et2O was added to a methanolic solution of the above
free base (0.15 g).

The resulting salt was collected via filtration and purified by

recrystallization from EtOH/Et2O to yield 0.08 g (42%) of 28 as a white solid: mp 268270 °C; 1H NMR (DMSO-d6) δ 3.44 (br s, 3H, NH3+, D2O ex), 7.27 (d, 1H, ArH), 7.62 (d,
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1H, ArH), 8.00 (s, 1H, ArH), 8.04 (d, 1H, ArH), 8.30 (d, 1H, ArH), 9.35 (br s, 1H, NH+,
D2O ex); IR (diamond, cm-1) 3263, 3069, 1649. Anal. Calcd (C9H7N2Cl·1.5 HCl) C,
46.33; H, 3.67; N, 12.01. Found: C, 46.67; H, 3.47; N, 11.99.

3-Amino-6-chloroisoquinoline (29).

Compound 29 was prepared according to a

literature procedure for a similar compound.194 A 2.5 M solution of n-BuLi in hexanes
(3.7 mL, 9.32 mmol) was added to a stirred solution of 53 (2.0 g, 7.77 mmol) in
anhydrous THF (50 mL) at -70 °C under a N2 atmosphere and allowed to stir for 30 min.
The reaction was quenched with absolute EtOH (50 mL) and then allowed to warm to
room temperature. The solvent was removed under reduced pressure and the resulting
residue was dissolved in CH2Cl2 (100 mL). The solution was washed successively with
H2O (100 mL) and saturated NH4Cl solution (100 mL). The organic extract was dried
(Na2SO4) and concentrated under reduced pressure. The crude product was purified
via column chromatography (silica gel; 1st column: CH2Cl2/MeOH; 40:1 to 20:1; 2nd
column: hexanes/EtOAc = 10:1) and then subsequently recrystallized from benzene to
yield 74 mg of 29 (5%) as a yellow solid: mp 228-230 °C (dec.); 1H NMR (CDCl3) δ 4.53
(br s, 2H, NH2), 6.65 (s, 1H, ArH), 7.18-7.21 (dd, 1H, ArH), 7.53 (s, 1H, ArH), 7.72-7.74
(d, 1H, ArH), 8.84 (s, 1H, ArH); IR (diamond, cm-1) 3428, 3300, 3159, 1647; Anal. Calcd
(C9H7N2Cl·0.125 CH2Cl2) C, 57.92; H, 3.86; N, 14.80, Found: C, 58.12; H, 3.87; N,
14.50.

2-Amino-7-chloronaphthalene Hydrochloride (30).

Absolute EtOH (5 mL) and

platinum oxide (2 mg, 5% w/w) were added to 60 (0.03 g, 0.17 mmol) and the mixture
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was allowed to stir at room temperature under a N2 atmosphere for 15 min. A H2
balloon was added and the reaction mixture was allowed to stir for 6.5 h. The reaction
mixture was filtered over Celite and the solid material was washed with absolute EtOH
(35 mL). The filtrate was evaporated under reduced pressure and the resulting beige
solid was dried under reduced pressure for 5 h to afford the crude free base of 30 (0.02
g). Hydrogen chloride gas was bubbled slowly through an ethanolic solution (≈3 mL) of
the crude free base for 10 min at 0 °C (ice-bath). The solvent was removed under
reduced pressure and the crude product as a hydrochloride salt was purified via
recrystallization from acetone to yield 0.01 g (34%) product as a brown solid: mp 262264 °C (lit.205 mp 261-263 °C).

2-Amino-7-chlorotetralin Hydrochloride (33). Compound 33 was prepared according
to a literature procedure for a similar compound.206 Sodium cyanoborohydride (0.08 g,
1.33 mmol) was added to a solution of 63 (0.20 g, 1.11 mmol) and NH4OAc (0.85 g,
11.07 mmol) in MeOH (15 mL) at room temperature.

The resulting yellow/green

solution was allowed to stir for 23 h. The reaction mixture was acidified with 10% HCl to
pH ≈ 2, concentrated under reduced pressure, and then extracted with CH 2Cl2 (2 x 75
mL). The aqueous portion was basified with 6 N NaOH to pH ≈ 10 and extracted with
CH2Cl2 (3 x 75 mL). The combined organic extract was dried (Na 2SO4), concentrated,
and the product was dried under reduced pressure for 2 h to yield 0.03 g (16%) of the
free base of 33 as a yellow/green oil: 1H NMR (CDCl3) δ 1.50-1.56 (m, 1H, CH), 1.891.94 (m, 1H, CH), 2.42-2.49 (m, 1H, CH), 2.67-2.91 (m, 3H, CH), 3.07-3.14 (m, 1H,
CH), 6.92-7.00 (m, 3H, ArH); IR (diamond, cm-1) 2920, 2849, 2658, 1573.
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The free base was converted to the HCl salt by dissolving the oil in absolute EtOH (8
mL); a saturated solution of HCl (g) in EtOH (4 mL) was added at 0 °C (ice-bath) and
the mixture was allowed to stir for 30 min. The reaction mixture was concentrated
under reduced pressure and washed with anhydrous Et 2O (10 mL) The resulting solid
was recrystallized from EtOH/Et2O to yield 0.02 g (50%) of 33 as a pink solid: mp >260
°C; 1H NMR (DMSO-d6) δ 1.68-1.78 (m, 1H, CH), 2.09-2.13 (m, 1H, CH), 2.75-2.85 (m,
3H, CH), 3.06-3.11 (m ,1H, CH), 3.43-3.46 (m, 1H, CH), 7.13-7.26 (m, 3H, ArH), 8.12
(br s, 3H, NH3+, D2O ex); IR (diamond, cm-1) 2920, 2719, 2627, 2556, 2037, 1621, 1599.
Anal. Calcd (C10H12NCl·HCl·0.25 H2O) C, 53.95; H, 6.11; N, 6.29. Found: C, 54.26; H,
5.71; N, 6.08.

2-Amino-5,7-dichloro-3,4-dihydroquinazoline Hydrochloride (38).

Compound 38

was prepared according to a literature procedure for a similar compound. 210 A solution
of BH3·THF complex (2.9 mL, 1 M) was added in a dropwise manner to 2-amino-5,7dichloroquinazolin-4(3H)-one (68) under a N2 atmosphere. The green reaction mixture
was heated at reflux for 1 h. A solution of 6 N HCl (1 mL) was added in a dropwise
manner at 0 °C (ice-bath) to hydrolyze the borate complex and excess reagent. The
dark-blue suspension was basified with 6 N NaOH (1.5 mL). The reaction mixture was
concentrated under reduced pressure and the resulting residue was extracted with hot
CHCl3 (2 x 15 mL). Crude product precipitated when the combined organic extract
cooled to room temperature. The combined organic extract was filtered. The filtrate
was evaporated to dryness and the product was recrystallized from CHCl 3.

The

combined solid was dried in an Abderhalden over toluene heated at reflux for 8 h to
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yield 0.09 g (59%) of the free base of 38 as an off-white solid: mp 207-208 °C; 1H NMR
(DMSO-d6) δ 4.34 (s, 2H, CH2), 5.87 (br s, 2H, NH2, D2O ex), 6.41 (br s, 1H, NH, D2O
ex), 6.48 (d, 1H, ArH), 6.78 (d, 1H, ArH); IR (diamond, cm-1) 3466, 3309, 3162, 1648,
1607.
2-Amino-5,7-dichloro-3,4-dihydroquinazoline (0.04 g, 0.20 mmol) was dissolved in
absolute EtOH (5 mL) at 0 °C (ice-bath). A saturated solution of HCl (g) in EtOH (5 mL)
was added and allowed to stir for 30 min. The solvent was removed under reduced
pressure and the resulting off-white residue was recrystallized from absolute EtOH,
washed with cold anhydrous Et2O, and dried in an Abderhalden over toluene heated at
reflux for 4 d to yield 0.04 g (68%) of 38 as an off-white solid: mp 272-273 °C; 1H NMR
(DMSO-d6) δ 4.48 (s, 2H, CH2), 7.03 (d, 1H, ArH), 7.36 (d, 1H, ArH), 7.85 (br s, 2H,
NH2, D2O ex), 8.69 (br s, 1H, NH, D2O ex), 11.22 (br s, 1H, NH+, D2O ex); IR (diamond,
cm-1) 3251, 3026, 2972, 2915, 2837, 1662, 1618. Anal. Calcd (C 8H7Cl2N3 HCl·0.25
EtOH·0.25 H2O) C, 38.02; H, 3.75; N, 15.65. Found: C, 38.07; H, 3.76; N, 15.57.

2-Amino-3,4-dihydroquinazoline Hydrochloride (39). Compound 39 was prepared
according to a literature procedure for a similar compound. 210 A solution of BH3·THF
complex (12 mL, 1 M) was added in a dropwise manner to a solution of 70 (0.50 g, 3.10
mmol) in anhydrous THF (6 mL) under a N2 atmosphere at 0 °C (ice-bath).

The

reaction mixture was heated at reflux for 5 h and then allowed to stir at room
temperature for 72 h. A solution of 6 N HCl (10 mL) was added in a dropwise manner at
0 °C (ice-bath) to hydrolyze the borate complex and excess reagent. The reaction
mixture was heated at reflux without a condenser to remove the solvent.
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The

suspension was basified with 15% NaOH and extracted with hot CHCl3 (25 mL). The
product precipitated when the combined organic extract cooled to room temperature.
The suspension was filtered and the solid was dried in a dessicator over NaOH pellets
to yield 0.23 g (49%) of the free base of 39 as an off-white solid: mp 228 °C (lit.211 mp
214-216 °C); 1H NMR (DMSO-d6) δ 4.27 (s, 2H, CH2), 6.51 (d, 1H, ArH), 6.63 (t, 1H,
ArH), 6.79 (d, 1H, ArH), 6.93 (t, 1H, ArH); IR (diamond, cm-1) 3390, 3307, 3108, 2819,
1653.
2-Amino-3,4-dihydroquinazoline (0.10 g, 0.07 mmol) was dissolved in absolute EtOH (5
mL) and allowed to stir at 0 °C (ice-water). A saturated solution of HCl (g) in absolute
EtOH (5 mL) was added and the reaction mixture was allowed to stir for 30 min. The
solvent was removed under reduced pressure and the resulting off-white residue was
dissolved in hot absolute EtOH.

The suspension was filtered and the filtrate was

concentrated under reduced pressure. The residue was recrystallized from absolute
EtOH and then dried in an Abderhalden over toluene heated at reflux for 12 h to yield
0.09 g (74%) of 39 as an off-white solid: mp 158-160 °C (lit.210 ·HI mp 199-200 °C); 1H
NMR (DMSO-d6) δ 4.49 (s, 2H, CH2), 6.97 (d, 1H, ArH), 7.09 (t, 1H, ArH), 7.18 (d, 1H,
ArH), 7.26 (t, 1H, ArH), 7.63 (br s, 2H, NH2, D2O ex), 8.51 (br s, 1H, NH, D2O ex), 10.83
(br s, 1H, NH+, D2O ex); IR (diamond, cm-1) 3261, 3088, 2963, 2870, 1671, 1626. Anal.
Calcd (C8H9N3·HCl·0.25 EtOH·0.25 H2O) C, 51.13; H, 6.06; N, 21.05. Found: C, 51.23;
H, 5.66; N, 20.92.

meta-Chloroaniline Hydrochloride (41). A 35 M HCl/Et2O solution (22.5 mL, 78.75
mmol) was added in a dropwise manner to a solution of m-chloroaniline (40; 10.00 g,
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78.39 mmol) in absolute EtOH (100 mL) at -10 C. The precipitated HCl salt was
collected by filtration, recrystallized three times from acetone, and dried (KOH) to yield
3.59 g (28%) of 41 as a white powder: mp 218-219 °C (lit.180 mp 221.5-222.5 °C).

[2-(4-Chloro-2-nitrophenyl)vinyl]dimethylamine (43). Compound 43 was prepared
according to a literature procedure for a similar compound.225 Dimethylformamide
dimethylacetal (11.6 mL, 87 mmol) and pyrrolidine (3.6 mL, 44 mmol) were added to a
solution of 4-chloro-2-nitrotoluene (42; 5.00 g, 29 mmol) in DMF (25 mL) at 110 °C
under a N2 atmosphere. The reaction mixture was allowed to stir for 1 h, diluted with
Et2O (200 mL), and washed with H2O (150 mL). Solid NaCl (≈ 3-4 g) was added to the
suspension and the organic portion was dried (MgSO4). The solvent was removed
under reduced pressure to afford 7.60 g (100%) of 43 as a dark-violet crude substance:
mp 43-45 ºC (lit.226 mp 44-46 °C); 1H NMR (CDCl3) δ 2.92 (s, 6H, CH3), 5.82 (d, 1H,
CH), 6.94 (d, 1H, CH), 7.21-7.29 (m, 1H, ArH), 7.38 (d, 1H, ArH), 7.85 (s, 1H, ArH); IR
(diamond, cm-1) 2976, 2930, 2853, 1691, 1596.

4-Chloro-2-nitrobenzaldehyde (44). Compound 44 was prepared according to a
literature procedure for a similar compound.227 Compound 43 (0.64 g, 2.80 mmol) in
DMF (2.5 mL) was added in a dropwise manner to a solution of NaIO 4 (1.80 g, 8.50
mmol) in H2O (5 mL) at room temperature. The reaction mixture was allowed to stir for
1.5 h. The crude reaction mixture was filtered and the solid was washed with toluene
(50 mL). The organic portion of the filtrate was washed with H 2O (3 x 25 mL) and
concentrated under reduced pressure.

The oily residue was purified by column
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chromatography (silica gel; hexanes/EtOAc; 5:1) to afford 0.32 g (61%) of 44 as a paleyellow solid: mp 66-68 ºC (lit.228 mp 67-68 °C, Et2O); 1H NMR (CDCl3) δ 7.76 (dd, 1H,
ArH), 7.94 (d, 1H, ArH), 8.10 (s, 1H, ArH), 10.39 (s, 1H, CHO); IR (diamond, cm-1) 3368,
3087, 2926, 1691, 1597.

3-(4-Chloro-2-nitrophenyl)acrylonitrile (45). Compound 45 was prepared according
to a literature procedure for a similar compound.229 Sodium hydride (0.55 g, 13.80
mmol) was added portionwise to a stirred solution of diethyl cyanomethylphosphonate
(2.45 g, 13.80 mmol) in anhydrous DMF (100 mL) at 0 °C (ice-bath). A solution of 44
(2.57 g, 13.80 mmol) in anhydrous DMF (25 mL) was added to the reaction mixture in a
dropwise manner (over 10 min). After another 5 min, the reaction mixture was poured
into ice-water and extracted with Et2O (100 mL).
(MgSO4) and concentrated under reduced pressure.

The organic portion was dried
The residue was purified by

column chromatography (silica gel; hexanes/EtOAc; 1:1) to afford 1.55 g (54%) of 45 as
a dark-purple oil: 1H NMR (CDCl3) δ 5.73 (d, 1H, CH), 5.85 (d, 1H, CH), 7.51-8.21 (m,
3H, ArH); IR (nujol, cm-1) 2958, 2905, 2844, 2344, 2215, 1514.

(E)-3-(2-Amino-4-chlorophenyl)acrylonitrile (46).
previous

reaction

was

isolated

by

column

The second product from the
chromatography

(silica

gel;

CH2Cl2/MeOH/NH4OH; 9:1:0.1) and recrystallized from benzene to afford the free base
(Rf = 0.9) of 46 as a light-brown solid (0.33 g, 25%): mp 159-160 °C; 1H NMR (DMSOd6) δ 6.03 (br s, 2H, NH2, D2O ex), 6.18 (d, 1H, CH), 6.55 (d, 1H, ArH), 6.73 (d, 1H, CH),
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7.44 (d, 1H, ArH), 7.76 (d, 1H, ArH); IR (diamond, cm-1) 3461, 3374, 3230, 3057, 2214,
1635, 1598.

7-Chloro-2-acetamidoquinoline (49).

Compound 49 was prepared according to a

literature procedure for a similar compound.230 Acetic acid (0.1 mL, 1.70 mmol ) was
added in a dropwise manner to acetic anhydride (0.14 mL, 1.51 mmol) at 0 °C (ice-bath)
and allowed to stir for 2 h at room temperature. The reaction mixture was added to a
solution of 28 (free base; 135 mg, 0.76 mmol) in anhydrous THF (25 mL) under a N2
atmosphere and allowed to stir for 30 min. The solvent was removed under reduced
pressure. Methanol (20 mL) was added, the reaction mixture was allowed to stir for 30
min and the solvent was removed under reduced pressure. Diethyl ether (20 mL) was
added, the reaction mixture was allowed to stir for 1 h and subsequently filtered. The
precipitate was dried in an Abderhalden over toluene heated at reflux for 12 h to yield
120 mg (72%) of 49 as an off-white solid: mp 209-210 °C; 1H NMR (CDCl3) δ 2.31 (s,
3H, CH3), 7.44-7.47 (dd, 1H, ArH), 7.69-7.72 (m, 2H, ArH), 8.53-8.55 (d, 1H, ArH), 8.598.60 (d, 1H, ArH), 10.24 (br s, 1H, NH); IR (diamond, cm-1) 3138, 1696, 1607.

4-Chloro-2-cyanomethylbenzonitrile (52). Compound 52 was prepared according to
a literature procedure for a similar compound.199

Ethyl cyanoacetate (6.81 mL, 64

mmol) was added over 10 min to a suspension of NaH (2.56 g, 64 mmol, 60%
dispersion in mineral oil) in DMSO (25 mL) at 0 °C (ice-bath). The yellow reaction
mixture was allowed to stir at room temperature for 30 min. Compound 51 (5.0 g, 32
mmol) was added as a solution in DMSO (25 mL) and the resulting peach-colored
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solution was allowed to stir at 90 °C for 9 h. Water (25 mL) was added and the reaction
mixture was heated at reflux for 8 h. The bright-yellow reaction mixture was allowed to
cool to 5 °C over 30 min. A 0.15 N HCl solution (20 mL) was added and the reaction
mixture was allowed to stir for an additional 30 min. The resulting precipitate was
filtered, washed successively with H2O (25 mL), 0.1 M NaOH solution (2 x 75 mL) and
brine (50 mL), and dried (Na2SO4) to yield 4.70 g of 52 (83%) as a pale-yellow powder:
mp 116-117 °C (lit.191 mp 119-120 °C); 1H NMR (CDCl3) δ 3.92 (s, 2H, CH2), 7.40-7.42
(dd, 1H, ArH), 7.57-7.59 (d, 1H, ArH), 7.61-7.62 (d, 1H, ArH); IR (diamond, cm-1) 3083,
2991, 2226, 1592.

3-Amino-1-bromo-6-chloroisoquinoline (53). Compound 53 was prepared according
to a literature procedure for a similar compound.231 Compound 52 (4.7 g, 27 mmol) and
a solution of HBr (g) in AcOH (25 mL, 30%) were allowed to stir for 1 h at room
temperature. Diethyl ether (50 mL) was added, and the reaction mixture was allowed to
stir for 30 min. The resulting yellow/orange precipitate was filtered, washed with Et2O (2
x 25 mL), suspended in EtOAc (150 mL), and neutralized with saturated aq NaHCO3
solution (100 mL). The organic extract was dried (Na2SO4) and concentrated under
reduced pressure. The crude product was washed with cold Et2O (2 x 50 mL) to yield
2.01 g of 53 (29%) as an orange solid: mp 175-177 °C; 1H NMR (CDCl3) δ 7.39-7.42
(dd, 1H, ArH), 7.72-7.73 (d, 1H, ArH), 7.87 (br s, 2H, NH2), 8.03-8.06 (d, 1H, ArH), 8.36
(s, 1H, ArH); IR (diamond, cm-1) 3222, 3183, 3045, 1664, 1552.
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3,6-Dinitro-1,8-naphthalic anhydride (57). Compound 57 was prepared according to
a literature procedure.195 1,8-Naphthalic anhydride (56; 10.0 g, 50.0 mmol) was added
to concentrated H2SO4 (40.4 mL) and the resulting green solution was cooled to 5 °C.
While avoiding a rise in temperature above 20 °C, concentrated HNO3 (9.3 mL) was
added in a dropwise manner to the solution. The yellow solution was heated to 60 °C
for 1.5 h and then allowed to cool to room temperature. The reaction mixture was
added to ice-water (100 mL) in a dropwise manner and the resulting precipitate was
filtered and washed with H2O (3 x 75 mL). The crude product was recrystallized from
glacial AcOH, washed with H2O (3 x 50 mL), and dried in an Abderhalden over toluene
heated at reflux for 12 h to yield 8.7 g (60%) of 57 as a yellow solid: mp 199-200 °C
(lit.195 mp 208-210 °C, glacial AcOH); 1H NMR (CDCl3) δ 9.50 (d, 2H, ArH), 9.56 (d, 2H,
ArH); IR (diamond, cm-1) 3071, 1782, 1741, 1597.

2,7-Dinitronaphthalene (58). Compound 58 was prepared according to a literature
procedure.196

Compound 57 (7.6 g, 26.37 mmol) was added over 4 min to a

suspension of copper powder (1.9 g) in boiling quinoline (previously distilled, 15.6 mL)
and then more copper powder (1.9 g) was added. After 1 h, the reaction mixture was
allowed to cool to room temperature and Et2O (250 mL) was added. The resulting darkbrown reaction mixture was filtered and the filtrate was washed with H 2O (2 x 100 mL).
The organic extract was washed successively with 15% HCl solution (2 x 75 mL), cold
saturated NaHCO3 solution (100 mL), and H2O (100 mL). The organic portion was dried
(MgSO4) and the solvent was removed under reduced pressure. The crude product
was purified via column chromatography (silica gel; hexanes/EtOAc; 2:1 to 1:1) and
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dried in an Abderhalden over toluene heated at reflux for 5 h to yield 0.8 g (13%) of 58
as an orange solid: mp 225-228 °C (lit.196 mp 234 °C, glacial AcOH); 1H NMR (CDCl3) δ
8.17 (d, 2H, ArH), 8.50 (dd, 2H, ArH), 9.04 (s, 2H, ArH); IR (diamond, cm-1) 3081, 1628,
1514.

2-Amino-7-nitronaphthalene (59).

Compound 59 was prepared according to a

literature procedure.197 A solution of NaSH (0.07 g, 1.27 mmol) in MeOH (2 mL) was
added over 15 min to a solution of 58 (0.19 g, 0.85 mmol) in MeOH (3 mL) and H2O (6
mL) heated at reflux. The dark-purple reaction mixture was heated for 3 h and then
poured into ice-water (50 mL). The resulting orange precipitate was filtered and washed
with boiling 10% aq HCl solution (25 mL). The filtrate was basified with 10% NaOH
solution and extracted with EtOAc (50 mL). The organic extract was dried (MgSO 4) and
the solvent was removed under reduced pressure to afford 59 (0.10 g, 64%) as an
orange solid: mp 159-162 °C (lit.196 mp 184.5 °C, EtOH); 1H NMR (CDCl3) δ 4.14 (br s,
2H, NH2, D2O ex), 7.13-7.17 (m, 2H, ArH), 7.76-7.83 (m, 2H, ArH), 7.99 (dd, 1H, ArH),
8.56 (d, 1H, ArH); IR (diamond, cm-1) 3486, 3383, 2920, 1631, 1518.

7-Chloro-2-nitronaphthalene (60).

Compound 60 was prepared according to a

literature procedure for a similar compound.198 Acetic acid (0.4 mL) and 59 (0.09 g,
0.48 mmol) were added to a stirred solution of NaNO 2 (0.07 g, 1.06 mmol) in
concentrated H2SO4 (0.4 mL) at 0 °C (ice-bath). The resulting solution was added in a
dropwise manner to a suspension of CuCl (0.17 g, 1.72 mmol) in concentrated HCl
solution (0.7 mL) at 0 °C (ice-bath) and the mixture was allowed to stir for 2 h. The
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black reaction mixture was poured into ice-water (50 mL) and the aqueous layer was
extracted with CH2Cl2 (50 mL). The organic extract was dried (Na2SO4) and the solvent
was removed under reduced pressure. The crude product was purified via column
chromatography (silica gel; hexanes/EtOAc; 20:1) to yield 0.02 g of 60 (19%) as a
yellow needle-like solid: mp 137-139 °C (lit.229 mp 139-140 °C, EtOH); 1H NMR (CDCl3)
δ 7.65-7.74 (m, 2H, ArH), 7.92-8.06 (m, 2H, ArH), 8.28 (dd, 1H, ArH), 8.80 (dd, 1H,
ArH); IR (diamond, cm-1) 2917, 2845, 1731, 1586, 1514.

3-Chlorophenylacetyl chloride (62).

Compound 62 was prepared according to a

literature procedure for a similar compound.203 Thionyl chloride (3.2 mL, 43.96 mmol)
was added to a stirred solution of 3-chlorophenylacetic acid (61; 5.00 g, 29.31 mmol) in
CH2Cl2 (12 mL) at room temperature. The yellow, translucent reaction mixture was
heated at reflux for 24 h and then allowed to cool to room temperature. The orange
reaction mixture was concentrated under reduced pressure. The product was purified
via Kuger-rohr distillation (0.5 Torr, bp 97-103 °C; lit.233 1 Torr, bp 77.5-78 °C) and dried
under reduced pressure for 2 h to yield 3.69 g (67%) of 62 as a yellow liquid: 1H NMR
(CDCl3) δ 4.05 (s, 2H, CH2), 7.08-7.10 (m, 1H, ArH), 7.19-7.25 (m, 3H, ArH); IR
(diamond, cm-1) 3358, 3065, 2912, 1790, 1599.

7-Chloro-β-tetralone (63) and 5-Chloro-β-tetralone (64).

Compounds 63 and 64

were prepared according to a literature procedure.204 Compound 62 (2.49 g, 13.17
mmol) was dissolved in CH2Cl2 (25 mL) and added via an addition funnel over 20 min to
a white suspension of AlCl3 (previously sublimed; 3.86 g, 28.98 mmol) in CH2Cl2 (125
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mL) stirring at -10 to 0 °C (cooling bath with CO2). Ethylene gas was bubbled into the
yellow mixture for 30 min, causing the temperature to rise to 5 °C, and then drop back
down to -5 °C. Ethylene gas was allowed to bubble slowly through the mixture for an
additional 1.75 h. Ice-water (100 mL) was added to the pale-yellow reaction mixture.
The organic layer was separated and washed successively with 10% HCl (100 mL),
saturated aq Na2CO3 (100 mL), and then dried (Na2SO4). The solvent was removed
under reduced pressure and the product was isolated via column chromatography
(silica gel; hexanes/EtOAc; 9:1) to yield 0.36 g (15%) of 64 as a yellow oil and 0.24 g
(10%) of 63 as a pale-yellow solid: mp 37-38 °C (lit.234 mp 38-39 °C). Both products
were dried under reduced pressure for 1 h and stored at -80 °C. 63: 1H NMR (CDCl3) δ
2.48 (t, 2H, CH2), 2.97 (t, 2H, CH2), 3.49 (s, 2H, CH2), 7.10 (m, 3H, ArH); IR (diamond,
cm-1) 3022, 2964, 2763, 1686, 1598. 64: 1H NMR (CDCl3) δ 2.50 (t, 2H, CH2), 3.17 (t,
2H, CH2), 3.53 (s, 2H, CH2), 6.96 (d, 1H, ArH), 7.09 (t, 1H, ArH), 7.23 (d, 1H, ArH); IR
(diamond, cm-1) 3064, 2916, 2849, 1817, 1715.

2-Amino-5-chlorotetralin Hydrochloride (65). Compound 65 was prepared according
to a literature procedure for a similar compound.206 Sodium cyanoborohydride (0.04 g;
0.62 mmol) was added to a solution of 64 (0.09 g; 0.52 mmol) and NH4OAc (0.40 g;
5.20 mmol) in MeOH (10 mL) at room temperature. The resulting pale-yellow/brown
solution was allowed to stir for 18 h. The reaction mixture was acidified with 10% HCl
solution (pH ≈ 2.0), concentrated under reduced pressure, and then extracted with
CH2Cl2 (2 x 50 mL). The aqueous portion was basified with 6 N NaOH (pH ≈ 10) and
extracted with CH2Cl2 (3 x 50 mL). The combined organic extract was dried (Na2SO4)
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and concentrated under reduced pressure. The resulting yellow oil was dried under
reduced pressure for 2 h to yield 0.03 g (32%) of the free base of 65: 1H NMR (CDCl3) δ
1.52-1.59 (m, 1H, CH), 1.95-2.01 (m, 1H, CH), 2.45-2.54 (m, 1H, CH), 2.63-2.71 (m, 1H,
CH), 2.89-2.97 (m, 2H, CH), 3.07-3.14 (m, 1H, CH), 6.90-7.13 (m, 3H, ArH); IR
(diamond, cm-1) 3340, 3276, 3060, 2927, 2855, 1568.
The free base was converted to the HCl salt by dissolving the oil in absolute EtOH (5
mL). A saturated solution of HCl (g) in EtOH (4 mL) was added at 0 °C (ice-bath) and
allowed to stir for 30 min at 0 °C (ice-bath). The reaction mixture was concentrated
under reduced pressure and washed with Et2O (10 mL). The resulting crude solid was
recrystallized from EtOH/Et2O to yield 0.02 g (18%) of 65 as a pink solid: mp 280-282
°C (dec); 1H NMR (DMSO-d6) δ 1.61-1.71 (m, 1H, CH), 2.02-2.05 (m, 1H, CH), 2.672.78 (m, 3H, CH), 2.99-3.04 (m ,1H, CH), 3.34-3.38 (m, 1H, CH), 7.06-7.18 (m, 3H,
ArH), 8.04 (br s, 3H, NH3+, D2O ex); IR (diamond, cm-1) 2921, 2718, 2627, 2556, 2037,
1620, 1599. Anal. Calcd (C10H12NCl·HCl) C, 55.06; H, 6.01; N, 6.42. Found: C, 55.03;
H, 5.95; N, 6.32.

4,6-Dichloroisatoic anhydride (67).
Method A.

Compound 67 was prepared according to a literature procedure.208

Chromium trioxide (0.33 g, 3.30 mmol) was added portionwise at 90 °C to a stirred
suspension of 4,6-dichloroisatin (66; 0.72 g, 3.31 mmol) in glacial AcOH (4 mL) and
acetic anhydride (4 mL). The reaction mixture was allowed to stir at 90 °C for 1.5 h.
Water (20 mL) was added to the green reaction mixture and the crude product
precipitated. The crude solid was collected by filtration, washed with H 2O (15 mL), and
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dried under reduced pressure for 1 h to yield 0.55 g of crude product (and starting
material) as a yellow solid. It was determined by 1H NMR that the crude solid was a
mixture of 4,6-dichloroisatin (66; 45%) and 67 (55%). This crude product was used in
the next step without purification.

Method B. Compound 67 was prepared according to a literature procedure for a similar
compound.232 A suspension of 4,6-dichloroisatin (66; 0.50 g, 2.32 mmol) in glacial
AcOH (2.5 mL) and concentrated H2SO4 (2 drops) was heated to 30 °C. The reaction
mixture was allowed to stir for 15 min and then an aqueous solution of H2O2 (0.3 mL;
30%) was added in a dropwise manner. The reaction mixture was slowly heated to 65
°C and after 5 h the reaction mixture was allowed to cool to room temperature. The
resulting precipitate was collected by filtration, washed with H2O (3 x 5 mL), and dried
under reduced pressure for 8 h to yield 0.32 g of crude product (and starting material)
as a yellow solid. It was determined by 1H NMR that the crude solid was a mixture of
4,6-dichloroisatin (66; 56%) and 67 (44%). This crude product was used in the next
step without purification.

2-Amino-5,7-dichloroquinazolin-4(3H)-one (68).

Compound 68 was prepared

according to a literature procedure for a similar compound. 209

S-Methylthioisourea

sulfate (0.30 g, 1.07 mmol) and Na2CO3 (0.11 g, 1.07 mmol) were added to a solution of
4,6-dichloroisatoic anhydride (67; 0.25 g, 1.07 mmol) and 4,6-dichloroisatin (66; 0.30 g,
1.37 mmol) dissolved in aq MeCN (11 mL, 80%). The resulting solution was heated at
reflux for 23 h. The reaction mixture was allowed to cool to room temperature over a
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period of 30 min, H2O (20 mL) was added, and the reaction mixture was allowed to stir
for 2 h. The reaction mixture was filtered and the precipitate was washed with aq MeCN
(3 x 15 mL; 80%). The solid was dried in an Abderhalden over toluene heated at reflux
for 24 h to yield 0.17 g (70%) of 68 as a beige solid: mp >300 °C; 1H NMR (DMSO-d6) δ
6.64 (br s, 2H, NH2, D2O ex), 7.13-7.15 (m, 2H, ArH), 11.10 (br s, 1H, NH, D2O ex); IR
(diamond, cm-1) 3385, 2925, 2257, 2130, 1652.
To recover the isatin starting material, the filtrate was concentrated under reduced
pressure, dissolved in EtOAc (100 mL), and washed with 15% HCl solution (50 mL).
The aqueous layer was basified with 10% NaOH and extracted with EtOAc (2 x 50 mL).
The combined organic portion was dried (MgSO4) and the solvent was removed under
reduced pressure.

2-Aminoquinazolin-4(3H)-one (70).

Compound 70 was prepared according to a

literature procedure for a similar compound.209 S-Methylthioisourea sulfate (5.56 g,
20.00 mmol) and Na2CO3 (3.20 g, 30.00 mmol) were added to a solution of isatoic
anhydride (69; 3.26 g, 20.00 mmol) in aq MeCN (100 mL, 80%) and the resulting darkbrown solution was heated at reflux for 23 h. The light-yellow reaction mixture was
allowed to cool to room temperature over a period of 30 min. The resulting precipitate
was collected by filtration and washed successively with aq MeCN (3 x 25 mL; 80%)
and H2O (75 mL). The solid was dried under reduced pressure and recrystallized from
absolute EtOH to yield 1.14 g (35%) of 70 as a white solid: mp >300 °C (lit.214 mp >250
°C); 1H NMR (DMSO-d6) δ 6.40 (br s, 2H, NH2, D2O ex), 7.10 (t, 1H, ArH), 7.20 (d, 1H,
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ArH), 7.55 (t, 1H, ArH), 7.88 (d, 1H, ArH), 11.03 (br s, 1H, NH, D2O ex); IR (KBr, cm-1)
3404, 3144, 3061, 1684, 1656, 1606.

C. Molecular modeling

All ligands and models were built in Sybyl (verson 8.1; Tripos Associates, St.
Louis, MO) on a Silicon Graphics workstation and given AM1 charges and geometries
based on MOPAC. A conformation search of MD-354 (21), in order to identify the
lowest-energy conformers, was conducted using Sybyl (Tripos Force Field, AM1).
In order to generate homology models of the inactive and active state of α2A-,
α2B- and α2C-ARs, first, a sequence alignment of the α2-ARs and other GPCRs was
created. Mimicking Bissantz et al., 214 an alignment profile of several GPCRs including
the primary sequences of human muscarinic cholinergic M1 (P11229), human
vasopressin V1a (P37288), human dopamine D3 (P35462), human adrenergic β2
(P07550), human δ-opioid (P41143) and bovine rhodopsin (P02699), all of which were
retrieved from the ExPASy Proteomics Server (http://www.expasy.org/) at the Swiss
Institute of Bioinformatics, was generated and further aligned to the human α2A-AR
(P08913) sequence using the ClustalX program (BLOSUM matrix series; gap opening:
15.0). Two alignments were generated as described above: (1) included amino acid
residues from the N-terminus to the IL-3 and (2) included amino acid residues from the
IL-3 to the C-terminus.236 Previously identified highly conserved amino acid residues
within GPCRs237,238 are aligned and there are no insertions or deletions in the
transmembrane regions.
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This alignment was used to generate the model of the α 2A-AR based on its
homology to human β2-AR (chain A of PDB entry = 2RH1; RCSB Protein Data Bank,
http://www.rcsb.org). The α2A-AR model was used as a template for α2B- and α2C-ARs,
which means sequence alignments of α2B-AR and α2A-AR, as well as α2C-AR and α2AAR, were first generated followed by mutating amino acid residues in the α 2A-AR model
to mimic the α2B-AR and α2C-AR. Ligand docking in these models was performed via
GOLD (Version 4.0; 10 genetic algorithm runs/15 Å sphere around conserved D3.32).
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